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Abstract 
 
Clinical trials are at the centre of advances in our understanding of stroke and 
its optimal treatment.  In this thesis the uses and properties of outcome 
assessment scales for stroke trials are described, with particular attention given 
to the modified Rankin Scale (mRS).   
 
Through comprehensive literature review I will show that mRS is the most 
frequently used functional outcome scale in clinical trials but efficacy of the 
scale is potentially limited by inter-observer variability.  Using a “mock” clinical 
trial design I demonstrate that inter-observer mRS variability in contemporary 
practice is moderate (k=0.57).  Adding these data to systematic review of 
published data, confirms an overall moderate inter-observer variability across 
ten trials (k=0.46). 
 
Differing strategies to improve mRS reliability will then be described.  I will 
outline development of a bespoke training package, international training scores 
across 2942 raters again confirms suboptimal reliability (k=0.67).  A pilot trial 
using endpoint committee review of video recorded interviews demonstrates 
feasibility of this approach.  Attempts to improve reliability by deriving mRS 
from data recorded in patients’ hospital records are not successful (k=0.34). 
 
In the final chapters I present a novel methodology for describing stroke 
outcomes – “home-time”.  This measure shows good agreement with mRS, 
except at extremes of disability.  Finally to put mRS in a historical context, the 
career of John Rankin and the development of his eponymous scale is recounted.3 
Summary of Thesis Chapters 
 
In chapter one a brief overview of outcomes assessment is provided.  Guided by 
the principles of clinimetrics (the study of properties and uses of scales in 
clinical practice in particular multidimensional assessment scales), uses, 
limitations and properties of several functional outcome measures are 
described.   
 
It has been argued that the clinical application of mRS is limited by substantial 
inter-observer variability.  In chapter two a systematic literature review of mRS 
reliability studies is described.  Ten studies of mRS reliability are presented.  
There is heterogeneity in reliability reported, overall reliability of mRS is 
suboptimal (k=0.46).  The studies of mRS properties that best mimic a 
contemporary clinical trial (multiple observers across different sites grading 
multiple patients) are shown to demonstrate particularly poor reliability of mRS.   
 
A number of potential functional assessment scales are available to trialists.  In 
chapter three, differing scales and methodologies for assessing functional 
outcomes stroke trials are described.  Six journals were chosen to represent high 
impact publications in Stroke Medicine, Neurology and General (Internal) 
Medicine, all were hand searched for trials describing functional outcomes in 
stroke survivors.  One hundred and twenty-six articles were reviewed.  Of forty 
seven outcome measures used, the most prevalent tool was the mRS (81 trials; 
64%).  Trialists continue to utilise instruments that are poorly validated.  The 
majority of papers did not provide details on how their functional outcome 
assessments were administered (93; 73%).  This heterogeneity in the use and 4 
description of functional outcome measures in stroke trials will potentially 
compromise comparison and meta-analysis across studies, explicit description of 
methodology should be mandatory for all trials and greater rigour is desirable.   
 
In Chapter four a mock clinical trial design is used to explore inter and intra-
observer variability of the scale.  Consenting stroke patients had mRS performed 
by two independent assessors, with the second interviewer in the pair assessing 
the patient blinded to colleague’s score.  For each patient assessed, one rater 
was randomly assigned to video record their interview.  After three months this 
interviewer reviewed and re-graded their original video assessment.  Across 100 
paired assessments, inter-observer agreement was found to be moderate 
(k=0.57); use of a structured interview (n=49) did not substantially improve 
reliability (k structured=0.50; k unstructured=0.64).  Intra-observer variability 
was good, but less than would be expected from previous literature (k=0.72).  
These results suggest that there remains substantial inter-observer variability in 
mRS grades awarded even when administered by experienced researchers.   
 
A previous criticism of mRS has been the lack of guidance on how to assess and 
grade patients.  In chapter five, the development of a video based mRS teaching 
and certification resource is outlined.  Formal assessment of training involved 
grading of real-life cases.  After training, most trainees (90%) achieved 
certification in mRS assessment.  The majority (85%) of investigators who did not 
reach an acceptable score on initial testing achieved certification after further 
exposure to the package.  Mass training in mRS assessment for clinical trials is 
possible.  Acceptability of the training has been demonstrated by its successful 
use in international stroke trials. 5 
   
In chapter six the training and certification data from the DVD resource are used 
to explore reliability of mRS across a large cohort of researchers.  In total, 2942 
assessments from 30 countries were analysed.  Overall reliability for mRS grading 
was good (k=0.67) with substantial heterogeneity across countries.  Native 
English language had little effect on reliability.  Within the United Kingdom, 
there was no significant variation by profession.  
 
In chapter seven data from a study of deriving mRS from patient’s hospital 
records are presented and discussed.  Fifty sequential patients attending the 
cerebrovascular outpatient clinic were included.  Two independent, blinded 
clinicians, trained in mRS, assessed case-records to derive mRS.  They scored 
“certainty” of their grading on a 5-point Likert scale.  Agreement between 
derived and traditional face to face mRS was calculated using attribute 
agreement analysis.  Case-record appraisers were poor at deriving mRS (k=0.34).  
Accurate mRS cannot be derived from standard hospital records.  Direct mRS 
interview is still required for trials. 
 
In chapter eight a pilot trial of group assessment of recorded mRS interviews is 
reported.  Remote assessment of endpoints by adjudication committee is 
commonplace in contemporary trials and has potential to improve data quality.  
Using patient videos from the study presented in chapter four, at three months 
after initial mRS assessment a panel experienced in use of mRS graded the 
videos assigning individual scores.  This process was repeated again after a 
further three-month delay.  Individual assessments were recorded and then the 
group discussed cases with final grading based on consensus.  Inter-observer and 
intra-observer variability of remote assessment of video mRS was quantified 6 
using attribute agreement analysis.  Inter-observer variability of individual video 
mRS assessors was moderate (k=0.67); intra-observer variability was moderate 
also (k=0.64).  There was significant agreement between consensus group mRS 
and standard mRS.  Remote assessment of mRS by adjudication panel is feasible 
and has acceptable reliability and validity.  Further studies using this video 
based approach are warranted.  
 
In chapter nine, using data from the “GAIN” trial, relationships between 
duration of stay in the patient’s own home or chosen residence post stroke – 
“Home-time” and other functional outcomes are explored.  Baseline data were 
from 1717 of 1788 patients; functional outcomes included NIHSS; Barthel Index 
(BI) and mRS.  Using analysis of variance with Bonferroni contrasts of adjacent 
categories, a significant association between increasing Home-time and 
improved mRS scores was found.  The relationship held across all mRS grades 
except 4-5.  Home-time offers a robust, useful and easily validated outcome 
measure for stroke, particularly across better recovery levels.  
 
To allow discussion of mRS and other outcome assessments to be placed in a 
historical context, chapter ten outlines the development of the original Rankin 
scale and its creator Professor John Rankin.  Using historical documents and 
publications, Rankin’s pioneering work in the nascent speciality of Stroke 
Medicine is described as well as the genesis of his eponymous scale. 7 
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Functional outcome assessment in stroke trials  
Stroke represents a substantial and increasing global health problem.  
Cerebrovascular diseases are the third leading cause of death and the single 
greatest cause of disability in most Western countries.(1)  Globally the burden of 
stroke is greater still, with the majority of incident cases in the developing 
world.(2)  The economic burden of stroke is substantial, acute and chronic care 
of stroke is estimated to consume greater than 5% of many countries total 
healthcare budget.(3)   
 
Prevention strategies and acute and longer term interventions for stroke 
patients have changed considerably in the last 20 years, in part driven by the 
increasing evidence base for both acute and rehabilitative strategies.(4)  To 
inform and improve the practice of stroke medicine there has been an 
exponential increase in clinical trials.(5)  A recent overview of randomised 
controlled trials in the field of acute stroke, reported an increase in the number 
of registered randomised controlled trials (RCT) per decade from 3 in the 1950’s 
to 99 in the 1990’s with corresponding increases in patient numbers per trial and 
improvements in overall quality of trial methodology.(6)  
    
In any field of medicine, clinical trials are designed to compare efficacy of two 
or more interventions.  To quantify the differences between treatment 
strategies requires some measure of effect.  Treatment effect or outcome can 
be measured in several different ways, with each approach having advantages 
and disadvantages. 32 
 
In many situations a direct measure may be appropriate.  For example in a basic 
comparison of antihypertensive therapies the outcome measure of choice may 
be a direct measure of blood pressure.  Such an approach is attractive in terms 
of immediacy and simplicity and lends itself to relatively straightforward 
comparative analysis.  However, as experience of clinical trials has developed it 
has become increasingly apparent that direct measurement of “bio-markers” 
does not always correlate with clinical outcome.(7)  This is especially true in the 
field of cardiovascular medicine, with multiple examples of well conducted 
clinical trials that reported significant benefits in terms of a relevant bio-
marker, with either no corresponding clinical effect or even an unexpected 
deleterious clinical effect.(8)  As example, the lipid lowering agent Ezetimibe 
has been shown to significantly lower mean serum levels of low density 
lipoprotein (LDL) but has shown no benefit in vascular risk reduction and may in 
fact be associated with increased risk of mortality.(9;10)   
 
With this in mind, measurement of outcomes more directly relevant to patients 
becomes more attractive.  As a primary aim of most medical interventions is to 
keep patients alive, the archetypal “hard” clinical outcome is mortality.  Using 
clinical outcomes such as mortality or incidence of event provides unambiguous 
data that are easy to collate and analyse.  Selection of optimal outcome(s) to 
use as clinical trial endpoint is more problematic.  Ultimately, clinical trials are 
designed to test potential treatment benefits for patients.  In cerebrovascular 
medicine, the physical, psychological and social cost of a stroke is only poorly 
represented by traditional trial endpoints.(11;12)  Even “hard” outcomes such as 
mortality or event rate provide a poor measure of the global effect of a stroke.  33 
In fact, it has been shown that most patients would rather be dead that suffer a 
disabling cerebrovascular event.(13)  Thus an outcome measure where death is 
“negative” but disabling stroke is “positive” will give little meaningful data.   
 
To better represent treatment effects, a number of outcome scales that make 
some measure of patient functioning have been developed and are now 
commonly used in clinical stroke trials.  The importance of functional outcomes 
as the optimal measure of clinical effect in stroke trials has been recognised by 
regulatory authorities both in America(14) and Europe.(15)  In this regard other 
cardiovascular disciplines could learn from stroke medicine – a recent analysis of 
clinical trials in diabetes mellitus suggested that majority of published trials 
continue to use bio-markers as endpoint and use of outcomes immediately 
relevant to patients was infrequent.(16) 34 
 
Functional assessment scales in stroke  
Assessment scales are designed to represent and measure quantities, qualities or 
categories.  Responses are collected across a variable number of domains, 
standardised against pre-specified grades and can then be quantified and 
collated.  These data can then be subject to statistical analysis.  Functional 
outcome scales use this process to describe aspects of patient ability and 
wellbeing. 
 
Post stroke functional recovery can be described in a number of domains and 
this is reflected in the large number of assessment scales available.(17)  The 
WHO international classification of functioning, disability and health proposes a 
conceptual framework that can be used as an aid to classification of outcomes 
data.(18) Patient recovery can be described in terms of physical impairment, 
functional activity (formerly disability) or societal participation (formerly 
handicap).  Assessment scales describing each of these domains are frequently 
used in contemporary stroke literature, examples from each domain include: 
NIHSS (National Institutes of Health Stroke Scale)(19) as a measure of 
impairment; mRS (modified Rankin Scale)(20) as a measure of functional activity 
and London Handicap Scale (21) as a measure of participation.  A further domain 
that trialists have attempted to measure is that of quality of life (QOL).(22) QOL 
scales build on measures of societal participation and attempt to assess physical, 
mental, societal and spiritual aspects of a patient’s condition.(12;23) (Figure 1) 35 
 
Impairment 
Activity 
Participation 
Quality of Life 
Figure 1: Venn diagram illustrating levels of functioning. 36 
 
Thus the need to robustly measure functional outcome for clinical stroke trials is 
evident, however the optimal methodology to describe these data remains a 
matter for debate.  The confusion regarding functional outcome measurement is 
in part a reflection of the large number of assessment tools available.  The 
University of Washington stroke research centre describe 20 different outcome 
assessment scales in common use in stroke trials, these include stroke specific 
tools and more general neuro-rehabilitative tools.  These selected instruments 
represent only a small proportion of the total number of scales potentially 
available.  Reference texts relating to outcome measures in neurological disease 
describe many hundreds of tools that have previously been used in clinical trial 
settings.(24;25)   
 
Describing properties of assessment scales 
The optimal functional outcome measure to be used will depend on the clinical 
application or research question to be answered.  Important properties of an 
instrument intended for use in a busy outpatient service will differ from the 
desired features of a tool for use in detailed research.  The ideal outcome 
measure would be easy to administer; would show consistency after repeated 
use and across multiple users; would capture information relevant to both the 
patient and the trialist and be able to detect small changes over time.(26)  No 
perfect outcome measure exists (or is likely to ever exist), however  
understanding of the properties of outcomes measures has increased and we can 
use this to comprehensively examine existing and novel assessment instruments. 
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Clinimetrics is the methodological discipline that focuses on quality of clinical 
measurements.(26)  Outcome scales are traditionally assessed in terms of 
validity, reliability and responsiveness and these will be described in turn.  
Other important properties of an outcome measurement include feasibility (in 
the desired setting); patient acceptability and cost benefit both in terms of 
economic and time resources.  Assessment of these latter properties is by their 
nature more subjective and will vary according to the outcome measure and its 
proposed usage. 
 
Validity  
Validity is defined as the relationship between the concept to be measured and 
the scale used for assessment.(27)  Validity can be defined using several inter-
related and complimentary methods.  Certain key measures of validity for 
example face validity are subjective and do not lend themselves to objective 
measurement.   
Criterion validity – does the scale agree with a known “gold standard”. 
Convergent validity - does the scale of interest agree with other instruments 
that purport to measure the same or similar outcomes. 
Construct validity – is there reasonable relationship between the scale and 
factors known to influence the property to be measured.  In stroke outcome 
assessment, a functional assessment tool should show a correlation with factors 
such as size of infarct; pre-morbid disability etc.  
Face validity – do the outcome data generated by an outcome scale make sense 
and agree with consensus opinion. 
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Responsiveness 
Responsiveness is defined as the ability to detect meaningful change over 
time.(27)  A stroke scale should be able to detect changes in patient ability as 
they progress through rehabilitation and recovery.  The minimal degree of 
change that is felt to be clinically significant will vary according to the trial.  
However even clinically modest improvements in functioning can have 
substantial meaning to patients and be important at a population level.(28) 
Increasing responsiveness is by its nature often at the cost of increasing 
complexity.  As example, with its six grades the Glasgow Outcome Scale 
(GOS)(29) is less responsive to change than the Barthel Index (BI)(30) with its 
hundred point scoring.  However, any change in GOS is clearly of clinical 
relevance while this may not be true of a single point change in BI. 
 
Reliability  
Reliability is a measure of both internal consistency in multi-item scales and of 
the reproducibility of repeat scoring by the same observer (intra-observer 
reliability) or between scorers (inter-observer variability).(31)  Measures of 
reliability should assess both reproducibility among the observer(s) and 
consistency across components of the scale. 
 
The optimal statistical methods to quantify and analyse reliability data remain 
contentious.  Inter and intra-observer reliability has traditionally been described 
in the medical literature using the kappa (k) statistic(32) – a measure of 
agreement across a number of observers for non-parametric scales.  k  statistics 
are calculated based on the observed proportion of agreement (Po) and the 
proportion of agreement expected by chance (Pe) where k=(Po–Pe)/(1–Pe).(33)  39 
Using this equation k can theoretically take any value from -1 to 1 where k=1 
defines perfect agreement between assessors, while k=0 defines no agreement 
other than that expected by chance.  Standard definitions of poor (k = 0-0.20); 
fair (k = 0.21 – 0.40); moderate (k = 0.41 – 0.60); good (k = 0.61 – 0.80) and very 
good (k= 0.81 – 1.00) agreement are now accepted.(34)  For clinical use a 
reliability of k=0.61 or greater has been arbitrarily chosen as “acceptable”.(32)  
In ordinal hierarchical scales an inter-observer difference of more than one 
grade in either direction implies a greater degree of variability than single unit 
change.  For this reason some authors have used weighting of kappa statistics 
(kw) to better represent the size of disagreement between observers, most 
commonly weighting is “quadratic”.(35)  
 
Although kappa statistics have proven popular in the biomedical literature, 
solely using this method to describe variability has a number of limitations.  
Kappa statistics are dependent on the number of observers and categories within 
the scale.  This makes for problematic comparative analysis of kappa statistics 
from different populations and studies.(32;34)  It has also been argued that the 
basic assumptions underlying kappa statistics will not be met in a “real life” 
clinical trial setting.  For example, kappa statistics assume complete observer 
independence, a situation that may not be met in a single centre trial, where 
observers are likely to work together and be aware of each others criteria for 
assessing recovery.(36) 
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The importance of optimal outcome assessment  
An understanding of the clinimetric properties of a scale is of more than 
academic interest.  Use of an inappropriate tool will jeopardise study quality 
and invalidate results, even if suitable rigour is exercised in all other elements 
of the trial.  The need for adequate validity of an outcome tool is intuitive, a 
functional assessment that does not measures the clinical property it is designed 
for will clearly provide meaningless data.  Similarly, the importance of scale 
responsiveness and the ability to detect meaningful change even if modest has 
already been discussed. 
 
The deleterious effects of poor outcome reliability are less intuitive but 
potentially the most relevant for contemporary stroke trials.  Poor reliability can 
substantially weaken the results of an otherwise well conducted trial.  High 
levels of inter-observer variability in assessment of a trial endpoint are a signal 
that certain outcomes are being misclassified.  Such misclassification will 
increase the likelihood of both type I (false positive) and type II error (false 
negative) and may ultimately decrease statistical power.(28)  “Real life” 
instances of the detrimental effects of misclassification on otherwise well 
conducted trials can be found in recent high profile studies from numerous 
biomedical disciplines.  As example, in a national trial of pneumococcal vaccine, 
modest misclassification of the cause of death (the trial’s primary endpoint) 
reduced trial power by 40%.(37)  In a recent neuro-trauma study, erroneous 
misclassification of outcome substantially reduced the observed treatment 
effect, reanalysis correcting for this misclassification revealed a significant 
benefit of intervention.(38)   
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Reducing variability is not only of significance when potential treatment effects 
are missed.   Reduction of endpoint misclassification will favourably impact upon 
trial power, reducing total number of patients required and thus reducing 
overall running cost.  In a heterogeneous clinical condition such as stroke, large 
numbers of patients are required to detect modest but meaningful treatment 
effects.(39)  In the planning and statistical “powering” of many recent studies, 
treatment effects have been overestimated and trials have ultimately been 
underpowered.(40)  These issues are compounded by the difficulties many stroke 
trialists have faced in recruiting to target.(40)  It must also be remembered that 
ideally robust trial results should be achieved using the fewest trial participants 
as possible, thus reducing exposure to a risky intervention or not denying an 
effective treatment to a control group.  Thus, there are clinical, economic and 
ethical reasons to design trials that are adequately powered with the fewest 
possible patients.  Improving reliability of endpoint data should offer a method 
for achieving this aim. 
 
To put this discussion of study endpoint quality in context, it is worth noting that 
several recent stroke trials (SAINT II(41); DIAS(42)) have been characterised by 
neutral results for compounds with good scientific and pre-clinical data.  It is of 
course possible that interventions such as neuro-protectants and novel 
thrombolytic agents simply have no efficacy in man.  However, the above 
discussion suggests a second possible explanation -   that in some cases 
important beneficial treatment effects may have been lost through suboptimal 
endpoint data collection and analysis. 
 42 
Prevalent functional outcome scales  
For the purpose of this thesis, functional outcome scales are those assessment 
tools used as endpoint in trials and that purport to measure more than mortality 
or disease state.  As discussed previously there are large numbers of functional 
assessment scales that have been used; continue to be used or have potential to 
be used in clinical stroke trials.  Using the WHO international classification 
system, well recognised examples of scales that purport to measure impairment; 
activity and participation will be described paying particular attention to 
strengths and weaknesses of differing assessment approaches.  The scales chosen 
for discussion represent those tools commonly used in acute stroke trials. 
 
The National Institutes of Health Stroke Scale   
The National Institutes of Health Stroke Scale (NIHSS)(19) is an example of a 
stroke specific impairment grading scale.  The scale was originally developed by 
neurologists as an aid to non-specialists in the initial assessment of stroke 
severity.  NIHSS uses clinical examination to measure limitation across a number 
of pre-specified physical domains.  Scores for individual components of the 
assessment are summed to give a total score between 0 (no objective deficit) 
and 43.    
  
NIHSS has grown in popularity and in many centres NIHSS assessment is a routine 
component of initial stroke “work up”.(43)  Advantages of the NIHSS are ease of 
administration and favourable reliability and responsiveness.(44;45)  Well 
validated training packages are available for NIHSS use and certification in 
competent use of the scale is a prerequisite for researchers in many acute stroke 
trials.(46)   43 
 
There are certain well documented weaknesses in the NIHSS that limit clinical 
utility of the scale.  The grading of the scale places an emphasis on left 
hemisphere damage and makes little assessment of cranial nerve function.  Thus 
with standard NIHSS scoring a patient with a posterior stoke can achieve a 
minimal score despite significant impairment.(47)  Many of the items 
incorporated in the NIHSS require the patient to be alert and so the scale may 
not differentiate impairment in the most severely affected strokes where 
patients may have fluctuant levels of consciousness.(17)  As with any impairment 
scale, by restricting its focus to physical functioning, NIHSS is less appropriate 
for assessment in the longer term.  At 90 days post stroke, many patients may 
have recovered motor function in their limbs but fewer will have returned to 
work or previous past-times. 
 
The Barthel Index 
The Barthel Index (BI)(48) is a general assessment scale used to quantify 
activities of daily living.  The scale was originally developed for use in long stay 
hospitalised patients to assess care needs, but has subsequently been used in 
many other areas including functional assessment post stroke.  The BI is scored 
according to ability and as such requires direct observation as well as historical 
data.  Patients are scored across a number of areas including dressing; toileting 
and mobility.  Scores are from 0 to 100 (or 0 to 20 if the modified BI is used).  
 
The BI is one of the best known activity scales, it is straightforward to 
administer and has been shown to predict long term outcomes, patients with BI 
scores totalling less than 40 are unlikely to return to independent living.  There 44 
is a comprehensive literature on clinimetric properties of the BI.  It is generally 
accepted that the scale has good reliability(49), although some authors have 
found high inter-observer variability in older patient groups (50) – a potential 
concern for stroke trialists as cerebrovascular diseases predominantly affect 
older cohorts.   
 
The clinical utility of the BI as trial endpoint is limited by well documented 
“ceiling” and “floor” effects. (51)  Patients can achieve maximal scores on the 
BI yet still have substantial residual impairment, while patients scored at the 
minimum of the scale can still show meaningful functioning.  Thus the BI is less 
responsive to the range of clinical improvement expected in a clinical stroke 
trial setting.  With its emphasis on activities of daily living, BI has also been 
criticised for disregarding other important aspects of recovery. (52) BI scores 
must be interpreted in the context of timing of administration.  (53)The “floor” 
effects of the BI are particularly relevant to acute stroke trials as in the first 
hours post event most patients will be bed bound and requiring nursing care.  
While following discharge home the basic activities measured by the BI provide 
little useful data on extended activities of daily living required to fully function 
and integrate in community environments. 45 
 
Stroke Impact Scale  
The Stroke Impact Scale (SIS) is a novel multi-level outcome assessment tool that 
was designed to assess a broad range of domains including physical functioning; 
cognition and societal participation. (54) The development of the SIS was 
informed by feedback from patients, their carers and therapists as to their 
perception of the most important aspects of stroke recovery. 
 
Unlike many traditional stroke assessment scales, the clinimetric properties of 
the SIS were robustly tested prior to dissemination and the scale continues to be 
modified to improve its use.(54)  SIS purports to measure certain domains not 
well quantified by other existing scales and as such provides one of the more 
comprehensive assessments stroke recovery.  However, despite the literature 
supporting the SIS it has been used infrequently in clinical trials and its 
generalisability as a functional outcome for stroke trials remains to be 
established. 
 
The modified Rankin Scale 
The modified Rankin Scale (mRS) is a stroke specific measure of functional 
recovery.  The precise meaning of mRS data has been debated.(55)  Certainly 
the scale offers a more comprehensive assessment than other activities of daily 
living scales such as the BI.  Some have argued that as mRS includes constructs 
such as ability to return to work, it represents a measure of societal 
participation.  However with an emphasis on perambulation it offers at best only 
a limited assessment of participation.  Most researchers now describe mRS as a 
“global disability” measure.   46 
 
The mRS grades outcome using an ordinal hierarchical scale that ranges from 
potential scores of 0 (no symptoms) to 5 (severe disability).  For clinical trial use 
an extra category of 6 (death) is often employed.  Each category of the mRS 
describes a broad range of global disability, as such responsiveness to change is 
less than with other scales.(52)  This can in fact be an advantage in the clinical 
trial setting as a single point change is likely to be clinically important.   
 
A growing literature describing clinimetric properties of the mRS is 
available.(31)  Convergent validity has been demonstrated by health care 
economics studies, with incremental mRS associated with significant increases in 
length of admission and cost of episode of care.(56)  There is a strong 
association between mRS and other functional outcome measures frequently 
used in clinical trials including NIHSS; BI; GOS and quality of life measures.(52)  
However mRS is not directly equivalent to these other activity measures, it has 
been shown that scores on a scale such as BI are not easily transformed into mRS 
grades.(57)  In terms of construct validity mRS scores have been found to have a 
reasonable agreement with several measures known to influence outcome 
following stroke including final infarct volume on imaging(58) and recanalisation 
score following thrombolysis.(59)  Importantly, mRS at 90 days has been shown 
to be an accurate predictor of longer term functional outcome; nursing home 
placement and mortality,(60) making 3 month mRS a useful marker of future 
outcome and thus a useful endpoint for clinical trials.  47 
 
The principal limitation of the mRS is variability in grading.  For a single level 
assessment scale such as mRS internal consistency is not an issue, however there 
is considerable potential for inter-observer variability in application and grading.     
A number of studies have attempted to quantify the reliability of mRS and will 
be discussed in the following chapter. 
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Administration of the mRS  
There is no formal guidance on how best to administer the mRS.  When first 
developed the scale was derived from a face to face interview with a research 
nurse.(20)  However a number of methodologies for collecting mRS based 
outcome data have subsequently been used in trials.   
 
Face to face interview 
The mRS assesses disability through patient’s historical descriptions of functional 
ability.  Unlike other assessment scales it does not require patients to 
demonstrate evidence of their ability in physical or cognitive domains.  Attempts 
to transform physical examination findings into relevant mRS grades have been 
described but this mixing of impairment and disability measures have not proven 
popular in the stroke literature.(61)   
 
It makes intuitive sense that a scale so dependent on historical information is 
graded using direct patient interview and much of the literature concerning 
clinimetric properties of mRS is based on traditional face to face interview.  
However, differing methodologies for conducting the mRS interview have been 
described.  In recognition of the variability with which mRS data may be elicited 
by patient interview and the further potential for variability in how these data 
are interpreted by the assessor – a  structured approach to mRS interview has 
been proposed.(62)  Various structured mRS interviews have been used, most 
using a “checklist” for data gathering.  Such an approach should provide a more 
comprehensive and systematic assessment of disability, however practical 
results when structured mRS has been used in the field have been 
conflicting.(63;64)  Further heterogeneity in face to face interview is seen in 49 
choice of interviewer.  Interviewers have been used from a variety of disciplines 
and backgrounds including physicians (from differing specialities); research 
nurses; medical students and non-clinical interviewers.  
 
Telephone / postal mRS  
As the mRS does not demand physical examination, remote assessment by 
telephone interview or postal questionnaire should be possible and may be 
preferable in terms of   simplicity and convenience for both researchers and 
patients.  No robust data could be found on the properties of postal based mRS.  
Clinimetric studies of postal versions of other stroke scales have been 
described(65;66), although we should be cautious in directly extrapolating from 
these other scales.  In a comparison of postal and interviewer administered 
versions of the GOS (65) there was overall moderate to good reliability; however 
a study using a postal version of the Stroke Impact Scale found reasonable 
clinimetric properties but cost savings of the postal approach were offset by high 
rates of non-response from participants.(66) 
 
Telephone assessment is commonplace in stroke and acceptable reliability of 
telephone based assessment has been demonstrated for scales measuring stroke 
free status(67) and cognitive impairment(68).  Studies of telephone based 
disability assessment, particularly mRS have yielded conflicting results.  In a 
German study of BI assessment, reliability of telephone and postal versions of 
the scale were equivalent and showed excellent agreement with traditional 
assessment.(69)  For mRS, independent groups have demonstrated results 
ranging from poor reliability (k=0.30)(64) using trained telephone assessors and 
structured interview to good reliability (k=0.74), although results of this later 50 
analysis are likely overestimated as single dichotomised mRS scoring was 
used.(70)  Drawing firm conclusions from this heterogeneous literature is 
difficult, however it would seem that direct interview is preferable to indirect 
assessments of mRS. 
 
Assessing mRS from interview of proxy 
Simple face to face interview with stroke survivors is not always feasible in  a 
clinical trial setting: cognitive impairment, speech disorder or inability of the 
patient to attend a research centre can complicate assessment.  Use of proxies 
to determine mRS is often used in such situations.  Again there are little data on 
the properties of such an approach and any understanding of the clinimetrics of 
proxy use must be extrapolated from studies of other stroke assessment scales.  
In a direct comparative study of patient and corresponding proxys’ scores on BI 
and Frenchay Activities Index (FAI) there was moderate agreement.(71)  In a 
comparison of proxy and patient responses to the SIS, there were significant 
differences in response for several key variables with proxies tending to over-
score disability.(72)  Agreement was best for observable physical domains.  In 
other studies of disease specific neurological scales it has been suggested that 
use of proxys may bias results, specifically family and informal carers may 
overestimate ability while health care workers and formal carers underestimate 
ability.(73) 
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Statistical analysis of mRS outcomes data 
Just as there is heterogeneity in methodology for collecting mRS outcomes data, 
so there is heterogeneity in the way such data are analysed.  In choosing a 
primary endpoint and corresponding statistical analysis trialists must endeavour 
to analyse data in a fashion that is both statistically appropriate and that will 
allow for detection of treatment effects with the fewest patients recruited.  
 
A popular method of analysing disability endpoints has been to dichotomise data 
into “favourable” and “non-favourable” outcomes.(74)  Many early stroke trials 
used a BI of greater than 60 to define patients with “good” functional 
outcome.(75)  With mRS a variety of cut offs have been used to define good 
outcome status.  There is no consensus as to the level of mRS that best 
represents acceptable recovery and choice has been partially dependent on the 
expected benefit of the therapy, the baseline disability of the cohorts under 
study and the level of recovery felt to be important not to “miss”.  For example, 
in a trial of intervention in the often fatal condition of malignant middle 
cerebral artery infarction a “good” outcome was defined as mRS 3 (moderate 
disability), while in trials of thrombolytic therapy, as better functional outcomes 
are expected this is reflected in the use of mRS 0-1 (no significant disability) to 
define treatment success.(75) 
 
Using data from completed clinical trials allows us to explore the potential 
effects of differing cut-off points on overall trial results.  Such an analysis has 
been completed and has shown that using a BI of 60 is an inefficient disability 
cut off, reducing overall power of a study.(76)  This makes sense as the 
distribution of post stroke disability represented by BI assumes a “U shaped 52 
curve” with few patients scoring BI in the middle range.  Shifting outcome cut 
offs to a higher BI allows for better determination of effect with smaller sample 
size, however use of the mRS is more efficient still.  In fact comparing BI scores 
of greater than 60 and mRS 0-1, sample sizes using the latter can be up to one 
fifth of that required for BI based assessment.(28) 
 
With any dichotomous endpoint a number of patients enrolled in the study will 
never contribute to the final outcome.  For example with a cut off of mRS 0-1, 
patients admitted with severe stroke may improve considerably and yet not 
reach the predefined level of acceptable recovery.  Exclusion criteria could be 
modified to only enrol patients likely to contribute to final result, however this 
will prolong recruitment.  In an attempt to make more efficient use of a 
complete trial data set, two or more endpoint cut offs can be created.  Stroke 
trialists have successfully created and used such trichotomised outcomes 
assessment.(77) 
 
More complex statistical analyses that make use of the complete spread of 
disability represented by mRS have been proposed.(78)  In the recent neuro-
protective trials of NXY-059 (SAINT I and II)(79) distribution of disability across 
mRS were compared in the two trial arms.  The precise statistical calculations 
employed for this analysis have been criticised,(80) (81)however the underlying 
premise of measuring change across the complete scale remains valid.  This 
“sliding” outcome assessment makes use of a concept of prognosis adjusted 
endpoint analysis.  More complex prognosis adjustment can be performed based 
on markers of initial stroke severity.  The beneficial effects on trial power of 53 
prognosis adjusted endpoints have been demonstrated using data from the 
neuro-protective study GAIN.(78) 
 
To allow detection of meaningful clinical effects with realistic patient numbers, 
trialists now often combine a number of “hard” clinical events into one global 
endpoint.(82)  Such an approach should give a more comprehensive analysis of 
recovery, allowing for measures of impairment, activity and perhaps even 
participation in a single scale.  Choice of constituent components is crucial for a 
global endpoint as the statistical power will be limited by the least efficient 
scale included.  Although popular in the stroke literature(83) and recommended 
in certain guidelines,(84) the use of global endpoints has been criticised for 
mixing conceptually distinct recovery descriptors.(82)  Ultimately such an 
approach provides an abstract result that is less immediate than a single well 
defined outcome.   
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Conclusion and hypotheses of the thesis 
 
The continuing advancement of acute and chronic stroke care is dependent on 
ongoing collection of robust clinical trials outcomes data.  In this regard 
functional endpoints are preferable for assessment of a disabling conditioning 
such as stroke.  Of the many scales available to measure functional outcome 
across the domains of impairment; activity; participation and quality of life, the 
modified Rankin Scale (a measure of global activity) is arguably the optimal 
assessment tool.  Although not originally developed for use in stroke trials, 
Rankin’s original stroke scale and its subsequent modification have been used in 
a number of pivotal stroke trials.  A literature on the clinimetric properties of 
the mRS exists and suggests good validity and responsiveness.  A potential 
limitation of mRS is its poor reliability.  Inter-observer variation and 
misclassification can ultimately impact on the power of a trial to detect a 
treatment effect.  Various methods of statistical analysis can improve the 
strength of mRS as a trial endpoint.  However, combining appropriate statistics 
with improved reliability of raw outcomes data would be more powerful still. 
 
In this thesis, use of mRS in the contemporary stroke literature will be described 
along with summary of the available literature on mRS reliability.  Reliability of 
mRS in a mock clinical trial setting will be explored along with the properties of 
mRS derived from patient case sheets.  Finally the potential effects of methods 
to improve reliability of mRS will be described including use of video based 
training and offline assessment of disability. 55 
 
Chapter two 
 
 
Reliability of the modified Rankin Scale 
 
 – a systematic review 56 
Introduction 
 
As discussed in chapter one, a perceived weakness of mRS grading has been the 
potential for inter-observer variability in assigned grades.  Problems of reliability 
may be inherent in the scale - mRS has been criticised for its relative lack of 
structure.   Rankin grades encompass a broad range of potential outcomes and 
boundaries between grades are poorly defined relative to other outcome 
assessment instruments.  Poor reliability is not a serious issue when the scale is 
used clinically, as one observer will chart functional change.  However, mRS is 
principally used as a tool for clinical trials and in a large scale study involving 
many raters reliability becomes more important.   
 
Attempts to quantify the reliability of mRS have been reported by several 
international groups, with conflicting results.(20;63)  Clinimetric studies of 
outcome scales are often small in comparison to the clinical trials in which these 
outcome scales are used.(81)  Thus single trials aiming to describe the properties 
of an assessment tool may not be adequately “powered” to answer the question 
of interest.  In any field where the evidence is based on several small scale 
studies, systematic review and meta-analysis can provide useful summary data. 
 
As previously discussed many methods of mRS administration exist and the 
optimal methodology for mRS assessment remains to be established.  Traditional 
mRS interview is conducted “face to face” with study personnel.(20)  Differing 
groups have attempted to improve reliability of stroke outcome scales using 
techniques such as standardising the interview process(62); providing training in 
use of the scale(46) or using video based technologies to allow remote 57 
assessment of mRS.(85)  To date the potential for such interventions to impact 
upon inter-observer variability of mRS is poorly described. 
 
The recent years have seen an increase in the number of studies exploring 
clinical properties of mRS and other scales.(17)  Previous reviews of stroke 
scales have concisely summarised important English language studies of mRS 
reliability.(31;86)  However, clinical trial use of the mRS is international.(87;88)  
Similarly, mRS is often employed by research nurses and professions allied to 
medicine.(89)  A contemporary, systematic review of the international literature 
including allied health care journals would compliment the ongoing work in this 
area.      
 
I sought to systematically review the literature concerning mRS reliability, 
collate relevant studies and perform meta-analysis to better understand the 
reliability of mRS as a stroke outcome tool. 58 
Methods 
 
Two clinical researchers with a background in stroke (TJ Quinn, J Dawson) 
independently reviewed the literature.  To date there are no specific guidelines 
on systematic review and meta-analysis of studies reporting clinimetric 
properties of scales.  Throughout the process I adhered to the PRISMA(90) and 
MOOSE guidelines for conduct of systematic review and meta-analysis in clinical 
trials and observational studies.(91)  In brief, these guidelines contain 
specifications for reporting analyses of observational studies in epidemiology, 
including search strategy, assessment of study quality and structuring discussion. 
 
Eligibility Criteria and Study Selection 
Participants: Study populations had to include human stroke survivors only. I 
used no restrictions for the mRS assessor and specifically did not exclude studies 
on the basis of background or training of observers. 
Study methodology: All studies purporting to measure mRS reliability through 
patient interview (inter or intra-observer variability of mRS scoring) were 
reviewed with no specific restrictions on the basis of study design, intervention 
or language.   
Outcomes: No restrictions on the basis of mRS assessment methodology were 
applied.  Studies using mRS and derivatives: Rankin Scale (RS)(92) and Oxford 
Handicap Scale (OHS)(93) were included for review.  However, only studies of 
mRS were included in the final analysis.  
 59 
Search Strategy 
A comprehensive battery of cross-discipline electronic databases were 
interrogated: AMED 1985 – 2008; British Nursing Index 1985 – 2008;  CINAHL1981 - 
2008;  Embase 1980 – 2008; Health and Psychosocial Instruments 1985 - 2008; 
Internurse.com 1995 – 2008; Medline 1950 – 2008; PsychINFO 1967 – 2008. 
 
Keywords were formulated using MeSH headings and study specific terms and 
were designed to be as inclusive as possible.  : Stroke*; Cerebrovasc*; Modified 
Rankin*; Rankin*; Oxford Handicap*; Observer variation* 
 
In addition to the electronic database search, contemporary reviews and key 
reference works were hand searched.(17;31)  To identify studies not yet in print, 
proceedings of scientific meetings for the period Jan 2006 – Nov  2008 were hand 
searched (American Stroke Association - International Stroke Conference; 
European Stroke Conference; World Stroke Organisation - World Stroke Congress; 
British Geriatric Society – annual scientific meeting).  Bibliographies of all 
retrieved articles were searched for further references and the process was 
repeated until no new articles were found.   60 
 
Abstracts were reviewed for appropriateness to the study question.  I retrieved 
the full text of any article that either reviewer believed may be relevant, data 
were extracted according to pre-specified criteria.    Appropriateness of studies 
to be included was decided by consensus. 
 
Where potentially relevant data were not available in the published manuscript, 
electronic or postal contact with the authors was attempted.  For those studies 
not published in English, professional translation services were used.  
 61 
Statistics 
As discussed in Chapter one, reliability is both a measure of consistency in multi-
item scales and a measure of reproducibility of results across differing test 
subjects or observers.  As a single item scale, internal consistency of mRS can be 
assumed.  Quantifying the reproducibility of repeat scoring between graders 
gives inter-observer variability.   
 
Reliability of mRS van be quantified using a number of statistical techniques.  
Inter-observer variability is traditionally described using either kappa (k) 
statistics or simple percentage agreement between observers.  Some studies 
have used quadratic “weighting” of kappa statistics (kw) to quantify degree of 
disagreement across the ordinal scale.  To allow for comparison and where 
available data permitted, both k, kw and percentage agreement were derived 
from the included studies.   
 
Based on previous work suggesting a beneficial effect of a structured interview 
approach(62) I planned the analysis to compare “structured” and “traditional” 
mRS.  A one group descriptive study using average absolute difference with a 
fixed effects model was performed using MIX software version 1.7 (www.mix-for-
meta-anlaysis.info).  [last accessed January 2010] 62 
Results 
The review profile is detailed in Figure 2.  From 3461 original titles, 312 
abstracts were eligible for review, 31 (20;62-64;70;72;85;87;93-114) studies 
were initially considered for inclusion and 10 studies involving 587 patients were 
included in the final analysis. (20;62-64;87;94;97-99;114) (Table 1)   
 
Two reports required translation (German and Portuguese)(87;114).  For one 
report(114) the authors provided additional data not available in the published 
manuscript and these have been included in the final analysis.  Other authors did 
not reply or were unable to provide additional information and for this reason 
certain data are missing from results tables. 
 
Of the reports considered, reasons for exclusion included but were not limited 
to: use of mRS in a non-stroke population (n=1)(102); use of outcomes other than 
mRS (n=5)(93;100;103;106;113;115) and use of dichotomised (favourable / non-
favourable) mRS outcome with no corresponding non-dichotomised data 
(n=2).(70;105)  In 5 reports, mRS data were reported with no patient interview, 
for example mRS derived from patient case-record or from a video based 
training exercise.(85;95;96;101;104)  A full description of all complete 
manuscripts considered and reasons for exclusion is provided in the appendix.   63 
 
For the purposes of presenting a comprehensive analysis of mRS reliability, I 
have included my own mRS studies in the systematic review.  A full description 
of the methodology and results of these studies will be presented in chapter 
four.  To avoid confusion, in the thesis my departmental study of mRS reliability 
(chapter four) will be referred to as the “study” and the data presented in this 
chapter will be referred to as the “meta-anlaysis”.  For reference the 
corresponding figures for mRS reliability if the departmental study is not 
included would be: 
Inter-observer reliability mRS (traditional approach) k=0.43 (0.39 – 0.50). 
Inter-observer reliability mRS (structured approach): k=0.65 (0.58 - 0.73). 
Intra-observer reliability mRS: k=0.91 (0.83 - 0.99). 
 
Inter-observer variability of mRS described in the included studies varied from 
“near perfect” (kw=0.95) to “poor” (k=0.25). (Table 2a/2b)  
 
In the included studies, multiple methodologies were used to administer mRS 
and study its properties. (Table 1)  Previous reports have suggested that factors 
such as: timing of assessment (acute or post discharge from hospital)(116;117);  
background and training of observers(118); native language(96); use of a 
proxy(119)
 and use of structured interview(62) can impact on stroke outcome 
scales or specifically influence reliability of mRS.  These data were extracted for 
the included studies if available.(Table 1)  Three studies purported to measure 
intra-observer variability of mRS.(63;94;97) (Table 3) 64 
 
Figure 2: Review profile for mRS reliability literature search. 
3461  Citations returned 
from literature 
search 
Abstracts included 
for further review 
312 
Studies reviewed 
in full 
31 
Studies included 
in final review  10 
10 studies identified from 
bibliographic review  
Rejected 
No mRS endpoints 109 
No inter-observer study 
86 
Review 26 
Repeat citation 70 
Rejected 
No mRS endpoints 6 
No inter-observer study 6 
Review 1 
Dichotomised mRS 2 
Non stroke patients 1 
No patient interview 5 
Rejected 
3149 not relevant 
Search terms 
 
stroke* OR cerebrovasc*           observer variation* 
AND               AND 
modified Rankin* OR Rankin* OR Oxford Handicap*  65 
 
Table 1: Studies of mRS reliability, with reference to study 
methodology. 
 
“Medical assessors” are stroke physicians or other clinicians;  
“S.I” Structured Interview 
 “Timing”: “Acute” any assessment performed within first seven days and while 
still hospital inpatient; “Chronic” represents all other assessments 
 
N/A information not available  
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 Table 2a: Reliability of traditional mRS as measured by kappa 
statistics and percentage agreement between observers. 
    
Kappa statistics are presented as standard kappa (k) and with quadratic 
weighting (kw).  Corresponding 95% confidence intervals are also given. 
 
 “N/A” – data not available  
 
 
Study  Kappa (k)  Weighted (kw)  Agreement (%) 
van Swieten 1988  0.56 
(0.45 - 0.68) 
0.91 
(0.71 - 1.00) 
65% 
Wolfe 1991  N/A  0.87 
(0.84 - 0.97) 
80% 
Berger 1999  0.56 
(0.41 - 0.71) 
0.88 
(0.58 - 1.00) 
N/A 
Wilson 2002  0.44 
(0.29 - 0.62) 
0.78 
(0.53 – 1.00) 
57% 
Newcommon 2003  0.72 
(0.55 - 0.89) 
N/A 
 
N/A 
Wilson 2005  0.25 
(0.16 - 0.35) 
0.71 
(0.53 - 0.88) 
43% 
Gur 2006  N/A  0.95 
(0.89 - 1.00) 
N/A 
de Canada 2006  0.45 
(0.31 - 0.60) 
0.70 
(0.58 - 0.82) 
58% 
Meyer 2008  N/A  0.90 
(0.59 - 1.00) 
N/A 
Quinn 2009  0.64 
(0.48 - 0.79) 
0.91 
(0.65 - 1.00) 
72% 
TOTALS  0.46 
(0.41 – 0.51) 
0.91 
(0.86 – 0.93) 
60% 68 
Table 2b: Reliability of mRS using a structured interview approach as 
measured by kappa statistics and percentage agreement between 
observers. 
 
Kappa statistics are presented as standard kappa (k) and with quadratic 
weighting (kw). Corresponding 95% confidence intervals are also given. 
 
 
“N/A” – data not available  
 
 
 
Study  Kappa (k)  Weighted (kw)  Agreement (%) 
Wilson 2002  0.70 
(0.56 - 0.85) 
0.93 
(0.67 - 1.00) 
78% 
Newcommon 2003  0.34 
(0.17 - 0.55) 
N/A  50% 
Wilson 2005  0.74 
(0.64 - 0.84) 
0.91 
(0.73 - 1.00) 
81% 
Quinn 2009  0.50 
(0.34 - 0.68) 
0.74 
(0.455 - 1.00) 
63% 
TOTALS  0.62 
(0.56 – 0.69) 
0.87 
(0.75 – 1.00) 
73% 69 
Table 3: Studies of intra-observer variability in mRS as measured by 
kappa statistics and percentage agreement between observers. 
 
Kappa statistics are presented as standard kappa (k) and with quadratic 
weighting (kw).  Corresponding 95% confidence intervals are also given. 
 
 
“N/A” – data not available  
† = average across structured and standard interview approaches. 
 
Study  Kappa (k)  Weighted (kw)  Agreement (%) 
Wolfe 1991 
 
N/A  0.95 
(0.88 - 1.00) 
 
86% 
Wilson 2005 
 
0.83 
(0.66 - 1.00) 
 
0.96 
(0.68 - 1.00) 
 
91% 
Quinn 2009 
 
0.72 
(0.61 - 0.82) 
 
0.93 
(0.81 - 1.00) 
 
77%† 
TOTALS    0.94 
(0.88 -1.00)  
84% 
 70 
Variability in mRS was described using k statistics (n=7)(20;62-64;87;94;114) kw 
(n=8)(20;62;63;87;97-99;114); intra-class correlation coefficient (ICC) 
(n=2)(87;114) and percentage agreement (%). (n=5).(20;62;63;94;97)  For all 
included studies there were insufficient data presented in the original reports to 
allow “back” derivation of other measures of reliability.  
 
Inter-observer variability of mRS varied from “near perfect” (kw=0.95) to “poor” 
(k=0.25) in the original descriptions. (Table 2a/2b)  Use of the structured 
interview was not consistently associated with improved reliability, with 
weighted kappa similar for the two approaches (structured mRS:kw=0.87; 
traditional mRS:kw=0.90). (Table 2a/b) 
 
In the included studies, diverse methodologies were used to administer mRS and 
study its properties. (Table 1)  No study met the “minimum” criteria to allow 
adequate assessment of quality: no description of patient selection (n=5); no 
data on blinding between assessors (n=5); inadequate description of mRS 
methodology (n=2); no description of location / timing of mRS (n=2).  As a result 
I decided to include all relevant studies regardless of poor methodological 
quality or potential bias. 
 
Three studies purported to measure intra-observer variability of mRS(62;94;97) 
with 162 patients included.  Overall intra-observer reliability was very good 
kw=0.94. (Table 3)  
 71 
 
Discussion 
 
The potential for variability to impact on the utility of mRS as a stroke outcome 
scale has been appreciated since its inception.(20)  Previous studies of mRS 
variability have described differing results.(63;97)  This review suggests that 
overall reliability of standard mRS is moderate but there remains potential for 
improvement.  There was some suggestion in the combined data that use of a 
structured interview may improve reliability, however the apparent benefits 
were lost when “weighted” kappas were applied.  The non-parametric nature of 
kappa and its derivatives does not allow for comparative meta-analysis and so 
the safest conclusion is that structuring mRS may partly improve mRS reliability 
but effects have not been consistent across studies.   
 
It is interesting that those studies with larger numbers of patients and observers 
reported poorer reliability.  The importance of maintaining inter-observer 
reliability in a contemporary clinical trial becomes readily apparent when the 
number of potential endpoint assessors is considered.  For a modest sized phase 
III clinical trial, several hundred patients may have to be enrolled.  Outcome 
assessment for such a trial will require a number of assessors at numerous sites.  
In the recent SAINT trials of the putative neuro-protectant NXY-059, over one 
thousand assessors from twenty-five countries were trained in outcome 
assessment for the study.(120)  In comparison numbers included in reliability 
studies are small, in this meta-analysis median number of patients was less than 
fifty with median two observers from a single site.  If we are to better 
understand the impact of mRS reliability on contemporary clinical trials, the 
ideal study methodology would involve a series of trained observers of differing 72 
backgrounds and from differing international centres, assessing mRS on pre-
selected patients at a fixed time-point following discharge.  Only one study in 
my meta-analysis approaches this “ideal” and it reports a concerningly low 
reliability for standard mRS.(63)   
 
Factors internal and external to the mRS interview may impact upon reliability.  
As well as structuring the interview, previous reports have proven or suggested 
that: timing of assessment (acute or post discharge from hospital)(121);  
background and training of observers(118;122); native language of assessor and 
patient(123) and use of a proxy(73;119;124) can impact on reliability.  There 
was considerable heterogeneity between studies in all these areas and this may 
have impacted upon results.  As example, only my own departmental study made 
use of a recognised mRS training resource.  This study reported no beneficial 
effect of structured interview, suggesting that the structured approach may be 
unnecessary if assessors are adequately trained.  Collation of studies with 
fundamental differences in methodology potentially weakens the meta-analysis, 
but is perhaps necessary for mRS work.  As will be described in the next chapter, 
clinical trials report substantial heterogeneity in mRS assessment with no 
consensus as to optimal approach.
 
 
The quality of included studies also varied.  For all studies certain data were 
incomplete for important contributors to trial quality such as blinding and 
patient selection.  This lack of detail is unfortunate but perhaps not surprising.  
Standardised criteria such as the CONSORT
 (http://www.consort-
statement.org/) [last accessed January 2010] statement have improved 73 
reporting of clinical trials.  No equivalent, universally accepted criteria for 
reporting of reliability / clinimetric studies are currently available.   
 
Heterogeneity was further evident in the statistical methods employed in 
reliability studies.  Several techniques have been used to describe reliability.(36)  
Four methods of describing reliability were used: kappa; weighted kappa; intra-
class correlation coefficient and percentage agreement.  Although all methods 
are appropriate, the resultant data are not readily interchangeable.  The ideal 
would have been to access individual patient data from each of the trialists, 
however these data were not available.  It is interesting that more authors chose 
to present data as “weighted” kappa.  For a rating scale where differences 
between observers are unlikely to be of more than 2 grades, a quadratic 
weighting system can “inflate” the final kappa and this was demonstrated in my 
data.  My own use of statistics demands some discussion.  No universally 
accepted method for analysis of multiple kappa statistics from differing 
populations has been described.  Recognising this limitation I used a group 
analysis technique that made the fewest assumptions of the underlying data.   
 
Accepting these limitations my meta-analysis does have certain strengths.  My 
literature searching strategy was as comprehensive and systematic as possible.  
The spread of reliability estimates obtained suggest no overt publication bias, a 
formal analysis of publication bias such as funnel-plot was not performed.  I 
considered a number of reports from non-English and “non-medical” sources and 
certain of these were included in the final analysis.  I was inclusive in my 
approach to reports, although excluded studies that would not help describe the 
variability of mRS in a clinical trial setting.  Studies using the original Rankin or 
OHS were excluded as these scales are no longer used in contemporary stroke 74 
research (for reference in comparable inter-observer reliability studies RS gave 
kw 0.79(113); OHS kw 0.72(93)).  Similarly, I excluded those studies where mRS 
was derived with no patient contact (from case notes; postal questionnaire).   
 
I also present studies of intra-observer variability of mRS, suggesting excellent 
reliability.  Here again problems in study methodology limit the strength of 
conclusions that can be drawn.  Two studies measured mRS at distinct periods in 
the patient’s recovery and as such are prone to recall bias and the potential for 
functional ability to change between assessments.(63;97)  My own study used a 
novel based approach that will be described in detail in chapter four.  Although 
theoretically interesting, intra-observer variability of mRS assessment may be of 
less relevance to clinical trials, where primary outcome assessment is usually 
performed once only.   
 
There remains uncertainty regarding the reliability of mRS as an outcome 
measure.  Available reliability studies are likely underpowered and have design 
flaws that limit their generalisation.  Those studies closest in their design to 
large scale contemporary clinical trials demonstrate potentially significant inter-
observer reliability.  These data suggest that researchers should conduct further 
studies using methodologies that “mimic” large scale clinical trials.  While we 
await definitive data on mRS reliability we must acknowledge that a degree of 
inter-observer variability is inherent in standard mRS grading and further work 
on methods to reduce variability will be equally important.   75 
Chapter three 
 
 
Functional outcome measures in contemporary  
 
stroke trials – a systematic review 76 
 
Introduction 
 
Accurate and meaningful assessment of patient outcomes is essential for 
observational studies and interventional trials.(125)  As stroke represents the 
leading cause of adult disability(56), an important consideration for any stroke 
trial is valid quantification of functional outcomes.  Some discussion of the 
clinimetric properties of functional outcome scales and summary of the debate 
regarding the relative strengths and limitations of diverse assessment 
instruments has already been presented.  At present there is no consensus on 
optimal outcome measure(s) for use as clinical trial endpoint.   
 
Post stroke recovery can be described in a number of domains.  Use of the WHO 
international classification of functioning, disability and health (15)
  
(http://www.who.int/classifications/icf/site/icftemplate.cfm.) [last accessed 
January 2010] as a framework for describing post stroke recovery states was 
discussed in chapter one.  Multiple assessment scales exist to describe 
impairment; activity (formerly disability) and societal participation (formerly 
handicap). For stroke trialists, stroke specific; bespoke and generic outcome 
assessment scales exist.(107)  Thus, there is potential for heterogeneity both in 
the domain measured and within that domain. 
 
In addition to heterogeneity in choice of outcome measure, there is further 
potential for heterogeneity in the methodology used to collect and describe 
functional data.  For many of the popular outcome measures, diverse 
approaches to data collection and statistical analysis have been employed, with 
little formal guidance on best practice.  Methods to improve reliability and 77 
validity of outcome assessment, such as observer training, are increasingly 
available.(46)  However, the frequency of their use in clinical trials is not well 
described. 
 
Some authors have suggested that heterogeneity in outcomes assessment is a 
particular problem in the field of stroke rehabilitation literature, although at the 
time of writing this has never been quantified.(126;127)  In fact, there are 
limited data on the extent of outcomes heterogeneity in all areas of stroke 
research.   
    
Previous review of functional outcome assessment in acute stroke trials  (1995 – 
1998) reported that the BI was the most frequently used end-point.(57)  Given 
the last decade’s exponential increase in stroke related research, an updated 
review of outcome measures in the stroke literature was required.   
 
I sought to describe the frequency of use, and methodology of application 
employed for functional outcome measurement in contemporary stroke 
literature. 
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Methods 
 
I performed a literature review of stroke trials contained in a selection of high 
profile international journals, targeted at general medical; neurology and stroke 
specific readerships.  Choice of publication was based on impact factor; target 
audience and frequency of publication of stroke related literature.  The aim was 
to describe outcomes particularly relevant to acute stroke trials and I did not 
include rehabilitation specific rehabilitation journals.  A similar analysis looking 
at the rehabilitation literature has recently been completed.(128) 
 
Following informal review of a number of titles I chose to restrict analysis to the 
following publications: “Stroke” (Lippincott, Williams and Wilkins for the 
American Heart Association); “Neurology” (Lippincott, Williams and Wilkins for 
the American Academy of Neurology); “Lancet” and “Lancet Neurology” 
(Elsevier); “New England Journal Medicine” ( NEJM - Massachusetts Medical 
Society) and “Journal of the American Medical Association” ( JAMA - American 
Medical Association).  The chosen publications were hand searched and titles 
were screened.  Abstracts of potentially relevant papers were independently 
reviewed.  To ensure no potential manuscripts were missed I reviewed all 
journal content, including letters and short reports.  In addition, an independent 
Medline search was performed across each title using the key terms “stroke” and 
“cerebrovascular accident” and limited to “human studies”; years “2001 – 
2006”.   79 
 
A “functional outcome” was defined as a quantified measure across any of the 
domains of impairment, activity or participation.  For this analysis, within the 
domain of participation I included those scales that purport to measure quality 
of life or related outcomes.  The functional measure did not have to be the 
primary endpoint of the trial.  A “stroke trial” was defined as any active 
intervention in stroke patients (ischaemic or haemorrhagic) or primary 
prevention.  I made no assessment of the quality of the trial’s aims, design or 
conclusions and included any manuscript that purported to assess an active 
intervention.  I limited the literature search to articles published in the period 
Jan 2001 to December 2006 inclusive, including only those trials that involved 
human subjects.   
 
Two independent researchers (TJ Quinn, J Dawson) reviewed all articles 
potentially meeting inclusion criteria.  Final choice of included manuscripts was 
by consensus.  Separate papers using the same trial dataset were only included if 
the functional outcomes described differed.  Complete manuscripts were 
reviewed and relevant data extracted on to a standard form.  Where additional 
methodology was described in on-line or paper supplement this was also 
accessed.  As the purpose of this review was to document outcome assessment 
tools as described in the published literature, no attempt was made to contact 
authors of manuscripts where description of methodology was unclear. (Figure 3) 80 
 
The following data were collated: intervention; year of publication; journal; size 
of study population; primary outcome measure; functional outcome(s) assessed; 
functional domain(s) assessed and for each functional assessment used I 
recorded: timing of assessment and method of assessment including details of 
any training offered.  Where the nature of an assessment instrument was not 
clear I sought the original description of the scale or referred to reference 
works.(129) 
 
I performed simple statistical analyses to compare functional outcomes 
assessment in general medical and stroke/neurology specific journals; comparing 
trials utilising an investigational medicinal product (IMP) and non-IMP trials.  
Proportions were compared using chi-square testing. All analyses were 
performed using Minitab software (version 14.0, Minitab Inc, PA, USA). 81 
 
 
 
 
 
 
3731  Potentially relevant 
citations 
Abstracts included 
for further review 
160 
Studies reviewed 
in full  126 
Rejected 
 No functional outcome 
assessment 34  
Phase I trials   n=4 
Phase II trials   n=46 
Phase III-IV trials   n=20 
Non-IMP trials   n=56 
Rejected 
3571 did not meet inclusion 
criteria 
Search terms 
stroke* OR cerebrovasc*            
LIMITS            
Human studies AND publication year “2001 – 2006” 
Figure 3: Review profile for functional outcomes literature 
search.  
 
Search included only pre-specified journals: 
Journal of the American Medical Association 
Lancet, Lancet Neurology 
Neurology, New England Journal of Medicine,  
Stroke 82 
 
 
Results 
 
From a total of 3731 screened articles, 160 were reviewed in full and 126 were 
considered suitable for inclusion in the analysis.  Included studies were a mix of 
pre-clinical, clinical and non-IMP interventions (phase I 4; phase II 46; phase 
III/IV 20; and non-IMP studies 56).  Study interventions included (but were not 
limited to) anti-thrombotic drugs 12; thrombolytic treatment 32; putative neuro-
protectants 19; rehabilitation strategies 29; stenting or mechanical intervention 
8 and stroke unit care 4.  There were three primary prevention studies with 
stroke related functional outcomes.  Median study size was 100 patients (range 9 
to 7121; IQR 367).  The numbers of trials from the chosen titles were: JAMA 5 
trials; Lancet 12; Lancet Neurology 3; Neurology 33; NEJM 6; Stroke 67. 
 
Forty-seven outcome measures were described in the included studies (full list 
available in appendix D).  In 100 studies, an assessment of functional outcome 
was used as the trial’s primary endpoint.  The median number of functional 
outcomes recorded per trial was 2 (range 1-9; IQR 2).  The most frequently used 
outcome measure was mRS, followed by BI and NIHSS (Table 4).  A composite or 
global scale that incorporated a number of outcome measures was used in 10 
papers; in 3 papers a bespoke scale created by the authors was employed.  
Seventy-seven studies purported to measure impairment; 103 activity and 11 
participation.  Six trials described recovery across the three domains.  The most 
frequently used impairment scale was the NIHSS; the most frequently used 
activity scale was the mRS; the most frequent participation measure was SIS. 
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Table 4: Frequency of use of functional outcomes assessment scales 
in contemporary stroke trials.  
 
“1
o endpoint” is number of papers where outcome measure is used as the 
studies primary endpoint, does not include studies where measure is part of a 
combined “global” endpoint.    
 
Outcome Measure  Number of Trials 
Instrument Used 
1
o Endpoint 
Modified Rankin Scale  81 (64.3%)  33 (26.2%) 
Barthel Index  51 (40.5%)  10 (7.9%) 
Nat. Institutes of Health Stroke Scale  35 (27.8%)  15 (11.9%) 
Scandinavian Stroke Scale  11 (8.7%)  2 (1.6%) 
Glasgow Outcomes Scale  8 (6.3%)  2 (1.6%) 
Frenchay Activities Index  6 (4.7%)  1 (0.8%) 
Timed Walk/ 6 Minute Walk  6 (4.7%)  3 (2.4%) 
EuroQOL  4 (3.1%)  0 
Fugl-Meyer Motor  4 (3.1%)  4 (3.1%) 
Wolf Motor Functional Test  4 (3.1%)  1 (0.8%) 
Rivermead Mobility Index  3 (2.4%)  1 (0.8%) 
Short Form 36  3 (2.4%)  1 (0.8%) 
Stroke Impact Scale  3 (2.4%)  0 
Berg Balance Scale  2 (1.6%)  1 (0.8%) 
Canadian Stroke Scale  2 (1.6%)  1 (0.8%) 
Tinetti Balance Assessment Tool  2 (1.6%)  1 (0.8%) 84 
 
Data on timing of outcome assessment were available for 113 trials.  Median 
time from ictus to assessment was 90 days (range 2 days – 5 years; IQR 150).  
Only 4 trials described use of training in outcome assessment.  Thirty-four 
papers described the methodology used to collect functional data (Table 5).  
Published descriptions of functional outcome measurement methodology were 
infrequent and did not increase from 2001 – 2006 (P=0.889). 
 
Comparing IMP and non-IMP studies, a greater total number of outcome 
measures were used in the latter (non-IMP 47 measures across 56 trials; IMP 15 
measures across 70 trials).  A greater number of functional measures were 
described per trial for non-IMP studies (median=3 versus median=2 P=0.029).  
There were no significant differences in number of papers describing recovery 
using impairment; activity or participation scales (IMP trials: impairment 41; 
activity 63; participation 3.  Non-IMP trials: impairment 36; activity 40; 
participation 3 P=0.529).  There were no differences in number of papers 
describing trial methodology (non-IMP 33.9%; IMP 32.9% P=0.256). 
 
For the most popular outcome measure (mRS) I collated information on data 
handling and statistical analysis.  The majority of studies (n=55) collected mRS 
data at 90 days post event (range 5 days to two years).  In 46 trials outcomes 
were dichotomised (mRS 0-1 – 16; mRS 0-2 – 18; mRS 0-3 – 9; mRS 0-4 – 3); 11 
trials used trichotomised outcomes.  MRS was the most popular outcome 
measure for each year studied, frequency of use did not significantly change 
across 2001 – 2006 (Table 6, P=0.426).  Papers presented in general medical 
journals were more likely to use mRS as clinical endpoint (Medical journals 
18/23; neurology journals 61/103 P=0.035). 85 
 
Table 5: Methodologies for assessment of stroke functional 
outcomes. 
 
 
Method for collecting functional outcomes data  Number of trials 
Case-sheet review  4 (3.1%) 
Face to face interview  13 (10.2%) 
Postal survey  2  (1.6%) 
Questionnaire  3  (2.4%) 
Structured interview  2  (1.6%) 
Telephone interview  17 (13.4%) 
No description of method  93 (73.2%) 86 
Table 6: Numbers of published stroke trials  
a) Providing comprehensive description of outcome assessment 
methodology employed.  
b) Using modified Rankin Scale as outcome measure. 
 
 
 
Year  (a)  Methodology 
described 
(b) mRS used as outcome 
measure 
2001   n=18  5  (27.8%)  10 (55.6%) 
2002   n=14  6  (42.9%)  6  (42.9%) 
2003   n=16  5  (31.3%)  10 (62.5%) 
2004   n=15  4  (26.7%)  11 (73.3%) 
2005   n=32  11 (34.4%)  23 (72.0%) 
2006   n=31  8  (25.9%)  21 (68.0%) 87 
 
Discussion 
 
There is an increasing variety of assessment scales available to describe post 
stroke outcomes.  I found significant heterogeneity in functional outcome 
assessments across a number of high-impact medical journals.  This 
heterogeneity was evident in choice of outcome, method of application and 
analysis of data.  For many studies, description of methodologies used to collect 
outcomes data was incomplete or absent. 
 
My analysis confirms that mRS is now the most frequently used functional 
outcome measure in stroke trials.  Where details of methodology were given, the 
majority of papers administered mRS at 90 days post event, used telephone-
based assessment and analysed data using dichotomisation. 
 
The University of Washington stroke centre describes 20 different outcome 
assessment scales in common use in the stroke trials. 
(http://www.strokecenter.org/trials/scales/scales-overview.htm.) [last 
accessed January 2010] My review of the recent stroke literature found 47 
outcome assessment instruments in current use.  These included a number of 
tools that are poorly validated or are recognised to have clinimetric weaknesses.  
Despite the variety of valid tools available, some authors continue to use their 
own bespoke assessment scales.   This substantial heterogeneity in trial end-
points makes meaningful comparisons between trials challenging and can 
preclude formal meta-analysis.   
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The majority of trials describe functional outcomes in terms of activity.  This is 
not surprising, as efficacious acute stroke treatments will show the greatest 
change on a suitably responsive impairment measure, this allows for adequate 
powering with smaller numbers.(39)  Surprisingly few studies attempted to 
describe participation, although arguably this is the most meaningful measure 
for the patient.  This may represent the relative lack of established, robust 
instruments to quantify this domain.  It may also reflect a fear that beneficial 
treatment effects may be swamped by variation in opportunities for 
participation. Domains of recovery are not interchangeable.  In fact, 
relationships between impairment, activity and participation measures are 
poorly understood.(130)   An argument can be made for describing recovery in 
more than one domain.  A small number of trials have taken this approach.  Six 
trials described outcomes across all three domains, either separately or 
combined into a single global outcome measure.   
 
For individual outcome measures there was heterogeneity in the methodology 
used to capture data.  This is perhaps unsurprising as for many of the outcome 
measures used there is little formal guidance on how to administer the tool.  I 
collated data on timing of assessment(131); use of training(85); background of 
assessor(108;132) and use of a standardised structured interview(62) - as each of 
these factors is known, or suspected, to impact on validity of outcome data.  
Comprehensive descriptions of methodology were infrequent, no trial was 
described in terms of all of the listed factors.  Where an attempt was made to 
describe methodology there was again marked heterogeneity.   
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It could be argued that full description of methodology is unnecessary as for 
many scales there is an agreed, albeit informal, approach to data collection 
among researchers.  While this may be true for certain, simple impairment 
scales, it is not true for the most popular tools.  Taking mRS as example, the 
scale has variously been applied using direct interview(20), telephone 
interview(64); video recorded interview(85); structured questionnaire(62) or 
through case-sheet derivation.(133)  In the majority of papers using mRS, no 
description of methodology was apparent.  It is likely that most of these studies 
used “traditional” face to face interview, however given the variety of 
assessment techniques available it is unacceptable to omit such details from 
manuscripts.  The optimal method for performing mRS grading is still debated, 
however it is recognised that mRS methodology can impact on the validity and 
reliability of the data collected.(31)  Thus, lack of clarity on grading techniques 
precludes critical assessment of trial quality.   
 
The lack of information on use of investigator training is concerning.  It is well 
recognised that training in use of an outcomes assessment tool improves 
reliability.(46)  A validated training program has been available for NIHSS scoring 
for many years(115); a specific mRS training package will be described in a later 
chapter.  It is disappointing then that only four trials specifically described 
training of assessors.  It is possible that training was utilised but not described in 
the methods section of the published report.  Word limits utilised in paper 
journals may force authors to remove sections of methodology they consider 
extraneous.  However, omission of a technique likely to impact on validity of 
data is clearly not acceptable and in the absence of any formal description the 
reader must assume training was not used.  The need for explicit description of 90 
training methods used could be incorporated into future CONSORT guidelines for 
presentation of clinical trials. 
 
The difficulty in defining clinically meaningful outcomes in trials of 
rehabilitation is well described.(134;135)  I found that non-IMP studies made use 
of a greater range of outcome instruments, and used more functional outcomes 
per trial.  However, there was no difference in quality of outcomes reporting.  
As rehabilitation is traditionally considered a more “holistic” specialty one 
would expect increased use of measures of participation.  My data do not 
support this assumption.  In interpreting these data, I recognise that no “power” 
calculation were performed and the modest numbers included may mask a true 
difference, I recognise also that the journals chosen for review did not include 
any rehabilitation specific titles. 
 
Previous authors have highlighted the lack of uniformity in numerical data 
handling procedures published in acute stroke trials.(136)  My review confirms 
heterogeneity in statistical analysis of functional outcomes data.  Taking mRS as 
example, the majority of papers dichotomised mRS to describe outcome - that is 
they transformed the ordinal categories into a binary outcome of good “or” poor 
outcome.  A range of mRS grades were used as cut-off point for defining good 
outcome, from mRS 1 to mRS 4.(137)    The rationale for using differing 
definitions of favourable outcomes is clear: expected “good” outcome from a 
condition such as malignant MCA infarct(138) will not correspond to expected 
“good” outcome from a transient ischaemic attack (TIA).(139)  However, 
dichotomising with no consistency between trials complicates comparison and 
meta-analysis.  More sophisticated methods of data handling have been proposed 91 
including use of global statistics, responder analysis and shift analysis and  
future trials will likely make more use of these techniques.(78;140) 
 
There are limitations in the data I have collected.  The large and increasing 
stroke literature precluded a comprehensive review of stroke outcomes across 
all published stroke studies.  I note that previous groups’ attempts to 
characterise acute stroke trials comprehensively have been unsuccessful(141)
 
due in part to the large numbers of published and unpublished studies in the 
field.(142)  Therefore I chose to limit my analysis to journals with a large 
international readership across the disciplines of neurology; stroke medicine and 
general internal medicine.  Thus my data are open to publication bias; however, 
the intention was to describe outcome assessment use in popular medical 
journals rather than across the complete stroke literature.  Although not 
comprehensive my search strategy was systematic.  I defined search terms of 
“functional outcome” and “stroke trial” in a manner that was robust but 
inclusive.  Such an approach is not without precedent and accepting these 
limits, my literature review still provided a mix of large-scale multi-centre 
trials; smaller hypothesis generating exercises and non-IMP interventions.  My 
intention was purely to describe current outcomes assessment methodology; I 
have not attempted to compare strengths and weaknesses of different 
instruments, discussion of this topic is presented in chapter one and 
contemporary published reviews are available.(17;86;143) 
 
Given the heterogeneity in outcome assessment scales that I have described, it 
could be argued that cross disciplinary stroke researchers should agree on a 
“core” set of outcome tools.  In the research setting a “common language” of 92 
instruments used would facilitate better use of the clinical information derived 
from these tools.  In a non-research clinical setting the use of a limited number 
of scales with which all members of the team are familiar would enhance 
communication between different professions and disciplines.   
 
The British Society of Rehabilitation medicine has recognised the benefits of 
such an approach and has developed a “basket of measures” – a series of expert 
selected assessment aids that they would recommend for routine use. 
(http://www.bsrm.co.uk/ClinicalGuidance/OutcomeMeasuresB3.pdf) [last 
accessed January 2010].  These measures were not stroke specific and may not 
applicable to acute stroke trials.   
 
An attempt to standardise stroke trial outcomes and in doing so promote 
collaboration can be seen in the recent Department of Health supported COSTAR 
project (Collaborative Stroke Audit and Research).  COSTAR are working towards 
agreed methodological standards including recommended approaches to 
consent, randomisation, blinding and assessment.  
(http://www.dh.gov.uk/en/Researchanddevelopment/A-
Z/Cardiovasculardiseaseandstroke/DH_4002086) [last accessed January 2010]. 
Recognising that complex interventions require multi-centre collaboration, pre-
planned collaboration between autonomous studies has been suggested, so 
called “epi-analysis”.  Such an approach requires standardisation of outcomes.  
 93 
As there is little specific guidance on outcome assessment, the lack of 
uniformity I have described is perhaps unsurprising.  For future trials, optimal 
outcome assessment should be based on established, clinimetric sound 
procedures, ideally with training available for assessors.  Regardless of the 
outcome scale chosen, trialists are urged to consider and describe fully the 
methodologies employed in assessment of stroke recovery. 94 
Chapter four 
 
 
Exploring the reliability of the  
modified Rankin Scale 
 95 
Introduction 
 
As demonstrated in the previous chapter, mRS is the most prevalent functional 
outcome measure in contemporary stroke literature.  Prior to any clinical or trial 
use, assessment scales should be proven “fit for purpose”.  Clinimetrics is the 
methodological discipline that describes clinical measurement quality.  Outcome 
scales are traditionally assessed in terms of responsiveness, validity and 
reliability.(26;144)  The original Rankin scale was not designed for clinical trial 
use and like many other stroke assessment tools, mRS became established as a 
study endpoint prior to any formal clinimetric assessment.(92)  Recent studies 
have quantified responsiveness of mRS(52) and proven excellent construct and 
convergent validity of the scale.(31;145) 
 
In the systematic review presented in chapter two, I have shown that a potential 
problem inherent in mRS grading may be inter-observer variability.  Poor 
reliability is a concern for trialists, as arguably for an instrument that will be 
used by many hundreds of raters in large-scale multi-centre clinical trials, 
reliability is the most important property of the scale.  My previous conclusion of 
heterogeneity in the degree of mRS variability, may be partly explained by 
differing study methodologies.  As trialists are principally concerned with the 
variability present in clinical studies, the most informative analysis of mRS would 
be conducted using current researchers working in a clinical trial setting and 
interviewing real stroke survivors.  Those few studies that have attempted this 
design, used only limited numbers of assessors and / or patients.(63) 
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Thus, there are several unanswered questions regarding reliability of mRS 
assessment.  Using a mock clinical trial design I set out to study the inter and 
intra-observer variability when mRS is applied by experienced and trained study 
personnel.  I further describe the effect of a structured interview format on 
properties of the mRS.  Finally, recognising that initial clinical judgement often 
influences final scoring in assessment scales, I described the ability of 
researchers to estimate disability from limited review, prior to formal mRS 
assessment.  
 
Methods 
 
Patients and assessors 
I approached sequential patients attending the Western Infirmary Glasgow, 
University Hospital cerebrovascular clinic for their routine post stroke 
assessment.  Clinic patients have usually been inpatient in the local acute stroke 
unit and typically attend for review at 90 days post stroke; however I did not set 
fixed time related or geographic exclusion criteria.  All patients were considered 
for inclusion.  If cognitive impairment or language problems precluded 
satisfactory mRS interview, a proxy (family member or carer) was used.  
Informed consent was given by all participants or designated proxy prior to 
recruitment and reconfirmed following the assessment.  The local ethics 
committee approved the study protocol.   
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To allow assessment of variability across a representative group I involved seven 
assessors: 4 stroke physicians and 3 research nurses.  All assessors had been 
trained and certified in mRS assessment
 using the bespoke training package (as 
outlined in chapter five) and all have considerable experience of mRS 
application in clinical trials. 
 
I used a stratified assessment technique to test the related hypotheses (Figure 
4).  The selection of mRS assessors; interview methodology used and selection 
for interview recording were all pre-specified using an online randomisation 
program (www.random.org/integers) [last accessed January 2010] and allocation 
was concealed from interviewers and patients using an opaque envelope system. 
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Figure 4: Schematic of evaluation process for mRS reliability 
assessment. 
 
 
A, B represent trained mRS assessors, selected from a pool of 7 research nurses 
/ stroke physicians.  Order of video interview (first or second in pair) and 
designation to A or B were determined by randomisation.  At three months, 
video recorded assessments were reviewed by the original interviewer and 
graded again. 
Stroke patients 
(n=100) 
Standard 
interview 
(n=51) 
Rater A/B 
Video 
Rater B/A 
Non video 
Rater B/A 
Non-Video 
Rater A/B 
Video 
Video mRS 
interview (n=99) 
3 month  
delay 
Structured 
interview 
(n=49) 99 
Statistical analysis 
 
Reliability was described with kappa (k) statistics - kappa statistics were chosen 
for primary analysis as clinicians are familiar with the test and as previous 
published studies of mRS reliability have used similar statistical techniques.   
 
Formal comparisons between kappa statistics are problematic, particularly if 
numbers in each group are not comparable.(34)  Therefore to allow for basic 
comparative analysis I also calculated the number of interviews where rater 
pairs agreed exactly on mRS, (expressed as percentage agreement) and 
compared values using chi-square testing.  Specific analyses performed for each 
hypothesis will be detailed in the relevant subsections.  All statistics were 
performed using Minitab software (version 14.0, Minitab Inc, PA, USA). 
 
Inter-observer variability for traditional mRS  
For each patient enrolled, two assessors allocated from the pool of seven 
performed mRS grading.  Interviews were performed using a standard mRS 
approach or a structured interview, with choice of methodology randomly 
allocated.  Thus patients had two independent assessments in succession, each 
using the same interview methodology (structured or standard mRS) and blinded 
to colleagues’ grading.  I used the previously validated, questionnaire style 
interview for the structured assessments as originally described by Wilson et 
al(62), with roughly half the assessments conducted using this structured 
interview approach.   
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This initial series of face to face paired interviews will be further referred to as 
“traditional mRS”.  I measured inter-observer agreement between the paired 
mRS assessments, first for all interviews and then with sub-analysis to compare 
structured interview against standard mRS.  I further evaluated duration of 
interview for the structured and standard mRS interview using paired “Student’s 
t” testing.   
 
Intra-observer variability  
One researcher from each interview pair was randomly selected for video 
recording.  Following advice from Media Services Department, University of 
Glasgow, audio-visual recording was captured using a portable digital camera 
(HDVR-HC1E 1080i digital HD video camera recorder - Sony, Japan) and stored on 
digital video disc using readily available image processing software (Windows 
Movie Maker - Microsoft, Washington USA).   
 
At a later date, the interviewer who performed the original mRS assessment 
viewed this recording and rescored mRS.  I left a minimum three month delay 
between interview and assessment of recording to reduce recall bias.  Repeat 
scoring was performed independently and raters had no access to their previous 
scores.  Assessment of intra-observer variability was made comparing all raters’ 
original, traditional mRS score to their subsequent video review score. 
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Estimating mRS  
To gauge the added value of formal interview, raters were asked to grade 
disability prior to beginning their formal mRS assessment.  This meant assigning 
a preliminary mRS using only such information as would be available in the first 
few seconds of patient interaction, for example assessment of patient mobility 
in the consulting room; or interaction with nurses or carers and initial 
conversation.  This score was recorded and sealed in an opaque envelope.  
Raters then conducted and scored the formal mRS assessment.  Properties of the 
preliminary mRS score were described by comparing these estimates to final 
mRS and by describing variability within the estimated scores 
 
Results 
 
Of 104 patients approached, 102 consented to mRS interview and video 
recording.  Of these, 100 video recordings were of sufficient technical quality to 
allow repeat grading and were included in the final analysis.  Patients reflected 
a heterogeneous group of stroke subtypes typical of 3-month survivors (total 
anterior circulatory stroke [TACS]16; partial anterior circulatory stroke [PACS] 
30; lacunar stroke [LACS] 43; posterior circulation stroke [POCS] 11; unclassified 
2).  Mean age was 69.8 (SD 12.9) years; mean NIHSS score at baseline was 5.5 
(SD 5.2) and median time since event was 12 weeks (IQR: 6 - 21).   Five patients 
had problems with communication such that assessment involved a proxy.  
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Inter-observer variability for traditional mRS  
Variability in traditional mRS grading was moderate (k=0.57) for the group of 
100-paired interviews, with least variability at extremes of mRS (Table 7).  Exact 
agreement in mRS was 67%.  I compared reliability from my study to 
independent data from other studies using the literature described in the 
previous meta-analysis, there was no significant difference between my data and 
other published studies (P=0.073).   
 
Of the traditional mRS assessments, 49 used a structured interview approach.  
There was no difference in spread of disability as graded on mRS between the 
two groups (p=0.699 on chi-square testing).  Use of the structured interview did 
not decrease variability (P=0.295; Tables 7).  Mean duration of mRS assessment 
was 4.9 (SD 2.4) minutes.  There was a significant difference between duration 
of structured (5.6 SD 2.5 minutes) and unstructured (4.2 SD 2.1 minutes) 
interviews (p=0.003).103 
 
Table 7: Group reliability of traditional mRS assessment. 
 
 
To quantify spread of disability the average number of patients scoring at each 
mRS grade is presented, these numbers were derived from total number of 
scores at a particular grade divided by the total number of assessors.  
Variability is described as un-weighted kappa (k). 
 
Modified Rankin 
Score 
Average no. of 
cases at this mRS 
Variability - k 
Traditional mRS 
0  16  0.70   
1  16  0.43   
2  33.5  0.51  
3  16.5  0.57   
4  15.5  0.66   
5  2.5  0.79  
Overall k  N/A  0.57 
Structured interview k  N/A  0.5 
Standard interview k  N/A  0.64 
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Intra-observer variability for mRS 
One patient withdrew consent for video assessment following recording, leaving 
ninety-nine video assessments that could be reviewed and scored by the original 
mRS assessors. Intra-observer reliability was good for the group; k=0.72; 77% 
complete agreement, this differs significantly from other published studies of 
mRS intra-observer variability (p<0.0001).  Intra-observer variability for 
individual raters were calculated, percentage agreement revealed no 
statistically significant difference between raters, although small numbers 
preclude definitive comparative statements and a trend towards differing 
reliability is seen (rater 1: 86%; rater 2: 89%; rater 3: 75%; rater 4: 40%; rater 5: 
63%; rater 6: 100%; rater 7: 91%). 
 
Estimating mRS 
A convenience (non-randomised) sample of preliminary mRS interviews was 
included.  As estimation of mRS is dependent on confidence in basic mRS 
administration, I included only the latter 40 mRS interviews in this analysis to 
eliminate any potential training effect.  Agreement between estimated and final 
mRS was 38%, reliability was poor k=0.16.  The median estimated mRS was 1.0 
(IQR 0-4), median final mRS was 2.0 (IQR 0-4).  Comparing estimated scores 
between the paired assessors, there was again poor agreement 30% and 
significant variability k=0.38. 
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Discussion  
 
Using a mock clinical trial design I assessed reliability of mRS across a large 
number of patients.  I have demonstrated substantial inter-observer and intra-
observer variability in mRS assessment.  Furthermore I have found that a 
structured interview approach does not significantly improve reliability and 
confirmed that researchers are poor at estimating mRS if they do not conduct a 
formal interview. 
 
Despite considerable experience in clinical use of mRS, the local team of 
clinicians and nurses show only moderate reliability in mRS grading.  This inter-
observer variability is in keeping with previous published estimates presented in 
chapter two.  With increasing use of mRS as trial end-point and ready availability 
of specific training resources some improvement in mRS reliability was 
expected.  Diverse study methodologies preclude any more definitive comment 
on these differences, suffice to say that problems with reliability represent an 
ongoing limitation of standard mRS as a trial endpoint.  In the absence of a pre-
training “control”, my findings do not allow us to comment on utility of the 
training resource or on any training effects associated with increasing 
experience of real life mRS administration.   
 
Variability was most apparent for mRS grades 1-4.  This is of particular 
importance for clinical trial endpoint analysis, where mRS outcomes are often 
dichotomised around these middle grades.(74)  Misclassification of endpoints 
increases the likelihood of type I and type II statistical error and decreases 106 
statistical power.  The potential impact of mRS variability on clinical trial results 
has yet to be modelled, but we must assume that poor reliability will influence 
final results.  Real life examples of trials compromised by variability in end-point 
classification are well recognised(37) and may be particularly relevant in the 
field of acute stroke.(28) 
 
Quantification of intra-observer reliability for clinical scales is challenging and if 
methodology is poor there is potential for bias.  Measuring test-retest variability 
over a short time period will be biased by observer recall of previous grading; 
delaying the second grading can allow for patient improvement or disease 
progression.  Previous published studies have not accounted for these sources of 
bias in their design and as such the negligible inter-observer variability they 
report for mRS should be questioned.(63;97)  The use of videos provides a more 
rigorous assessment of intra-observer reliability and may explain the significantly 
higher variability demonstrated.  As trialists are unlikely to be performing serial 
mRS over short time periods, it could be argued that proving intra-observer 
variability of mRS is of little clinical relevance.  However, I describe these 
findings as further evidence of the imperfections of standard mRS as an endpoint 
assessment tool. 
 
Use of a structured interview approach to mRS assessment did not reduce inter-
observer variability in this cohort.  The authors of one questionnaire style 
structured interview previously reported significant improvements in 
reliability(63); however other groups have failed to replicate these findings(64) 
and at present the structured interview is infrequently utilised by stroke 
trialists.  My results show that for experienced raters, fully trained in mRS 107 
administration, use of a structured approach may have little to add.  The 
difference in interview duration between the traditional and structured 
approach with no improvements in reliability, suggests that certain components 
of the structured interview may be redundant.   
 
My final analysis described efficacy of initial limited disability assessment as a 
predictor of final mRS grading.  Such an approach is not without precedent.  It is 
recognised that for many scales, raters may not perform a comprehensive 
assessment; rather they will estimate final grading based on initial basic review 
and “clinical intuition”.(146)  For disability scales, including mRS, full 
assessment has been reduced to a limited number of key questions while 
preserving clinimetric properties.(147)   The mRS is heavily weighted towards 
locomotor independence and so I hypothesised that distinction between higher 
and lower grades may be possible simply by observing the patient entering the 
clinic.  I have shown that experienced raters are poor at predicting final mRS 
from initial assessment and that a formal interview is still required to grade 
disability.   
 
A particular strength of this study was the mock clinical trial design simulating 
those situations where mRS is likely to be used.  I adopted an inclusive policy, 
studying a large representative cohort of stroke survivors.  I deliberately 
selected a panel of assessors from different clinical backgrounds as previous 
work has suggested that profession and training may impact on reliability of 
outcomes assessment.(108;132)  Limited numbers of patients and use of 
assessors from similar backgrounds have compromised previous studies of mRS 
reliability.  The use of video recording to assess intra-observer variability was 108 
successful with minimal expenditure in terms of money and training.  Other 
centres have also demonstrated efficacy of remote video based mRS 
assessment.(85)  These results suggest feasibility of remote video based mRS 
assessment as a further aid to improve reliability.  
 
Although the number of patients included in the analysis is greater than in many 
previous studies of mRS, there were still relatively few assessors and all were 
from the same department.  Ideally I would have involved multiple centres in 
the analysis.  In particular, to better represent the range of assessors seen in a 
contemporary trial, I should have included therapists and other health care 
workers as well as physicians and dedicated research nurses.  In this regard this 
chapter’s study is complemented by the work presented in chapter six describing 
moderate to good overall reliability on a five patient mRS assessment exercise 
across a large cohort of international trialists. 
 
I deliberately chose to test a number of related hypotheses using a pre-defined 
structured design, thus deriving substantial data from a single clinical 
encounter.    However, I pre-specified several hypotheses to limit the risk of 
drawing false conclusions as a result of multiplicity.  My results do not negate 
the potential benefit of training and I would encourage trialists to continue to 
use specific mRS training resources.   109 
Future trials designed to improve mRS assessment are planned, pending these 
results, these current data encourage caution in use and interpretation of 
standard mRS.  As measures to date have not substantially improved mRS inter-
observer variability a possible option for future trials is to limit the number of 
observers.  Remote adjudication panel assessment of laboratory and imaging 
endpoints is commonplace in contemporary multi-centre trials and perhaps 
should now become routine for assessment of functional outcomes.  I will 
explore this concept and a possible methodology for use in clinical trials in 
Chapter 8. 
 
In conclusion, I have shown that despite increasing familiarity with mRS and 
availability of specific training packages there remains substantial variability in 
mRS that could compromise clinical trial results.  Further measures to improve 
mRS reliability are urgently required.  Possible strategies to improve reliability 
of functional outcome assessment including mass training of observers; group 
assessment and novel outcome measures will be described in the following 
chapters. 110 
Chapter five 
 
Initial experiences with a Digital Training resource 
for modified Rankin Scale assessment  
in clinical trials 
 111 
Introduction 
Potential problems of reliability have been demonstrated for standard mRS 
application, using both my own mock clinical trial and through review of other 
available literature.  Various strategies have been proposed to improve 
reliability, including video recording(85) and use of a structured interview(63).  
The importance of reducing variability has already been discussed, but it is 
worth re-emphasising that reliability of the mRS is of more than clinimetric 
interest.  Inter-observer variability will increase the risk of endpoint 
misclassification which can introduce bias, impact on type I or type II error 
rates(14) and ultimately estimated effect size will be reduced. It has been 
argued that statistical under-powering has contributed to the lack of significant 
treatment effects seen in recent acute stroke trials.(148) 
 
Until recently mRS users had little guidance on rating.  This lack of guidance 
likely contributes to the unfavourable inter-observer variability present in 
traditional mRS grading.  Use of a training resource to improve consistency in 
the application of the mRS makes intuitive sense.(149)  In the original work 
describing inter-observer variation in mRS scoring, the authors commented that 
improvements could be achieved if observers were afforded the chance to 
practise use of the scale but that “…such training is hardly realistic in the 
context of a multi-centre trial.”(20)  Recent improvements in audio-visual 
technology mean mass training across a number of centres is now feasible and 
economical. 112 
 
A variety of potential formats are available for training.  A stand alone package 
would allow better standardisation and dissemination than a lecture based series 
while a programme incorporating “live” assessment of real patients is preferable 
to purely text based instruction.  The former approach is not without precedent.  
A well validated video based training programme and certification procedure 
exists for the NIHSS and it is now a requirement that clinical trial investigators 
complete this training and undergo certification.(46)  The strengths of the NIHSS 
programme - in particular its mix of didactic teaching, video explanation and 
assessment procedure – could be easily applied to the mRS.   
 
As a department, we developed a training digital video disk (DVD) and 
accompanying explanatory booklet, which include recordings of real Rankin 
assessments, certification cases and further recertification cases.  This has been 
used successfully in two large scale clinical stroke trials.(79;150)  Although brief 
reference to certification scoring has been made in a previous review(28), to 
date there has been no detailed description of the training package, its 
development and the initial experience of its use.  I present this here along with 
the initial results of the certification programme.  A more detailed analysis of 
training scores will be described in the proceeding chapter. 113 
Methods 
 
Development of the mRS training - audio visual Issues 
A criticism of the early NIHSS video training was poor image quality, an 
important consideration as subtle clinical signs may have a substantial effect on 
final scoring.(46)  In an interview based assessment such as the mRS, high 
quality sound recording is of equal importance.  To ensure optimal audio fidelity 
expert technical help was enlisted (Media Services Department, University of 
Glasgow). A recording studio was used for the majority of interviews, where 
patient disability made travel to the studio inappropriate, the Media Services 
mobile crew filmed in the hospital.   
 
A DVD based format was chosen for the recorded materials contained in the 
training resource.  This reflects the gradual replacement of conventional VHS 
recordings with DVD and the easy availability of economical DVD players.  It also 
recognised the improved clarity of sound and vision afforded by this format.  
Digital recording ensures optimal quality even after mass reproduction.  Finally, 
this allows for ease of transfer to a web based server.  Internet based NIHSS 
training has facilitated cost-effective global dissemination of the training 
package. 
 114 
Patient Selection 
The stroke liaison team based in the Western Infirmary Glasgow selected 
suitable patients from recent admissions to the acute stroke unit or local 
inpatient rehabilitation facility.  The stroke unit accepts all patients presenting 
within 72 hours of onset of suspected stroke irrespective of age or severity of 
the neurological deficit, thus a cohort of patients with varying degrees of 
disability and background co-morbidity were available.  The intention was to 
include at least one patient from each potential mRS category.  Thirteen 
patients were selected of whom four were used as training cases, five were used 
for initial assessment and four were used for recertification.  To reflect clinical 
practice, in one case disability was such that answers were provided by a carer.  
Although the final selection of patients was a sample of convenience, they were 
felt to be representative of a “real life” cross section of post stroke outcomes 
and to be suitable for inclusion in the training package.  Consent for videotaping 
and use for training and research purposes was obtained from all patients in line 
with national and local protocols. 
 
For the training component of the package, two patients with easily categorised 
disability were chosen as initial “introductory” cases. The remaining two training 
cases were chosen to highlight perceived problem areas in the application of the 
scale.  Each of the training cases was followed by an explanatory discussion of 
the correct mRS score and the rationale for this grading.  An accompanying 
booklet gave background information on the general principles of mRS scoring, 
including detailed definitions of the categories and discussion of what is 
considered to be best practice in the application of the scale.  In formulating 
this advice, reference was made to the original description of the modified 115 
Rankin and to recent work using a structured interview.(63;92)  To minimise 
potential language problems a transcript of the text was provided with 
translation into local language.  Assessment for certification was performed in a 
variety of settings including individual viewing of the cases, group viewing within 
a centre and supervised group viewing sessions at formal training meetings. 
 
Recording and Scoring of the Assessments: 
Recordings of the interviews were analysed and scored independently by two 
observers who were both experienced in mRS grading (Professor KR Lees [KRL] 
and Doctor HG Hardemark [HGH]).  No attempt was made to script the mRS 
assessments and there was little post interview editing.  It was immediately 
identified during the piloting of the study that some of the answers given by 
patients were ambiguous and in at least two of the cases debate arose as to the 
most appropriate category.  However, a decision was made to keep the 
complete interviews as recorded - it was felt that scenarios artificially scripted 
to fit a mRS grade neatly would not have adequately prepared assessors for the 
difficulties inherent in grading real patients. 
 
Scoring for the assessment component of the package took account of those 
patients who did not unequivocally fit a single grade.  A final decision on correct 
grading was made by KRL and HGH, supplemented by the analysis of results from 
an international pilot involving 100 participants.  A correct grade was defined as 
one assigned by both trainers and by >50% of trainees. A grade of “acceptable” 
response was defined arbitrarily as one which was deemed by the trainers to be 
incorrect but that followed the basic scoring guidelines and had been assigned 
by a substantial minority (10-49%) of assessors in the pilot.  Any grade offered by 116 
<10% of assessors or that clearly did not follow the accepted scoring was defined 
as unacceptable.  Using these scoring rules any candidate who graded all cases 
correctly, including “acceptable” answers, was awarded certification (Table 8).  
This scoring system was developed so that certification was only awarded to 
assessors who demonstrated a good knowledge of mRS application, but 
recognises that some merit should be given for “acceptable” but incorrect 
answers.  To minimise variability, assessors were instructed to choose the more 
severe mRS grade when hesitating between two scores. 
 
Certificates of completion were awarded, along with separate confidential 
feedback on actual score achieved to all who achieved the target.  Scores for 
individual patients were not released.  Assessors who did not achieve 
certification on first attempt were encouraged to review the training material 
and resubmit an amended set of grades for the full set of certification cases.  No 
specific feedback on errors made was provided.  Candidates could attempt 
certification as often as required.  Successful completion of the training 
materials and examination was a prerequisite for trialists involved in the NXY 
series of neuroprotection trials.(41;120;150)  117 
 
Table 8: Scoring system for certification using the mRS training 
resource. 
 
Explanation of the scoring criteria used to define “correct” and “acceptable” 
gradings are described in the main body of the text. 
 
 
Grading  Certification 
5/5 cases correct  Pass (Qualified 5) 
 
4/5 cases correct, 1 acceptable  Pass (Qualified 4) 
 
3/5 cases correct, 2 acceptable  Pass (Qualified 3) 
 
Any other combination  Fail (Not Qualified) 
 118 
Results  
 
The majority of respondents were part of the investigating team from countries 
involved in the “Stroke – Acute Ischemic – NXY-059 Treatment” (SAINT-I)(120) 
trial only or in both the SAINT-I and the “Cerebral Haemorrhage and NXY-059 
Treatment” (CHANT) study.(150)  Assessors comprised a mixed group of principal 
and co-investigators, study nurses and research assistants (Table 9). 
 
The correct mRS scores for the certification cases, along with the proportion of 
scores assigned by observers are shown in Table 10.  To allow continued use of 
the training resource, the “correct” scores for assessment and recertification 
were not made public and are shown in a different sequence to the cases on the 
DVD.   
 
There was a spread of opinion on all of the cases, with submitted answers 
spanning 3 – 5 Rankin grades for each answer.  For three of the cases the 
majority of respondents opted for the correct grading; in two of the cases 
opinion was split with a substantial proportion of assessors (39.2% and 40.4%) 
choosing a lower mRS grading than the correct answer.  This variation in opinion 
was accounted for in the final scoring, and the lower grading was defined as an 
“acceptable” answer.  Twenty three assessors gave two scores, despite explicit 
instructions to choose the best single score.  If the scores given were the correct 
and an acceptable score then a pass was allowed otherwise the grading was 
considered invalid.   119 
 
Percentages of respondents achieving acceptable scores for the certification 
assessment are given (Table 9).  The majority of assessors 1464, (81.3%), 
achieved a “pass” on the certification exercise.  However, only 38% of these 
individuals graded all of the five cases correctly.  The remainder of the group 
comprised those assessors who wrongly assessed one or both of the previously 
described equivocal cases, but whose assessment was still defined as 
acceptable.  Of the 336 who did not achieve certification on first attempt, 85% 
scored a “pass” on second attempt.  120 
Table 9: mRS certification scores by background training. 
 
For explanation of Qualified 5, 4, 3 see Table 8. 
 
 
 
Position  Not Qualified  Qualified 3  Qualified 4  Qualified 5 
Co-investigator 
(n=747) 
125  
(16.7%) 
96  
(12.95) 
224  
(30.0%) 
302  
(40.4%) 
Principle 
investigator(n=159) 
28  
(17.8%) 
18  
(11.3%) 
48  
(30.2%) 
65  
(40.9%) 
Study nurse  
(n=212) 
53  
(25.0%) 
29  
(13.7%) 
64  
(30.2%) 
66  
(31.1.%) 
Other 
(n=682) 
130  
(19.0%) 
71  
(10.4%) 
228  
(33.4%) 
253  
(37.2%) 
Total  336  214  564  686 121 
 
Demographic data on assessors submitting for certification were collated.  
Results of the certification assessment are presented by training (Table 9).  A 
more detailed analysis of mRS training scores by country, centre participating in 
trial and profession will be presented in the next chapter.   
 
It was intended that the recertification process would be undertaken at one year 
post initial training, as such full data on recertification are presently limited to 
only 370 results.  Of these only 6.5% assessors failed to achieve a satisfactory 
score (Table 10).  
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 Discussion 
 
Consistency in grading of post stroke disability is crucial both in daily clinical 
work and in the context of a clinical trial, although with potentially hundreds of 
assessors grading endpoints, for contemporary trial purposes, consistency is 
more important than accuracy and consistency in trials is more important than in 
routine clinical work where a single clinician assesses the patient.  Potential for 
significant variation in application of the modified Rankin scale has been 
demonstrated in previous chapters.  The digital training resource for mRS 
grading was developed in an attempt to improve the situation.  My results show 
that mass training of observers in use of the mRS is achievable in the context of 
a clinical trial via the use of a novel DVD training package. 
 
Several issues arose during development of the DVD which deserve comment.  No 
specific criteria were used to select patients for the training or certification 
components of the package, although patients used for assessment were judged 
to be suitably taxing to allow a valid assessment of ability.  A clustering of 
grades around the mid-range was noted in the cases selected to be used for the 
certification process.  It has been shown that clinicians are comfortable to assign 
grades at the extremes of the Rankin Scale, possibly because these grades are 
well defined or because deviation can be in one direction only.  This pattern was 
also demonstrated in my own study of mRS reliability, described in chapter four.  
Thus, it was decided to proceed to use this relatively biased sample.  
Furthermore, it is in this mid-range of scores that the reliability of the mRS and 
discrepancies between raters assumes the greatest importance; mRS based 124 
             
outcomes are frequently dichotomized, with mRS ≥ 4 defining poor outcome 
(DESTINY trial)(138) or scores ≤ 2 defining good outcome (ECASS II).(151) 
 
It is difficult to measure adequately the “success” of a multidimensional 
intervention such as an educational resource.  Analysing only pass rates for the 
assessment is a relatively crude measure, as it is likely that even those viewers 
who failed the initial certification will have gained improved knowledge of the 
mRS scores and assessments.  Despite this, the high rate of satisfactory scoring 
on the certification exercise is reassuring. 
 
Assessors were given confidential feedback on their total score.  This allowed all 
users to review the cases and perhaps to correct any grading errors.  Data are 
not available for all the second attempts at certification, which raises the 
possibility of sample bias but the high pass rate seen provides further support for 
utility of the training package.  Given that the training package is the only 
educational resource available for training it is safe to assume that this 
improvement was achieved with no extra tuition other than repeat viewing of 
the package and knowledge of previous scoring. 
 
Purists will argue that my data do not conclusively prove the benefit of the 
training package.  The primary purpose of the package was to improve reliability 
of mRS grading in large clinical trials so a “control” arm of assessors not exposed 
to training was not factored into this original study.  Extrapolating evidence 
from the success of the NIHSS and other video certification schemes(46) suggests 
this was a logical decision.  Assuming that the training will not worsen 125 
             
reliability, it was felt to be unethical to deprive trialists of the training in an 
effort to prove efficacy of the resource.   
 
It is widely accepted that there is too little formal guidance on application of 
the mRS(17) and few would argue against an attempt at formalising its use.  
Anecdotally, feedback from participants has been uniformly positive and there is 
little to suggest that exposure to the digital training worsens mRS grading or 
introduces systematic bias.  Even if the training were to influence grading 
systematically, it could be argued that if all assessors were taught to grade in 
the same fashion, and in a manner which reflects the mRS categories, that this 
could only improve outcome assessments for trial purposes. 
 
Pragmatic evidence of utility of the training package comes from its application 
in the SAINT-1(120) and CHANT studies.(150)  During conduct of these studies 
over 1500 investigators were trained.  It cannot be proven that this did improve 
the quality of endpoint assessment but demonstrates the feasibility of mass 
training and given the inherent problems with use of the Rankin scale is unlikely 
not to have helped.  I believe that formal mRS training should be routine for all 
acute stroke trials.  It is recognised that some questions as to optimal delivery of 
the package remain unanswered, such as how best to address the issue of 
repeated failure to achieve certification and whether training should be 
performed alone or in a group setting with the opportunity to discuss the cases 
and content.  Work is ongoing to answer these questions(46)  and already there 
is scope for further improvements, for instance making the training available on 
the internet could ease dissemination to the target audience.  An online mRS 
training resource that makes use of the original training materials described in 126 
             
this chapter has now been launched by “Training Campus” (http://trials-
rankin.trainingcampus.net) [last accessed January 2010] and collation and 
monitoring of training data continue. 
 
Although accepted in the stroke literature from inception, the modified Rankin 
was not clinimetrically tested prior to its use.(92)  These data being collated 
from the Rankin certification process provide a powerful tool for better 
definition of the properties of the scale.  Analysis of the inter-observer and 
intra-observer variability of the scale with further sub-analysis of individual 
components of the scale and relationships to country of origin and level of 
training will be presented in the next chapter. 
 
We live in a digital age, and utilising the available technology to deliver 
educational resources makes scientific and economic sense.  Strategies to 
improve the reliability of the mRS are needed, and it is likely that electronic 
dissemination of teaching material to participants in multi-centre clinical trials 
will be widely used in future.  I have demonstrated that digital training in post 
stroke assessment is feasible and accepted by most potential assessors.  Further 
work to quantify the potential impact of such training on the quality of future 
stroke trials is required. 127 
             
Chapter six 
 
 
Variability in modified Rankin Scale scoring across 
a large cohort of international observers 128 
             
Introduction 
 
Through my own study and review of the available literature I have attempted to 
describe the variability seen when mRS is used in a clinical trial setting.  
Individual studies of mRS properties provide useful data; however, by limiting 
themselves to a few experienced raters from a single centre or city they likely 
underestimate the true variability of mRS assessment manifest in a large scale, 
international trial.   
 
To improve quality of multi-centre trials a standardised approach to outcome 
measurement is required.  One potential method of improving consistency is to 
offer training and examination in endpoint classification.  Case-based training in 
application of the NIHSS is well established, and as discussed in the previous 
chapter, successful completion of the NIHSS training is a pre-requisite for several 
stroke trials.(45;46)  As a department, we have developed a comprehensive 
training package for mRS assessment, consisting of: written educational 
materials; video based tutorials and mRS cases for grading.  A full description of 
the package is available in the previous chapter.  In brief, investigators study 
the training resources and then attempt an assessment exercise that comprises a 
series of real time mRS interviews for grading.  Examination attempts are 
externally graded and success leads to certification in mRS training.   
 
The mRS training resource has been available for almost four years and has been 
widely used.  Thousands of assessors from various countries and backgrounds 
have attempted the certification exam.  These data have been collated centrally 
and offer a powerful resource for analysis of mRS variability and its 129 
             
determinants.  Using these training data I describe variability in mRS assessment 
across a large cohort of international researchers.  To explore reasons for mRS 
variability I further described mRS reliability by country, native language and 
background speciality of assessor. 
 
Methods 
 
MRS training data  
The video based mRS certification exercise comprises 5 non-scripted interviews 
with stroke survivors.  There is a further recertification exam comprising 4 
cases.  Interviews were originally recorded in English.  Fully translated training 
packages, with native speakers overdubbing the interview, have been made 
available for Finnish, French, German, Italian, Portuguese, Spanish and Swedish 
researchers; a subtitled Chinese version has also been produced. 
 
Certification data are collated and scored centrally.  Investigators can submit 
responses individually or through a local study co-ordinator.  Standardised paper 
or electronic score sheets are used and mRS grades are then transcribed directly 
onto an electronic spreadsheet.  Score sheets that are incorrectly completed or 
poorly legible are returned to the assessor for resubmission.  An assessor who 
fails to achieve certification is invited to review the training materials and 
resubmit on the assessment exercise, no guidance is given on errors in original 
grading.  There is no limit on the number of attempts an assessor can make.  
Initial certification is valid for one year after which time raters are invited to 
take a further assessment. 
 130 
             
“Correct” mRS grades for each video interview were derived by two experts in 
mRS grading and were informed by the results of previous pilot data.  MRS 
certification is graded using a “pass” / “fail” system.  Embedded formulae 
within a dedicated electronic database automatically calculate the investigator’s 
final grade.  Again, complete description of the process used to score mRS 
grading is available in chapter five. 
 
Certification data were anonymised prior to analysis of reliability; to allow for 
pre-specified analyses: data on participating centre; location (country) of 
participating centre and profession of the rater were maintained, any other 
identifying information was removed.  I did not seek formal written consent to 
use these anonymous data in my study of reliability.  Consent was assumed as 
some degree of data collection and analysis is evidently necessary for scoring 
and quality control.  As with any registry, participants can ask for details to be 
removed.  Throughout the period of data collection and since my publication of 
the mRS training system methodology I have received no such requests.  
 131 
             
Statistical Analyses    
To assess for significant differences in certification performance between 
countries; professions and centres I used chi-square analyses, comparing 
proportions achieving the following certification results: fail; pass 3/5 correct; 
pass 4/5 correct; pass 5/5 correct.  As numbers in the group “pass 3/5” were 
small, to allow for meaningful statistical analysis, the group “pass 3/5” were 
combined with the “fail” group. 
 
To maintain consistency with all previous analyses, variability was described 
using kappa statistics (k), where k=1 defines perfect agreement between 
assessors, while k=0 defines no agreement other than that expected by chance.  
Agreement was described across the cohort of observers and against the 
“standard” of pre-defined correct answers.  Using an equivalent approach I also 
described variability at each potential mRS grading.  I performed two principal 
analyses: first describing reliability for assessors’ initial attempt at the mRS 
exercise; and a second analysis limited to those assessors who successfully 
completed the exercise.  Further sub-analysis was performed to describe 
agreement by country and by native English and non-native English language 
countries.  Native English speakers were arbitrarily defined as any assessors from 
centres in Australia, Canada, New Zealand, South Africa, United Kingdom and 
United States of America.   
 
Variability by background profession was also described.  Background profession 
was classified as Neurology; Geriatrics/Care of the Elderly; specialist stroke 
physicians not specifically trained in neurology or geriatric medicine were 
classified as “General Medicine”.  Non-physician, clinical research assistants 132 
             
were classified as “Research Nurses”.  Background was extracted from submitted 
assessment documentation.  Where background was not available these data 
were collected from the host institution.  To eliminate the effect of language 
and country I limited the background analysis to UK based assessors.  To assess 
for potential bias in grading, median and Inter-quartile range (IQR) were 
calculated for each grading, although these ordinal data should be described 
with non-parametric statistics, to further describe any patterns in grading I also 
calculated mean mRS and standard deviation.  An equivalent analysis describing 
variability by institution was performed for UK assessors. 
 
All available certification attempts have been included in the analyses.  Kappa 
statistics were described using attribute agreement functions.  Statistics were 
performed using Minitab software (version 13.1, Minitab Inc, PA, USA). 
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Results 
 
Certification assessments have been collated since March 2003.  The total 
number of assessments to date is 2,942 (2636 1
st certifications [5 cases]; 306 re-
certifications [4 cases]).  Thus, data on 14,404 mRS assessments were available.  
Certification cases spanned a range of potential mRS scores: for mRS grade 2 I 
included 1 video case for assessment; mRS 3 = 4 cases; mRS 4 = 3 cases; mRS 5 = 
1 case.    
 
Country of origin was available for 2349 certification attempts.  Assessors were 
based in a variety of international centres (n=30 countries).  The majority of 
assessors (1958, 75%) achieved certification at first attempt; 20 assessors 
required a 3
rd attempt at certification; 4 assessors required 4 or more attempts. 
 
Proportions of countries achieving certification grades of: fail; pass 3/5 correct; 
pass 4/5 correct and pass 5/5 correct are presented graphically for all countries 
submitting more than 50 assessments.  Presented data represent performance 
according to assessor’s first attempt (Figure 5a) and performance limited to 
those assessors who achieved certification (Figure 5b).  There was a significant 
difference in the performance of countries for both analyses (P<0.0001). 
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Figure 5a: Performance on the mRS certification exercise, first 
attempt.   
 
Data are for all countries submitting more than 50 assessments.   
Key: 
nq=not qualified 
Q3=qualified 3/5 answers correct;  
Q4=qualified 4/5 answers correct;  
Q5=qualified 5/5 answers correct. 
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Figure 5b: Performance on the mRS certification exercise, limited to 
researchers who passed the certification exam.   
 
Data are for all countries submitting more than 50 assessments.   
Key: 
Q3=qualified 3/5 answers correct;  
Q4=qualified 4/5 answers correct;  
Q5=qualified 5/5 answers correct. 
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Inter-observer variability and variability against the “correct” grade are 
presented for all countries submitting more than fifty certification assessments, 
along with total variability across the cohort (Table 11).  Other countries 
included in the overall analysis comprise a mix of Asian, European, Canadian and 
African centres.  Variability by country ranged from fair to very good.  
Variability for the entire cohort was good, with no difference between English 
speaking and non-English speaking countries.  For the complete cohort of 
assessors variability at each level of mRS grading is presented (Table 12).  
 
UK assessors comprised a mixed group of disciplines.  Although reliability in mRS 
grading varied with professional background (Table 13), there was no significant 
difference in certification assessment results (P=0.321).  All groups tended to 
underscore disability.  Heterogeneity in reliability was also present across the 
various UK centres.  For those centres with greater than 5 raters completing the 
examination (anonymous) results were: centre 1 (n=22) k: 0.59; centre 2 (n=12) 
k: 0.70; centre 3 (n=11) k: 0.74; centre 4 (n=11) K: 0.43; centre 5 (n=6) k:0.67; 
centre 6 (n=6) k:0.80.  For this analysis there was a significant difference in 
performance across the UK centres P=0.001. 
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Table 11: Modified Rankin Scale variability by country of assessor, 
tabulated for all countries submitting more than 50 certification 
attempts.   
 
Variability is measured using un-weighted kappa statistics (k) and is presented 
as both inter-observer variability and variability against a standard of pre-
defined “correct” grade.   
 
Two analyses are presented:  
a) observers first attempt at assessment exercise  
b) limited to those assessors who achieved an overall “pass”. 
 
Reliabilities scored as “moderate” or poorer (using standard scoring criteria) 
are highlighted in bold text.   138 
             
 
  (a) 1
st attempt  (b) Passes only 
Australia 
n=111 attempt 1/ n=110 pass 
k=0.60 
(0.77 standard) 
k=0.79 
(0.86 standard) 
Belgium 
n=49 / 46 
0.64 
(0.73) 
0.72 
(0.78) 
Czech Republic 
n=49 / 48 
0.70 
(0.68) 
0.74 
(0.70) 
France 
n=72 / 67 
0.60 
(0.64) 
0.83 
(0.52) 
Germany 
n=162 / 159 
0.66 
(0.78) 
0.77 
(0.84) 
Hungary 
n=57 / 54 
0.60 
(0.70) 
0.75 
(0.79) 
Italy 
n=147 / 130 
0.55 
(0.34) 
0.62 
(0.38) 
Netherlands 
n=58 / 49 
0.53 
(0.50) 
0.75 
(0.76) 
Portugal 
n=63 / 53 
0.66 
(0.80) 
0.84 
(0.91) 
Slovakia 
n=42 / 40 
0.72 
(0.75) 
0.75 
(0.77) 
South Korea 
n=55 / 30 
0.52 
(0.67) 
0.74 
(0.81) 
Spain 
n=314 / 299 
0.73 
(0.84) 
0.83 
(0.90) 
Sweden 
n=56 / 41 
0.55 
(0.65) 
0.71 
(0.74) 
UK 
n=109 / 95 
0.59 
(0.69) 
0.74 
(0.77) 
USA 
n=172 / 162 
0.61 
(0.73) 
0.77 
(0.84) 
     
Native English 
n=580 total  / 389 pass 
0.66 
(0.77) 
0.69 
(0.77) 
Non-native English 
n=1769 / 1251 
0.67 
(0.76) 
0.71 
(0.78) 
All 
n=2942 / 2151 
0.67 
(0.76) 
0.71 
(0.78) 
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Table 12: Variability in mRS scoring across a large cohort.  
 
 
Columns a) and b): Variability described using standard kappa statistics (k) at 
each grade of modified Rankin Scale,  
Columns c) and d): Median and mean mRS at each “correct” grade for all 
attempts at mRS; restricted to those who achieved certification.  
 
NB original assessment exercise did not include patients from full range of 
disabilities. 
 
mRS  Inter-
observer 
variability 
Variability 
against 
standard 
Median (IQR) 
Mean mRS (SD) 
All assessors 
Median (IQR) 
Mean mRS (SD) 
“Passes” only 
0  -  -     
1  0.19  -     
2  0.48  0.56  2 (1 - 2) 
1.7 (0.46) 
2 (2 - 2) 
1.8 (0.47) 
3  0.74  0.79  3 (3 – 3) 
2.8 (0.51) 
3 (3 - 3) 
2.8 (0.40) 
4  0.95  0.97  4 (4 - 4) 
3.9 (0.43) 
4 (4 - 4) 
3.9 (0.31) 
5  -  -     140 
             
Table 13: Inter-observer variability (k) with variability against 
“standard” mRS (standard) in mRS scoring and median / mean 
submitted grade for UK assessors by background profession.  
 
Variability is described using standard kappa statistics. 
 
Data are presented as median (Inter-quartile range) and mean (95% confidence 
interval) 
 
  k 
standard 
 
Median (IQR) 
Mean (95% C.I) 
mRS 2 
Median (IQR) 
Mean (95% C.I)  
mRS 3 
Median (IQR) 
Mean (95% C.I)  
mRS 4 
Gen. Med.  
(n= 13) 
0.66 
0.77 
2 (1 – 2) 
1.67 (1.35, 1.98) 
3 (3 – 3) 
2.87 (2.72, 3.02) 
4 (4 – 4) 
3.95 (3.87, 4.04) 
Geriatrics  
(n= 23) 
0.54 
0.68 
2 (2 – 2) 
1.91 (1.73, 2.10) 
3 (3 – 3) 
2.91 (2.73, 3.10) 
4 (4 - 4) 
3.89 (3.79, 3.98) 
Neurology  
(n= 16) 
0.56 
0.65 
2 (2 – 2) 
2.00 (1.80, 2.19) 
3 (3 – 3) 
3.03 (2.78, 3.28) 
4 (4 – 4) 
4.00 (4.00, 4.00) 
Res. Nurse  
(n= 58) 
0.65 
0.72 
2 (2 – 2) 
1.79 (1.67, 1.91) 
3 (2 – 3) 
2.77 (2.66, 2.88) 
4 (4 – 4) 
4.00 (3.97, 4.02) 
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Discussion 
 
I have demonstrated considerable inter-observer variability in mRS grading 
across a large cohort of international investigators.  Variability was apparent for 
all included countries, however within the cohort there was substantial 
heterogeneity with a number of countries achieving only fair – moderate 
reliability.  These data confirm the potential for end point misclassification in a 
clinical stroke trial and suggest some reasons for this variability in scoring.  
 
The statistical techniques used to describe variability demand some discussion.  
As has been previously discussed, there is no accepted standard test for 
measurement of reliability.  Use of kappa statistics has been criticised, as the 
basic assumptions underlying the calculations rely on observer 
independence.(152)  I recognise that complete rater independence can never be 
guaranteed in a trial setting but chose to use kappa statistics in this study as 
clinicians are familiar with the test and previous studies of mRS reliability have 
used a similar approach.  Traditional kappa statistics do not allow for 
comparative analysis.  To assess whether the differences seen between countries 
were significant I compared proportions achieving a “fail” or one of the “pass” 
grades using accepted techniques.  Having thus established a significant 
difference in mRS grading between countries, I then described the inter-observer 
variability in terms of kappa statistics.  142 
             
 
I present two analyses of inter-observer variability that describe differing 
aspects of mRS reliability.  Analysis of assessors’ first attempt at mRS gives an 
approximation of reliability across all potential stroke investigators.  The second 
analysis, limited to assessors who successfully completed the training exercise, 
provides a better representation of the variability that would be seen in a 
contemporary stroke trial (the majority of trials that make use of the mRS 
training resource demand successful certification before the investigator can 
assess trial patients).  Although this second measure is consistently better than 
the first, there is still substantial variability with heterogeneity across countries.  
By defining “correct” mRS grades for each patient interview, I was able to 
compare variability against a pre-defined standard.  For certain countries there 
was a marked discrepancy between inter-observer variability and variability 
against the standard: this suggest that cohorts of raters were consistent in their 
grading but that this grading was inaccurate. 
 
These data compare favourably with previous estimates of mRS inter-observer 
variability described in chapter two.  I would hope that any improvement in 
reliability will in part represent the beneficial effect of the mRS training 
resource and perhaps increasing familiarity with mRS as a method of functional 
outcomes assessment.  However, there is no room for complacency – even those 
assessors who successfully completed the assessment demonstrated variability.  
Thus although my results are encouraging there is still some way to go before 
mRS variability is minimised. 
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Across the complete cohort of assessors, inter-observer variability was greatest 
for grades 1 and 2.  This finding has been demonstrated both in my departmental 
study of mRS reliability and in the other mRS studies.  For clinical trial endpoint 
analysis, mRS outcomes are often dichotomised at grades of 1,2 or 3.  Thus, in 
this training cohort, variability is potentially greatest for those mRS grades most 
likely to influence final trial result.  Increased variability at these middle grades 
is well described. It may be attributable to better definition of the highest and 
lowest categories, or to the potential for misclassification in one direction only 
at extremes of mRS.(31) 
 
The substantial variation in reliability observed between countries is intriguing.   
These data suggest that this is not purely a function of language as countries 
with native English performed similarly to other countries.  I acknowledge the 
global nature of contemporary medical practice where a given institution may 
have a number of international staff and that most centres recruiting for 
international trials will be staffed by teams familiar with English.  It is possible 
that socio-cultural factors related to perceptions of disability and handicap may 
influence patterns of grading.  For this reason, in collaboration with the 
University of Glasgow, international centres are producing new assessment cases 
in native language and featuring local stroke survivors.  I recognise that my data 
will include countries that may have a number of centres relatively 
inexperienced in stroke trials / mRS assessment.  Increasing use and familiarity 
with the scale may help to remove some of this variability.  The available data 
do not allow for assessment of training effects, I encourage stroke trialists to 
continue to use available and forthcoming recertification materials as data from 144 
             
these resources will allow for future analysis of training effect and hopefully 
should demonstrate greater improvements in reliability. 
 
My analyses of UK assessors suggest that heterogeneity in measured reliability is 
not only accounted for by nationality.  Accepting the smaller numbers of 
certification attempts available, there was again heterogeneity between centres 
and between professions, although only the analysis across differing centres 
revealed a significant difference in performance.  Inter-observer variability 
between differing professional backgrounds has been demonstrated for other 
neurological outcome scales including the Barthel Index(153) and the Unified 
Parkinson's disease rating scale motor examination.(132) 
 
Some aspects of my methodology demand discussion.  Although describing 
variability through performance on a video based assessment allows for 
standardisation across a large number of raters, there is the potential to 
overestimate reliability using this method.  Variability recorded in a series of 
traditional face to face mRS gradings would likely be substantially higher, as 
assessors can employ various approaches to patient interview.  In creating the 
mRS assessment I had to strike a balance between including a broad range of 
cases at varying levels of disability and having an assessment that was short 
enough to be acceptable to a large population of researchers.  The final choice 
of included cases deliberately focuses attention on those mRS grades known to 
demonstrate greatest variability i.e. mRS 2 -4.  For future training packages 
more cases from extremes of the mRS spectrum will be included. 
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The strengths of my analysis are its size and international scope.  Major acute 
stroke trials may involve as many as 400 hospitals at international sites, each 
with 2-5 raters.  Previous descriptions of the clinimetric properties of mRS have 
been limited to few observers often from single centres.  Certification in mRS 
grading was required for a number of recently completed and ongoing multi-
centre stroke trials and investigators from many of the leading stroke research 
centres are included in this analysis.  The initial users of the novel resource may 
well have over represented enthusiasts and specialists in the field who already 
have considerable experience of mRS.  For this reason I waited until the mRS 
teaching package was well established before attempting any analysis of the 
training data. 
 
Having demonstrated this inter-observer variability in mRS, it is incumbent upon 
stroke trialists to take steps to improve reliability in outcomes assessment.  The 
DVD training package was designed for this purpose and has been a success.  
However, even those raters who achieve certification still demonstrate a degree 
of inter-observer variability and I suspect that training alone will not eradicate 
variability.  Other methodologies to improve mRS assessment are available or 
are being developed and certain will be described in the following chapters of 
this thesis.  146 
             
I have demonstrated inter-observer variability in a large representative cohort of 
international researchers.  Although country and background profession seem to 
influence this variability, the significant differences between similar local UK 
centres suggest that reasons for variability are more complex than simple socio-
geographic differences.  As variability between assessors may never be fully 
explained the stroke community should continue to pilot novel methodologies to 
minimise inter-observer variability in clinical trials. 147 
             
Chapter seven 
 
 
Deriving modified Rankin Scale grades from 
patient case records 148 
             
Introduction 
 
In my discussion on the use of functional outcome measures in contemporary 
stroke trials (chapter three) it was established that mRS is the preferred 
disability outcome scale and that mRS data have been collated using a variety of 
assessment methodologies.  Traditionally mRS grading has been based on face to 
face(20) or telephone interview.(64)  Such an approach is possible for a 
prospective trial, but does not allow for retrospective disability grading.  
Previous observational studies have attempted to derive mRS using information 
contained in patient case-records.(133;154)  The clinimetric properties of such 
an approach have not been described.  We should be cautious of assuming that 
novel methods of outcomes assessment will provide robust data.   
 
Assessment of functional capacity is an important element of stroke clinic 
review.  As each mRS grade describes a broad range of disability, reasonable 
estimation from narrative case-record information should be possible.  Several 
stroke assessment scales in common usage can be successfully derived from 
routinely collected data.  The NIHSS(155); the Canadian Neurological Scale 
(CNS)(156) and the Scandinavian Stroke Scale (SSS)(157) score have all been 
derived with acceptable validity and reliability. 
 
I hypothesised that mRS could be derived accurately and reliably from 
information recorded at outpatient follow up. 
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Methods 
 
Patients were recruited through the local stroke unit.  The Western Infirmary 
acute stroke unit manages all patients with known or suspected cerebrovascular 
disease admitted to the main hospital.  The department is based in a large 
teaching hospital with a predominantly Caucasian, urban patient demographic.  
At discharge from the unit, patients are allocated three-month outpatient 
hospital clinic follow up.  A sequential series of these outpatients consented to 
participate in the study of video based mRS assessment described in chapter 
four.  From this trial population I further selected patients for inclusion in the 
mRS derivation study using an online random sampling process 
(www.random.org). [last accessed January 2010]   The study had full ethical 
approval, with patients or proxies providing written consent.    
 
Patients attending the clinic for their routine consultation were first seen and 
managed by a stroke clinician according to normal practice.  Doctors leading the 
outpatient consultation were not aware that their case-record notes would be 
used for retrospective analysis.  The unit provides no guidance on 
documentation during clinic review and does not use pre-specified “pro-formas” 
in the clinical setting.   
 
The paper based case records for the study patients were collated.  Two 
independent stroke physicians then derived mRS grades from these case-records, 
blinded to each others mRS grades.  They were given access to complete case-
records with no external editing unless explicit reference was made to mRS.  In 
addition to mRS grading, researchers documented degree of confidence in their 
assessment using a 5 point Likert scale that ranged from 0=“not at all confident” 150 
             
to 5=“extremely confident”.  All clinicians involved were fully trained in mRS 
assessment, using the previously described digital mRS training package.  
 
For each outpatient full mRS assessment was video recorded, immediately 
following the routine consultation.  These interviews were performed according 
to the recommendations of the mRS training programme by certified raters half 
of the interviews followed a structured format as described originally by 
WiIson.(62)  Four stroke physicians and one research nurses later reviewed these 
video recordings and independently assigned mRS grades, with final “correct” 
mRS decided by group consensus.(Figure 6) A more detailed description of this 
video based central mRS adjudication is given in chapter eight.   
 
I calculated agreement between “correct” (ie. group derived, consensus) mRS 
and derived mRS and the corresponding inter-observer variability using attribute 
agreement analysis.  Accuracy of mRS grading was described by calculating 
median and IQR of actual mRS for derived mRS grades.  I performed all 
statistical analysis using Minitab software (version 13.1, Minitab Inc, PA, USA). 151 
             
 
Figure 6: Schematic diagram of evaluation process for case-record 
derived mRS versus “correct” mRS. 
  50 patients 
Outpatient review 
with functional assessment 
Case-records 
with clinic notes 
Video of mRS 
assessment 
Case-record 
derived mRS 
Case-record 
review 
(2 assessors) 
“Correct” mRS 
majority scoring  
Video review 
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(5 assessors) 152 
             
Results 
 
Fifty patients were selected, median age was 78 years (range: 30-92); median 
mRS was 2.  The group comprised a variety of stroke subtypes (8 TACS; 17 PACS; 
6 POCS; 19 LACS).  Patients were reviewed at a median of 16 weeks (range 2-56) 
from index stroke event.  One patient withdrew consent after interview and was 
not included in the final analysis.  To ensure there was no recall bias, I excluded 
four patients where one or both of the case-record reviewers had been involved 
in their care. 
 
Both reviewers were confident in their grading (median confidence 3, [IQR 3 – 
4]; reviewer 1 = 3, [IQR 2 – 3]; reviewer 2 = 4, [IQR 3 – 4]).  There was no 
statistically significant relationship between certainty of derived mRS and 
proportion of correct grades (p=0.727).  Derived mRS showed poor agreement 
with correct grade (overall k=0.34; appraiser 1 k=0.35; appraiser 2 k=0.31) and 
between observers (k=0.33).(Table 14)  Agreement was greatest at extremes of 
mRS.  Case-record reviewers tended to underscore disability (Table 15 and 
Figure 7).   
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Table 14: Agreement with “correct” (standard) mRS and agreement 
between observers for case-record derived mRS.  
 
Variability is described using standard kappa statistics (k). 
N/A indicates not applicable 
No patients with mRS 5 were included in the study 
 
mRS  Agreement with standard (k)  Inter-observer agreement (k) 
0  0.52  0.49 
1  0.24  0.06 
2  0.27  0.15 
3  0.34  0.48 
4  0.28  1.00 
5  N/A  N/A 
Total  0.33  0.34 
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Table 15: Accuracy (median and IQR) for derived mRS versus 
“correct” mRS. 
 
N/A indicates not applicable 
No patients with mRS 5 were included in the study 
 
“Correct” 
mRS 
Combined 
derived mRS 
Reviewer 1 
derived  mRS 
Reviewer 2 
derived mRS 
0 
n=8 
0 
(0 - 0) 
0 
(0 - 0) 
0 
(0 - 0) 
1 
n=7 
1 
(0 - 1) 
1 
(0 – 1) 
1 
(1 – 2) 
2 
n=17 
1 
(1 - 2) 
1 
(0.5 – 1.5) 
2 
(1 – 2.5) 
3 
n=9 
2.5 
(0 - 3) 
2 
(0 – 3) 
3 
(0.5 – 3) 
4 
n=5 
3 
(3 - 4) 
3 
(2.5 - 4) 
4 
(3 - 4) 
5 
n=0 
N/A  N/A  N/A 
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Figure 7: Box and whisker plot of accuracy (median and IQR) for 
derived mRS versus “correct” mRS for both raters. 
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Discussion 
 
Modified Rankin Scale data derived from patient case-records have unacceptable 
accuracy and reliability for use in clinical research.  This contrasts with other 
commonly used stroke scales, where quantitative outcome data have been 
reliably described using qualitative case-record information.(155;156) 
 
Those scales that have been successfully derived from case-record have 
measured physical impairment only.  Transforming bedside neurological 
examination into a quantitative scale is straightforward if comprehensive 
physical exam is recorded.  As a global disability scale, mRS review requires 
measures of physical, cognitive, emotional and functional status.  Such data may 
not always be recorded during a busy outpatient assessment.   
 
Although case-record reviewers were poor at deriving mRS, it is interesting that 
they felt able to derive a score for every patient and were confident in their 
grading for the majority.  This may explain why previous trialists have been 
happy to use case record abstracted mRS without first testing the validity or 
reliability of this approach.    
  
My results should be generalisable to other centres involved in stroke trials.  
Patients were reviewed at approximately 3 months from event, the period when 
mRS is traditionally assessed.  Review was performed by practising stroke 
physicians trained in use of mRS.  Specific pro-formas are not used for data 
capture and consulting doctors can document as much information as they wish.  
The department’s clinical staff comprises internal medicine physicians with a 157 
             
stroke interest.  It is possible that in the context of a specific rehabilitation, or 
privately funded service, consultations may be longer with more emphasis on 
disability.  Patients included in the study represented a spread of functional 
ability.  It is noted that no patients with mRS 5 were included in the analysis, 
this reflects the outpatient setting of the study.  As I was interested in reliability 
of case record derived mRS for use in a clinical trial, omission of the most 
severely disabled stroke survivors seems reasonable – these patients would be 
unlikely to be recruited to a trial. 
 
The poor reliability inherent in standard mRS assessment has now been well 
described.  To ensure that the “correct” mRS grading was suitably robust, I used 
the data generated from the previous study of video based mRS assessment, 
utilising multiple independent raters with final mRS chosen by consensus.  
 
Although reliability of case record derived mRS was poor, these results must be 
interpreted in the context of other published literature discussed in Chapter 
one.  From the previous review I described studies reporting an equally 
concerning poor reliability of traditional mRS using direct interview: k=0.34 for 
derived mRS; k=0.25 in one study of traditional mRS.(63)  I would suggest that 
improved reliability of mRS assessment is needed across all modalities, however 
any novel methodologies should have clinimetric properties studied prior to 
clinical trial use. 
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Accurate mRS for clinical trial use cannot be derived from standard hospital 
records.  Even amongst those cases where the appraiser was “certain” in their 
scoring, the proportion of correct grades was no better than chance.  Deriving 
mRS from hospital records or other data sources should not be encouraged - a 
directed interview remains essential. 159 
             
Chapter eight 
 
Pilot trial of remote adjudication for  
modified Rankin Scale assessment  
in clinical stroke trials 160 
             
  
Introduction 
 
I have discussed a number of methods that may assist in reducing the inter-
observer variability associated with mRS assessment.  The original modifications 
to Rankin’s eponymous scale were in response to a perceived subjectivity in its 
application.(20)
   I have discussed the initial experiences of a training resource, 
although this package should improve mRS application robust evidence of 
efficacy is yet to be demonstrated.  Use of a structure approach has been 
studied and discussed in this thesis (Chapter two) and other published works, 
with variable results.(63;64)  In essence, studies to date suggest that this 
approach may reduce but does not completely negate inter-observer variability. 
 
Remote review of clinical trial endpoints, often by central committee, is 
common in contemporary multi-centre clinical trials.(158;159)  Distancing 
endpoint assessment from the study centre, allows for better “blinding” and less 
potential for bias.(160)  Other potential benefits of central adjudication are 
numerous and include: greater consistency in grading; opportunity for “quality 
control” of trial data and experience and diligence of the “expert” assessment 
panel.(161;162)  Thus, addition of a group review approach should result in more 
robust endpoint data.  In stroke trials, remote adjudication of imaging, 
laboratory and clinical endpoints is well established, while remote assessment of 
functional outcomes is uncommon.  
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Sources of variation in mRS include questions asked by the interviewer, the 
responses provided and the interpretation of these responses by the rater.  In a 
multi-centre international trial involving many hundreds of raters, the grading 
process may carry greatest scope for variation.  Separating mRS assessment from 
grading with remote review of mRS interview could aid standardisation.  Remote 
grading of functional assessment presents a greater logistic challenge than 
review of “hard” data such as laboratory results.   
 
A possible solution is to record video footage of the assessment for later “off-
line” playback.  Such an approach is not without precedent: in the development 
of a video based mRS training package described in chapter five, incorporation 
of “live” recordings of patient assessments allowed for mass training and 
certification.  This resource has proven popular and demonstrates that remote 
review of mRS is feasible.  Similarly, a Japanese group used remote assessment 
of video recorded mRS interview to study efficacy of an mRS questionnaire.(85)   
Although encouraging, these studies of video based mRS assessment do not 
necessarily extrapolate to the large scale clinical trial setting, as they 
incorporated only a limited number of assessments of selected patients and 
made use of professional video recording facilities.  As mRS assessment is 
principally based on patient interview a less technically demanding option for 
remote review would be audio recording of the assessment for later playback, 
although again such an approach has not been formally studied.  
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Although video based remote mRS assessment seems intuitively attractive, there 
is a danger in prematurely assuming the clinical utility of what is a novel 
assessment technique.  In this regard, a salutatory lesson can be learned from 
the practice of retrospectively deriving mRS from patients’ case records.  As 
described in chapter seven - this technique became established in trial 
methodology before any formal clinimetric assessment and has subsequently 
been shown to have unacceptable reliability.  Although trialists are principally 
concerned with mRS reliability a full clinimetric assessment should also include 
measures of validity, acceptability and cost-effectiveness. 
 
I hypothesised that remote review of video based mRS assessment by endpoint 
adjudication committee would be feasible, would demonstrate acceptable 
clinimetric properties in a clinical trial setting and would be superior to audio 
only recordings. 
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Methods 
 
Study participants 
Subjects were recruited from the Western Infirmary Cerebrovascular Clinic.  
Details of the clinic have been described in the preceding chapters.  Stroke 
survivors attending the clinic for routine three-month review were approached 
and consented between August 2006 and February 2007.  All post stroke patients 
were considered, regardless of demographics; co-morbidity or functional ability.  
For those patients with language or cognitive impairments, the carer 
accompanying the patient to clinic was included in the mRS assessment to act as 
proxy. 
 
I used a stratified, sequential design to test properties of remote video mRS 
assessment (Figure 8).  The basic study design, builds upon the study of inter-
observer variability of traditional mRS described in chapter four.  All 
randomisations (assessors; assessment for video recording; cases for audio only 
assessment) were performed using an online resource (www.random.org). [last 
accessed January 2010] and allocation was concealed from participants, using an 
opaque envelope system. 
 
I designed studies to address the following: Inter-observer and intra-observer 
variability of mRS (reliability); validity of group (consensus) mRS; and 
comparison of remote review of mRS interviews using full video playback or 
audio only.  Separate components of the study will be described in turn.  The 
local ethics committee approved the study protocol and arrangements for use 
and storage of patient data.  164 
             
Analysis of reliability 
Seven assessors comprising four stroke physicians and three research nurses 
performed the initial mRS assessments.  All assessors were trained and certified 
in mRS assessment and had considerable experience of use of the scale in 
clinical trials. 
 
Patients were approached following routine clinic review.  Consenting patients 
had an independent mRS assessment performed and captured on video by a 
randomly selected researcher from the pool of seven.  Following interview, mRS 
grading was recorded and sealed in an opaque envelope.  The researcher 
conducting the interview also managed the video recording process.  No formal 
training in use of video recording equipment was given. 
 
Three months later, all seven researchers reviewed the complete set of video 
mRS recordings, including their own interviews.  They were asked to grade mRS 
based on the recorded assessments.  Video review was performed independently 
and blinded both to original mRS grading and to colleagues’ grades.  A delay of 
three months was chosen to minimise recall bias while allowing timely 
completion of the study.  These individual video based mRS grades were used to 
describe inter-observer variability within the group.  This inter-observer 
variability was compared with data from previous study of traditional mRS 
conducted by the same research team and in the same unit. 165 
             
After a further three months, a group of 5 researchers from the original cohort 
(4 physicians; 1 study nurse) reviewed and graded the video recordings for a 
second time.  As before, video based mRS grading was performed independently 
and blinded to previous and colleagues’ scores.  These second grades were 
compared with original video mRS grades to assess intra-observer variability. 
 
To maintain consistency with my own and others group studies, kappa (k) 
statistics were used to describe agreement, using accepted definitions of poor (k 
= 0.00-0.20); fair (k = 0.21 – 0.40); moderate (k = 0.41 – 0.60); good (k = 0.61 – 
0.80) and very good (k= 0.81 – 1.00) agreement.(34)  Traditionally, k values of > 
0.61 are taken as acceptable for a clinical test.(32)  The number of interviews in 
which raters agreed exactly on mRS, was calculated and expressed as 
percentage agreement.  Analysis was performed using Minitab software (version 
14.0, Minitab Inc, PA, USA). 
 
Group (consensus) review 
At a final group viewing of the mRS videos, the panel’s 5 researchers were 
allowed to discuss their grading with mRS scoring by consensus.  The group were 
not obliged to score and in cases where no consensus could be reached, this was 
recorded.  The group was also asked to grade quality of the video recording 
using free text and document any technical faults.  As many of my proposed 
measures of validity require a single scale, consensus mRS results were used for 
this purpose. 
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To assess convergent validity, agreement between video mRS and original face 
to face mRS interview score was described using attribute agreement analysis.  I 
further compared individual video mRS scores to the consensus score.  For 
individual raters, proportions of original mRS grades that agree with final 
consensus were calculated and compared using chi-square analysis. 
 
As part of the group exercise, randomly selected video interviews were first 
presented as audio only playback.  The group graded these audio cases and then 
watched the original complete video and re-graded as necessary.  Variability 
within the group’s audio mRS scores and variability between audio mRS grading 
and full video mRS were described using attribute agreement analysis.  
 
Technical specifications 
In consultation with the Media Services Department, University of Glasgow I 
developed a suitable recording system for clinical trial use.  Final choice of 
hardware for video recording was: HDVR-HC1E 1080i digital HD camera recorder 
(Sony, Japan) and ATR97 omni-directional condenser boundary microphone 
(Audio-technica, Ohio, USA).  Digital recordings were transferred to video-disc 
using Windows Movie Maker (Microsoft, Washington USA). The accompanying 
Windows Media Player application (Microsoft, Washington USA) was used for 
playback during video review. 
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Results 
 
Of 104 patients approached, 102 consented to video recording of mRS interview 
with 1 patient subsequently withdrawing consent following the recording.  Full 
demographics of the study population have been described in chapter four. 
 
Of completed recordings, 99 were of sufficient technical quality to allow 
assessment, 7 videos had technical problems that did not preclude mRS grading 
(3 poor sound quality; 4 poor visual quality).  Mean duration of recorded mRS 
assessment was 4.9 (SD 2.4) minutes.  After watching 99 videos suitable for 
review, the group was able to reach a consensus score in 96.  Based on group 
consensus, final distribution of disability was: mRS 0=14 patients; mRS 1=25; 
mRS 2=23; mRS 3=20 mRS 4=11; mRS 5=3. 
 
Reliability of remote video review of mRS  
Inter-observer variability for remote review of video mRS was good on first and 
second viewing (k1=0.67, 47% matched (95% CI: 36.1 – 57.5); k2=0.66 44% 
matched (95%CI:33.4-54.3)), variation was least at extremes of grading (Table 
16, Figure 9).  Reliability of remote video mRS assessment was favourable 
compared to my previous estimate of mRS variation using traditional face to face 
interview (k=0.57; 67% matched (95% CI: 56.6 – 75.7)).  Differences in trial 
methodology do not allow for direct comparative analysis.   
 
Intra-observer variability was good (k=0.64, 28% matched (95% CI: 14.0-37.9) 
again with least variation at extremes of the scale. (Table 16)  
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Validity of remote video review of mRS 
Group review of video mRS showed moderate agreement with traditional face to 
face mRS k=0.57 (65 matched 95% CI: 57.6 – 72.0)).  Agreement with individual 
remote video scores was good k=0.77 (47 matched 95% CI: 36.1-57.6) (Table 17).  
Differences between consensus and individual scores could not be attributed to a 
single rater systematically scoring differently to the group, as percentage 
agreement with consensus was similar across the group (range 70% - 76% 
agreement; p=0.651). 
 
Audio only mRS 
Forty one cases were randomly selected (again using the online random number 
generator previously described) for analysis of audio only mRS assessment and 
mRS was derived for 39.  All raters agreed that the remaining 2 cases could not 
be assessed without corresponding visual information.  There is no method to 
incorporate such missing data within traditional kappa statistics and as such 
these cases were excluded from analysis, with the resulting statistics likely over 
estimating reliability of an audio only approach.  Accepting this limitation, 
reliability of audio only mRS review was k=0.62 (31% matched (95%CI: 17.0 – 
41.0)).  Comparing responses for audio only and the equivalent full video review, 
agreement between scores was k=0.67 (matched 26%, 95% CI: 20.1 – 30.0).(Table 
18) 
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Table 16: Inter-observer and intra-observer variability for video 
based modified Rankin Scale (mRS) assessment. 
 
Variability is described using standard kappa (k) statistics. 
 
 
mRS 
Inter-observer 
variability (k) first 
video review 
Inter-observer 
variability (k) second 
video review 
Intra-observer 
variability (k)  video 
review 
0  0.83  0.80  0.80 
1  0.64  0.60  0.60 
2  0.52  0.52  0.53 
3  0.65  0.65  0.60 
4  0.78  0.77  0.72 
5  0.94  0.94  0.94 
overall  0.67  0.65  0.64 170 
             
Table 17: Variability comparing group consensus modified Rankin 
Scale (mRS) to traditional mRS assessment and individual video 
assessment. 
 
Variability is described using standard kappa (k) statistics. 
 
mRS  Variability (k) consensus 
v. traditional mRS 
Variability (k) consensus 
v. individual review 
0  0.75  0.88 
1  0.52  0.75 
2  0.58  0.64 
3  0.58  0.73 
4  0.71  0.83 
5  0.83  0.97 
Overall  0.63  0.77 
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Table 18: Reliability of modified Rankin Scale (mRS) across a number 
of modalities. 
 
Agreement is measured by kappa (k) and quadratic weighted kappa (kw) 
statistic, presented as k (95% confidence interval).  
 
For reference k=0.61 is considered acceptable for a clinical scale. 
 
* Is agreement across the group (greater than 2 raters compared)
mRS modality  Variability (k)  Weighted (kw)  Agreement (%) 
Standard  
Face to Face 
0.57 
(0.46 – 0.69) 
0.83 
(0.63 – 1.0) 
67% 
Video mRS 
(first viewing) 
0.68 
(0.64 – 0.72) 
0.92 
(0.85 – 0.98) 
47%* 
Video mRS 
(second viewing) 
0.66 
(0.63 – 0.70) 
0.91 
(0.85 – 0.98) 
44%* 
Video mRS 
(intra-observer) 
0.67 
(0.61 – 0.71) 
0.89 
(0.80 – 0.98) 
75% 
Audio mRS 
 
0.67 
(0.61 – 0.73) 
0.88 
(0.78 – 0.96) 
31%* 172 
             
 
Discussion 
 
Variability in mRS grading limits its utility as a clinical trial endpoint.  Measures 
to improve reliability have been developed but no perfect solution has been 
described.  I developed a novel video based mRS assessment for use in clinical 
trials and have demonstrated acceptable clinimetric properties of this approach. 
 
As has been discussed, variability in assessment implies a degree of 
misclassification of endpoints.  Removing this inherent “noise” from the data 
should decrease the likelihood of a type II error and ultimately improve 
statistical power.(39)  Attempts to standardise mRS assessment by creating and 
distributing training resources for stroke researchers have already been 
discussed.  In this pilot I attempted a converse but complementary strategy – 
limiting mRS assessment to a selected group of individuals. 
 
Analysis of inter and intra-observer variability of remote mRS was encouraging.  
Variability in video mRS assessment was equivalent or less than that seen locally 
for traditional face to face mRS assessment.  The apparent improvement in 
variability was welcome but unexpected and demands some consideration.  It is 
well recognised that subjects perform a task differently if they know they are 
being observed – the “Hawthorne effect”.(163)  The good reliability seen with 
video review may in part be related to interviewers conducting a more complete 
assessment “for the camera”.  If this effect can be sustained and video 
assessments remain rigorous, I would expect increasing use of video based 
technologies to improve overall standards in mRS interview.  The objectivity 173 
             
afforded by review of interview, distant from time constraints and distractions 
of clinical work, with the ability to review the consultation repeatedly until 
happy with a final grading may also have impacted on reliability.  
 
Although my prime concern was mRS reliability, for this novel assessment 
methodology it was important to test as many clinimetric properties as possible.  
There is no standard methodology for describing validity.(145)  In the absence of 
a recognised gold standard, I assessed convergent validity using direct 
comparison of the scale to other measures of the outcome of interest.  My 
results suggest that remote group review of video mRS is a valid measure of post 
stroke disability. 
 
There are other clinimetric properties that can be assessed.  Responsiveness, the 
ability to detect meaningful change over time, was not assessed.  As a single 
measurement of mRS is usually analysed as a trial endpoint, most often at 90 
days post ictus, I felt that analysis of responsiveness was of lesser importance 
than other properties.  A literature describing responsiveness of stroke outcomes 
scales is available.(52)  I did not formally measure acceptability or cost-
effectiveness but can extrapolate from the data collated.  Only three (2.9 %) 
patients refused video recording of mRS, a good recruitment rate for any 
intervention and certainly suggestive of acceptability; in a trial, patients 
consent to outcome assessment at the outset.  The audio-visual equipment used 
in the trial was deliberately chosen to be economical and I made use of widely 
available computer software.  When compared to the costs reimbursed to a 
centre for each patient recruited to an industry sponsored trial, the initial 
expense in setting up such a system is minimal.   174 
             
 
My sub-study of remote mRS assessment based on audio playback suggests that 
this approach may not be suitable for clinical trial use.  I could find no previous 
study utilising an audio only approach; the closest equivalents have concerned 
“live” telephone based mRS.(64;67;70)  Acceptable reliability of telephone 
based assessment has been demonstrated for scales measuring Glasgow Outcome 
Score (164) and cognitive impairment(68).  Studies of telephone based disability 
assessment, particularly mRS have yielded conflicting results.  Independent 
groups have demonstrated poor reliability (k=0.30)(64) and good reliability 
(k=0.74)(70), although results of this later analysis are likely overestimated as 
single dichotomised mRS was used.  In summary it seems variability is increased 
by use of telephone based mRS assessment and as such my finding of poor 
reliability of audio only feedback is in keeping with the available literature. 
 
As well as the potential to improve trial data quality, there are numerous other 
possible benefits to video recording of mRS assessment.  The video format allows 
for repeated review and discussion of challenging cases.  Following a difficult 
interview the assessor could review their interview and re-grade if necessary.  
Feedback from central reviews may help educate colleagues less experienced in 
mRS application and raise overall standards.  Finally, preserving a recording of 
interview facilitates quality control and provides another barrier to research 
fraud.  Although this pilot was concerned only with mRS there is no reason that 
my approach could not be applied to other disability assessment scales in stroke 
or other areas of neurology. 
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My aim was to develop a system for future use in a multi-centre trial setting.  A 
possible option would have been to “add” video mRS assessment to an ongoing 
clinical trial.  To avoid “contamination” of results with potential treatment 
effects I opted for the single pilot study of remote mRS described.  Patient 
selection criteria were deliberately inclusive.  I included a large representative 
cohort of stroke patients including patients for whom assessment of disability 
may be challenging.  The low baseline stroke severity of this cohort represents 
the outpatient setting of the study and is representative of a clinical trial 
population.  I selected a panel of assessors from different clinical backgrounds as 
previous work has suggested that profession and training can impact on 
reliability of outcomes assessment.(132) 
 
Previous reports describing development of “tele-stroke” systems emphasise the 
importance of high definition audio and visual recording to ensure 
reliability.(165)  The ideal would be use of professional recording studio 
facilities to achieve optimal audio-visual capture.  Such an approach is not 
practical in a clinical setting.  Thus in choosing audio-visual recording equipment 
for video mRS I needed a compromise between hardware that was portable, 
allowing for use in clinic or at bedside and a system that provided high fidelity 
recording.  Critics may argue that with two videos unable to be graded because 
of technical issues and a further seven videos possibly compromised, I have not 
demonstrated technical feasibility.  However, no formal training in use of 
hardware was given prior to video recording and the majority of technical errors 
were made early in the study.  As such I would expect a much lower rate of 
technical problems if full training and support were offered.   In a trial, even if 
some video recordings were to be found useless and time did not allow re-176 
             
assessment, the original rater’s contemporaneous grading could stand as a 
substitute for analysis. 
 
I acknowledge the preliminary nature of my study of remote mRS assessment.  
There were certain weaknesses in methodology that could be addressed in 
future work.  My study was based in a single centre, using a team of researchers 
who have worked together for many years.  All the researchers involved in this 
work and the majority of patients speak English as a first language.  Differences 
in culture, language and health care systems may compromise reliability if 
remote assessment is performed across multiple international centres as would 
be required for a large scale clinical trial.  The limited number of local 
researchers experienced in mRS assessment precluded creation of a separate 
review panel not involved in the original mRS assessments.  I took measures to 
limit the effect of recall bias but for future study of remote mRS assessment an 
independent review body would be a prerequisite. 
 
In conclusion I have demonstrated feasibility and acceptable properties of 
remote video based assessment of mRS.  These pilot data now need prospective 
confirmation, along with more detailed analyses of feasibility; economics and 
data safety in a multi-centre clinical trial setting.177 
             
 
 
Figure 8: Schematic of remote modified Rankin Scale (mRS) 
assessment methodology. 
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Figure 9: Spread of video mRS scores for differing mRS grades.  
mRS  0  1  2  3  4  5 
0  102  11  9       
1  12  152  33       
2  3  41  144  26  2   
3      32  95  9   
4        21  71  4 
5            27 179 
             
Chapter nine 
 
Time spent at home post stroke  
“Home-time” – a meaningful and robust  
outcome measure for stroke trials 180 
             
 
Introduction 
 
The thesis has demonstrated the need for robust assessment of post-stroke 
recovery in both
 clinical and trial work.  Of the many tools that exist to quantify 
functional
 outcome, I have chosen to focus on the mRS as this is the most 
frequently used functional outcome scale and has been used in a number of 
landmark stroke trials.(120;151)  Despite its popularity with trialists, mRS has 
limitations – in particular I have now demonstrated potential for substantial 
inter-observer variation.  Although I have outlined certain approaches to 
improve reliability, training in administration; use of a structured interview, no 
single approach has negated the effect of inter-observer variability. 
 
The ideal outcome measure would be simple to understand and
 apply with 
acceptable validity, variability, and responsiveness.
  To date, no stroke outcome 
measure adequately meets these criteria.
  Creation of a novel instrument is 
unlikely to achieve immediate
 widespread acceptance.   
 
An alternative is to derive surrogate
 outcome measures from routinely collected 
patient data.  For
 example, duration of inpatient stay lends itself to health 
economic
 analysis because inpatient days account for much of the expenditure
 
associated with stroke.  A relationship between mRS and hospital bed occupancy 
has been demonstrated.(56)  However, inpatient stay is not an ideal measure
 of 
post stroke functional outcome.  Despite significant advances in acute stroke 
treatment there remains substantial mortality, rates within the first few weeks 181 
             
remain high and in survivors many require ongoing care in Nursing home or 
equivalent.(166)  Early mortality and transfer to
 a long-term care setting after 
severe stroke will each be associated
 with shorter stay and thus potentially skew 
outcomes data based on hospital “bed days”.(167) 
 
I hypothesized that duration living independently in the community
 could serve 
as an appropriate outcome measure less likely to
 be confounded by the survival 
and transfer issues discussed.  To explore this hypothesis, I measured
 duration of 
stay in the patient’s own home following stroke event —"home-time"— using data 
from a comprehensive, prospectively gathered stroke outcomes trial.
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Methods  
 
 I analyzed data that had previously been extracted from the original records of 
the GAIN International trial conducted in 1998 to 1999 and first reported in 
2000.(168) GAIN was a multi-centre randomized, double-blind, placebo-
controlled trial of the putative neuro-protectant “gavestinel” administered in 
acute stroke.  Patients were aged greater than 18 years old with symptoms of 
acute stroke, including limb weakness.  Prior to stroke event, all were previously 
independent and were randomized and treated within 6 hours of onset of stroke.  
All original data extraction and preparation for statistical analysis were 
performed by two researchers (Tau-Pin Chang and Jennifer S. Lees).  
 
The GAIN trialists collected outcomes data across a number of functional 
domains: mRS, BI, and NIHSS.  Functional outcomes scores were collated at 1 
month and 3 month intervals from recruitment.  Outcomes on mRS were 
assessed by local observers according to a standard scoring system.  No formal 
training or certification was offered.  To assist consistency, observers were 
offered advice on scoring of BI in the form of a video based demonstration but 
no certification procedure was in place.  All observers had been trained and 
were certified in use of the NIHSS scoring system. 
 
Resource use data were recorded at 90 day follow-up visit based on interviews 
with patients or a proxy (relative / caregiver) these data were supplemented by 
review of hospital records.  In particular, detailed data regarding duration of 
hospitalization or time spent in nursing facilities were gathered.  Data on non-
hospital placement post discharge were also collected and categorised using the 183 
             
following six labels: own home, relative’s home, intermediate-care facility, 
nursing/convalescence home, rehabilitation facility, or undefined.   
 
For the purposes of this analysis, all high-dependency and medical bed-days 
were grouped together and considered separately from days spent in nursing or 
institutional residential care.  Days spent in the patient’s own home were 
grouped together with time spent in a relative’s home, these data were used to 
calculate "home-time." 
 
Only those outcomes actually recorded at 90 +/- 17 days were used in this 
analysis; missing data were not imputed.  Resource use was censored at 90 days.  
When final follow up occurred earlier than 83 days in a patient who survived past 
90 days, last known placement was extrapolated to 90 days; patients in whom 
dates of placement were not recorded were excluded from analysis.  
 
For this preliminary analysis, I used one-way analysis of variance
 (ANOVA) to 
assess home-time trends for mRS, NIHSS, and BI comparing
 adjacent categories 
by Bonferroni testing.  All analyses
 were performed using StatsDirect statistical 
software version
 2.4.5 (StatsDirect Ltd, Cheshire, UK).
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Results  
 
Full outcome data were available for 1717 of the 1788 intention to
 treat 
patients.  Data were incomplete for 15 patients and 56
 withdrew from the study 
before 90 days.  Mean age was 69.7 (S.D 12.2)
 years, 737 (42.9%) were female, 
321 (18.7%) had intracranial
 haemorrhages as the index event, and mean 
admission NIHSS score was 13.1 (S.D 6.2). 
  
Mean time in the hospital was 28 days and mean home-time was
 31 days. Home-
time was significantly associated with changes
 across mRS (P<0.0001), NIHSS 
(P<0.0001), and BI (P<0.0001).  On analysis of between-category differences, 
home-time was significantly
 associated with change across all mRS categories 
except mRS
 4 to 5. (Figure 10, Table 19) 185 
             
 
 
Figure 10: Mean 90-day home-time ±95 CI versus mRS. 
  
P<0.0001 comparing adjacent categories except  
mRS 4 to 5 (P=0.37)  
and mRS 5 to 6 (P=0.0003).186 
             
 
Table 19: Relationship between Home-time and mRS. 
 
 
* P<0.0001 comparing preceding column 
 
Analysis of NIHSS and home-time revealed a significant association
 with NIHSS 
categories 0 to 1 (P<0.0001), 1 to 2 (P<0.0017),
 2 to 3 (P<0.0013), and 4 to 5 
(P<0.0001).
  Home-time was significantly associated with change across BI
 
categories 100 to 95 (P<0.0001) and 95 to 90 (P<0.0001).
 Change across all other 
categories of NIHSS and BI were non-significant. (Figures 11 and 12)
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Discussion  
 
I have shown that home-time has a significant association with
 post stroke 
disability as measured by mRS, particularly across the
 better recovery levels.  
Although intuitive, this relationship
 has not been demonstrated previously. I 
have already established that mRS is the preferred outcome
 measure in acute 
stroke trials and my demonstration of the relationship between home-time and 
mRS outcomes, provides
 strong evidence of the validity and potential utility of 
home-time as a novel
 trial endpoint.
  
 
Home-time has potential advantages over mRS in application and
 interpretation.  
Given the problems of inter-observer variability associated with mRS,
 an 
objective measure such as home-time should give better
 reliability and would 
not require the formal training that has been described for mRS.  “Perfect” 
reliability would not be possible, even for a measure such as home-time.  
Historical data regarding discharge, transfer to rehabilitation etc was first 
collated from patient or proxy and such is prone to recall bias.  Using hospital 
records to check these dates should help remove some inaccuracy.  The 
continuous
 nature of home-time data lends itself to more powerful statistical
 
techniques than traditional dichotomized or ordinal outcome
 measures.(136)  
Home-time is generalizable and although I have used stroke trial data in this 
analysis it could be applied to
 any disabling condition.
  188 
             
A further strength of home-time is its immediacy.  Discussion
 of possible 
treatment benefit is essential for informed consent.
  The abstract outcome 
measures used in trials make this already
 challenging task more difficult.  Some 
centres are piloting the use of patient videos to illustrate mRS grades to patients 
and carers in an effort to improve informed consent for cerebrovascular 
intervention (personal communication, University of Heidelberg).  Home-time 
offers an outcome
 measure that should be easily understood by the lay public 
and
 other medical professionals.
  
 
Association of home-time with NIHSS and BI was less convincing.  I do not 
interpret this as a failing of home-time; rather,
 home-time accentuates the 
limitations of NIHSS and BI.  "Floor
 and ceiling" effects of the BI are well 
recognized and were discussed in chapter one.(51)  NIHSS measures
 physical 
impairment, it takes no account of ability to
 compensate for functional deficit.  
At ninety days post event, it is likely to be
 responsive to change only at extremes 
of outcome.(169)  In support of this I have shown that home-time
 change across 
grades was significant only at extremes of the scales that denote almost 
complete recovery.
  
 
Patients in the GAIN study were broadly representative of a
 clinical trial 
population.  However, all patients in GAIN were
 independent at baseline. Home-
time may be less valid as an outcome
 measure if applied to a more disabled 
population such as seen
 in routine clinical practice.  For clinical trials, pre-
morbid
 residence at home could be an objective entry criterion.
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Rehabilitation is often necessary post stroke, reducing home-time in the short 
term to achieve longer-term improved outcomes.(170)  As such,
 a 90-day cut off 
is most appropriate for home-time analysis.  For the majority of stroke survivors, 
it is unlikely that meaningful inpatient rehabilitation will
 continue past 90 days.  
Ninety-day outcome assessment has become
 standard in clinical trials and so 
ascertainment of home-time
 would not necessitate changes to study protocols.
  
 
I do not claim home-time to be the perfect measure of outcome;
 it is prone to 
many of the same limitations as other accepted
 outcome scales.  By measuring 
home-time at specific cut offs,
 data may be biased by "early" and "late" 
responders, those
 patients whose recovery time from disabling stroke is 
substantially
 longer or shorter than average.  Although important at the 
individual
 patient level, such influences are less important in the context
 of 
large multi-centre trials and it is in this area that I propose
 the use of the home-
time instrument.
  
 
It is assumed that increasing home-time is a positive outcome because
 return 
home is desired by most patients and will reduce total costs. 
 Home-time makes 
no measure of level of care required to facilitate
 discharge; a large package of 
supplemental carers and home modifications may allow return home but
 at 
substantial economic expense.  Potential for provision of
 care by state or family 
will vary between countries, this could potentially bias home-time data if 
recorded in a number of international centres as is the norm for a large scale 
clinical trial.  The data available from the GAIN trial did not allow for 
meaningful sub-analysis of home-time by country.  However, the influence
 of 
country and culture is not unique to home-time; significant
 differences across 190 
             
countries are also seen for the disability measures of mRS and
 BI in the GAIN 
data set.(154)  Other socio-demographic factors external to the
 patient such as 
marital status, dependents, and healthcare insurance
 may influence home-time, 
but such data are not routinely collected
 and so appropriate analysis could not 
be performed.
  
 
Despite its plausibility, I recognize that the potential utility
 of home-time needs 
to be confirmed.  I have derived home-time
 retrospectively from previous trial 
data and thus can make no
 assessment of its use in real-time clinical practice.  
However,
 GAIN was a typical, multi-centre, intention-to-treat trial and,
 as such, 
I assume that the findings would hold for future trials.
  Rather than replace 
established instruments, home-time could
 complement other trial end points.  
Integration with other scales
 could generate a powerful global outcome 
statistic.(82)  It would
 be of interest to examine home-time in existing trial data 
sets
 of thrombolysis or haemostasis.
  
 
In summary, home-time assessment offers robust, objective, easily
 
communicated information on stroke outcomes.  Trialists are encouraged
 to 
measure home-time and consider its inclusion as a clinical
 end point.
  
 
  
Figure 11: Median “Home-time” versus Barthel Index  
 
as measured at ninety days post stroke event 
 
 
Data are presented graphically as : 
  Median (diamond) 
  IQR (rectangle) 
  Range (line) 
 
 
Figure 12: Median “Home-time” versus National Institutes of Health 
Stroke Scale  
as measured at ninety days post stroke event 
 
 
Data are presented graphically as : 
  Median (diamond) 
  IQR (rectangle) 
  Range (line) 
 
Note small numbers of patients at higher NIHSS levels. 
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Chapter ten 
 
Dr John Rankin; his life, legacy and the 50th 
anniversary of the Rankin stroke scale  
– a historical review 195 
             
Introduction 
 
Dr John Rankin (1923-1981) is one of the many distinguished alumni of the 
former University Department of Materia Medica and Therapeutics, Stobhill 
Hospital Glasgow.  While his varied international career encompassed pulmonary 
physiology, occupational medicine and public health, he remains best 
remembered in the UK for his early stroke publications.  In a series of articles 
published 50 years ago in the Scottish Medical Journal he described early 
rehabilitative stroke medicine using a novel grading system.  
 
Half a century on and Rankin’s eponymous stroke scale has become the endpoint 
of choice in acute stroke trials.  This thesis has concentrated on current and 
future use of the modified Rankin scale.  To put this work in a historical context, 
this chapter describes Rankin’s remarkable career and the legacy of his work, 
with a particular focus on his stroke research and grading systems.  The 
historical data presented are gathered from Rankin’s published research 
manuscripts and editorials; newspaper articles and other papers from University 
of Glasgow and University of Wisconsin, Madison.  196 
             
 
Rankin and the University of Glasgow 
 
John Rankin was born in Glasgow in 1923 into an academic family, his father 
being a noted Professor of Physics.  Rankin began his own academic studies at 
the Medical Faculty of the University where he achieved several prizes and 
excelled in pathology.  Successfully completing his medical degree, he was 
awarded the prestigious Rockerfeller scholarship to pursue post-graduate study 
at University of Wisconsin, Madison. He achieved his MD in 1947.(171)  During his 
year in Madison Rankin forged strong transatlantic research links, which 
remained prominent throughout the rest of his career.  Rankin was always 
thankful for the opportunities afforded by his scholarship and it is fitting that 
University of Wisconsin now offer the “John Rankin Travel Award” to facilitate 
international medical research.  
 
Rankin left Madison in 1948, completing training in London before returning to 
his native Glasgow to work within the University Department of “Materia Medica 
and Therapeutics”, Stobhill Hospital.  Stobhill was unusual for its time, having 
an established academic department within a municipal hospital that 
predominantly cared for older and chronically unwell patients.(172)    Working in 
this environment of scholarly research and real-life clinical medicine clearly 
influenced the young Rankin.  When he eventually led his own department of 
medicine, he vociferously opposed the traditional culture of elitism that 
separated academia from routine patient care.  
 
Stobhill was a general hospital providing a range of medical and surgical 
services.  Originally designed to house the large number of patients with 197 
             
“encephalitis lethargica” following the first world war, a number of beds 
remained specifically set aside for “chronic sick” patients.  During Rankin’s time 
at Stobhill these beds mostly comprised patients with rheumatic heart disease or 
stroke.(173)  The combination of an active academic department, a young 
physician with innovative research ideas and a cohort of long term stroke 
inpatients was potent.  Despite serving only three years on the staff at Stobhill, 
Rankin collected unique and unparalleled observational data on cerebrovascular 
diseases. 
 
In a period where active intervention for stroke was uncommon and where 
therapies that were employed (such as barbiturate coma) often contributed to 
mortality, Rankin’s optimistic attitude to stroke was highly unusual.  He argued 
that positive results could be achieved through rehabilitation, time and 
encouragement, and that there was no place for the therapeutic nihilism 
exhibited by his peers.(174)  Rankin’s belief in early mobilisation was strongly 
influenced by primate work simultaneously being carried out at University of 
Wisconsin by Travis and Woolsey.(175)  Together the three researchers 
developed theories of the brains ability to regain function following insult - 
effectively an early model of neural plasticity.(92) 
 
Within the chronic sick beds of Stobhill, Rankin effectively created a prototypic 
stroke unit.  It is certainly true that Rankin’s ideals of multidisciplinary working 
and early rehabilitation remain core principles of contemporary stroke 
care.(176)  We can only assume that other faculty staff shared Rankin’s views on 
the value of rehabilitative services.  Of the eight doctors who comprised the 198 
             
Department of Materia Medica in the late 1940s, three went on to achieve chairs 
in the nascent speciality of Geriatric Medicine. 
 
Rankin’s early stroke manuscripts gave an indication of the themes that would 
come to characterise his future career: a belief in providing a scientific evidence 
base to clinical work; recognition of the social aspects of disease and the need 
for preventative rather than curative medicine.  Although remembered for his 
scholarly achievement at Stobhill, Rankin remained a practical physician, 
popular with his patients and respected by his junior staff.  It is telling that 
Rankin’s final manuscript on stroke described a bespoke apparatus for 
prevention of drop foot in the paralysed limb.(177)  However, in some less 
enlightened passages he did comment that only poor outcomes could be 
expected in “artisans” or “women at an age when the call of the family or the 
home no longer exist.”(92) 199 
             
Figure 13: Picture of Dr John Rankin during his time at Stobhill 
Hospital, Glasgow (circa 1951). 
 200 
             
Figure 14: Department of Materia Medica Stobhill Hospital, Glasgow. 
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Rankin in Madison 
 
It has been commented in neurology texts, that following his time at Stobhill, 
Rankin’s subsequent career passed unnoticed.(157)  It is true that Rankin did not 
progress his original cerebrovascular work, rather he took an unconventional 
career “side-step” - returning to University of Wisconsin in 1953 as an 
undergraduate physiology instructor and eventually pursuing post-doctoral 
research in pulmonary alveolar diffusion.  The University of Wisconsin was 
founded on principles of equality of access and multidisciplinary delivery of 
education, and as such it seems appropriate that the idealistic Rankin remained 
in Madison for the remainder of his life.   
 
The reasons for Rankin’s return to Madison and the basic sciences are not clear.  
It has been suggested that frustration at treating what he saw as a preventable 
disease, encouraged Rankin to forsake Stobhill and stroke medicine.  Primary 
prevention of morbidity was the driving force for the rest of his distinguished 
career.  Combing his knowledge of pulmonary physiology, clinical medicine and 
his passion for public health he conducted large scale, long-term field research.  
Along with researcher Helen Dickey he was instrumental in defining the 
pathogenesis of the farmers lung type of hypersensitivity pneumonitis.(178)  In 
later work he described other industrial lung diseases(179) and alerted the 
public to the possible environmental and health effects of the industrial rubber 
industry.(180) 202 
             
 
During his 23 years at the University of Wisconsin medical school Rankin rose 
through the ranks to achieve chairs in Medicine (1964); Preventative Medicine 
(1968) and become chief of Pulmonary Medicine (1970).  In recognition of the 
part that the state played in the health of the nation, Rankin served on an 
increasing number of governmental organizations – over 112 in his lifetime.  In 
spite of the considerable time he gave to administrative and state matters 
Rankin remained a prolific researcher and devoted teacher.  He published over 
70 scientific papers, 11 book chapters and 40 abstracts, many posthumously.  
The most tangible aspect of Rankin’s legacy at University Wisconsin is the small-
scale physiology laboratory he developed into a world class research centre – 
now the John Rankin Pulmonary Medicine Laboratory.  One can only guess as to 
what he may have achieved had he stayed in Glasgow and pursued the study of 
stroke.   
 
Rankin died in his home aged 57, having taken his own life.  It was speculated in 
the press at the time that increasing state driven budget cuts to his research 
program precipitated this tragic event.  If this is the case, it is grimly ironic for a 
man who gave so much of his time to governmental committees and who 
passionately believed that medicine and state should work together.  Rankin 
himself had prophetically commented, “whenever you have a conflict between 
economics and health, health loses out”.  Tributes were many; from patients, 
students, professional colleagues and friends.  The University of Wisconsin gave 
a fitting epitaph when in obituary they described him as “the near-ideal model 
of scholarship, service and humanitarianism”.(181) 
 203 
             
Rankin, Stroke Medicine and Development of the 
Stroke Scale 
 
Despite his many laudable achievements it is for his early stroke work that 
Rankin is best remembered in the UK - in particular his tool for describing post-
stroke disability.  Rankin shared his experiences of stroke care while in Glasgow 
in a series of papers submitted to the newly published periodical – The Scottish 
Medical Journal (which had emerged from the Journal of the Royal Medico-
Chirurgical Societies of Glasgow and Edinburgh and the Edinburgh Obstetrical 
Society).  He summarised his research in a seminal manuscript, which was 
subsequently presented across three papers in the journal:  Cerebral vascular 
accidents in patients over the age of 60.  Volume 1: General considerations(174); 
Volume II: Prognosis(92); Volume III Diagnosis and Management.(182)  In these 
papers he presented critical review of an embryonic stroke medicine literature; 
described his failed attempts at establishing a West of Glasgow stroke registry 
and reported his observations of 206 stroke patients admitted through his 
department and followed to death or discharge.  It was in this work that Rankin 
described his eponymous stroke scale, a tool that was to become instrumental in 
future stroke studies and that has formed the basis of much of this thesis.  
Despite Rankin’s impressive ground-work, a “Materia Medica” stroke unit with a 
comprehensive database of cerebrovascular disease was not realised in the 
Western Infirmary until the early 1990s. 204 
             
For any physician with an interest in cerebrovascular disease, these papers 
remain fascinating and prove Rankin’s exemplarily knowledge of stroke 
medicine.  It is evidence both of Rankin’s forward thinking and of the 
disappointingly slow progress that has been made in stroke since, that many of 
the observations made in these original papers remain true today.  As an 
example, although no evidence-based acute stroke therapies were available 
during Rankin’s lifetime, he correctly surmised: “at the onset when treatment is 
likely to be of most value, accurate diagnosis is often difficult and sometimes 
impossible.”  Unfortunately in this age of sophisticated imaging and increasing 
numbers of proven and potential acute interventions, diagnosis of acute stroke 
remains a clinical challenge.(183) 
 
Comparison of observations made by Rankin with recent cerebrovascular 
literature provides further salutary evidence of the prescient nature of Rankin’s 
essays:  
 
John Rankin 1957 “The importance of these lesions (stroke) is widely realised 
but is hardly reflected in the volume of research devoted … compared even to a 
disease as rare as myasthenia gravis.” 
 
Rothwell et al 2004 “Stroke and stroke research remains depressingly under-
funded.”(184) 205 
             
 
John Rankin 1957 “the number of deaths increases yearly … and in many 
instances admission to the appropriate ward is delayed because of shortage of 
beds.” 
 
UK stroke audit 2004 “Despite evidence of efficacy…two thirds of stroke units 
are having to ration access to this limited resource.”(185) 
  
Rankin described good outcomes in the majority of patients cared for using his 
unorthodox methods of holistic stroke care.  To aid his descriptive work he 
formulated a novel outcome scale.  Rankin’s instrument consisted of five 
hierarchical grades of “functional recovery” from Grade I – no significant 
disability to Grade V severe disability (appendix F).  In early stroke work it was 
not uncommon for authors to describe a bespoke outcome measure.  Although 
some other authors made use of the scale(186), during Rankin’s lifetime there 
was little to distinguish his scale from others cited in the literature.  It was not 
until the development of intervention trials that the scale was “rediscovered”. 
 
For the first multi-centre trial in neurology - the UK TIA study(187)
 - trialists 
needed an easily administered measure of stroke outcomes.  Rather than 
develop a de-novo instrument they turned to Rankin’s eponymous scale.  
Following initial pilot work, the UK TIA team revised the wording of Rankin’s 
original gradings to allow for better reliability – the modified Rankin scale 
(mRS)(20).  The mRS was subsequently used in the first International Stroke Trial 
(IST)(188).  The success of these trials alerted the stroke community to the 
utility of Rankin’s scale.  206 
             
 
The UK TIA authors attempted to further refine the mRS through the 
development of the Oxford Handicap Scale (OHS)(93).  However, OHS was felt to 
add little to the mRS, was infrequently used by trialists and has been largely 
abandoned by the stroke community.  In comparison mRS has seen increasing use 
in the scientific press.  A review of the literature in the late 1990s reported mRS 
as the second most popular disability outcome measure in stroke work.(57)  My 
own review of recent stroke trials has demonstrated that mRS is now the 
preferred disability outcome measure of UK and international researchers.  In 
many of the pivotal clinical trials that have shaped modern stroke practice, mRS 
has been used often as primary end-point.  Recent examples include “landmark” 
studies of thrombolytic therapy(189), neuro-protectant(190) and surgical 
treatment of stroke(138).  We must assume that Rankin’s original work 
describing this stroke outcome scale is one of the most referenced articles in the 
SMJ’s 50 year history.  
 
Rankin’s scale was developed to aid his descriptive analysis of the natural history 
of stroke and its putative treatments.  It is not clear if he intended for others to 
use the scale for trial outcome.  Indeed, the multi-centre clinical trials that 
characterise contemporary cardiovascular medicine were unknown during 
Rankin’s tenure at Stobhill.  It was many years after the Rankin scale had 
become popular as a stroke research tool that researchers began to analyse its 
clinimetric properties.  A subsequent body of literature, including much of the 
work in this thesis, has demonstrated the limitations of standard mRS 
administration and in particular the potential for substantial inter-observer 
variability.   207 
             
In recognition of this potential weakness of the scale, stroke researchers are 
now using modern technologies to improve application of the mRS and examples 
include the DVD based training resources and digital recording of mRS interviews 
for later off-line assessment discussed in this thesis.  Given that Rankin’s scale 
was developed during his time in Stobhill hospital it is appropriate that much of 
this work is being conducted by a team based in the University of Glasgow.  
 
John Rankin excelled as scholar, teacher, administrator and physician.  The 
legacy of his stroke scale continues to influence research and it is likely we will 
continue to refer to Rankin’s early Scottish Medical Journal publications well 
into the 21
st century. 208 
             
Conclusions and future directions 
 
In this thesis I have presented a body of work, exploring the use of outcome 
scales for stroke trials.  From systematic review of the literature I have shown 
that the most prevalent functional outcome measure is the mRS, most often 
performed at ninety days post ictus and via telephone interview.  Further 
systematic review and meta-analysis has shown the potential for substantial 
inter-observer variability in mRS grading.  This finding is supported by my own 
departmental study of mRS reliability.  Potential interventions to improve mRS 
reliability include standardising the interview process; training assessors and 
using novel methodologies for data collection.  Through literature review and my 
own study I have demonstrated that a structured approach to mRS assessment 
does not consistently improve the quality of the data.  I have further outlined 
the development of a DVD based training resource for mRS assessment that has 
been used by thousands of international researchers.  Analysis of these 
submitted training data have shown that mRS variability is present across 
countries and across medical disciplines.  Novel methods of collecting mRS 
outcomes should be tested prior to clinical use.  My study of deriving mRS from 
patients’ case records demonstrated poor reliability.  However, pilot study of 
using remote video based assessment has suggested initial efficacy. 
 
Although I have presented and discussed a number of studies of mRS assessment, 
using a broad range of research techniques, there is still much that is unknown 
regarding the properties and application of this scale and there is substantial 
potential for further important studies in this area. 209 
             
 
Where methodology is sufficiently described, mRS is most often performed using 
telephone based assessment.  The properties of a telephone based mRS 
interview are poorly described in the literature, while properties of other mRS 
assessment methodologies such as postal questionnaire have never been 
described.  Use of an assessment technique that does not rely on direct 
interview is attractive in terms of convenience and economics.  However, as 
demonstrated by my study of case record derived mRS, reliability of a technique 
should not be assumed.  Using a “mock clinical trial” design, as described in 
chapter four, a prospective blinded assessment of telephone mRS (or other 
assessment) would be possible and would provide useful data for planning future 
trials. 
 
In this thesis, “success” of the video based training package is evidenced 
through its popularity with trialists and rates of satisfactory performance on the 
final certification assessment.  Although encouraging, these data do not prove 
the efficacy of the resource as a teaching aid.  A study of untrained researchers 
could test the impact of the resource on mRS scoring.  The researchers would 
grade a series of mRS interviews (“live” or recorded) and scores would be 
collated.  They would then attempt the training materials and certification 
exercise.  On successful completion of training, they would grade a further 
series of mRS interviews.  Inter-observer agreement and agreement with (group 
adjudication panel) “correct” mRS could be described in the standard fashion.  
To account for possible learning effect of repeated mRS interview a control 
group, not exposed to the teaching materials, could be used.  Such an approach 
would lend itself to the online environment of current mRS training.   210 
             
 
In chapter eight I outlined pilot data describing use of remote video based mRS 
assessment.  I acknowledge the preliminary nature of this work but initial results 
are encouraging.  To robustly test the properties of video based assessment in a 
clinical trial setting would require a larger multi-centre study.  Future studies 
comparing reliability between adjudication panels would help better define the 
clinimetrics of video based group mRS.  Informed by the pilot work presented in 
this thesis, a multi-centre study of central adjudication of video based mRS has 
been devised and with funding from the Chief Scientist Office is due to begin 
this year (2009). (Successful grant application included as appendix)  
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Appendix A: modified Rankin Scale 
 
SCORE  DESCRIPTION 
0  No symptoms at all 
1  No significant disability despite symptoms; able to carry out all usual 
duties and activities 
2  Slight disability; unable to carry out all previous activities, but able to 
look after own affairs without assistance 
3  Moderate disability; requiring some help, but able to walk without 
assistance 
4  Moderately severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance 
5  Severe disability; bedridden, incontinent and requiring constant nursing 
care and attention 
6  Dead 
TOTAL (0–6): ____ 
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Appendix B: Barthel Index 
Feeding 
0 = unable 
5 = needs help cutting, spreading butter, etc., or requires modified diet 
10 = independent  
Bathing 
0 = dependent 
5 = independent (or in shower) 
Grooming 
0 = needs to help with personal care 
5 = independent face/hair/teeth/shaving (implements provided) 
Dressing 
0 = dependent 
5 = needs help but can do about half unaided 
10 = independent (including buttons, zips, laces, etc.) 
Bowels 
0 = incontinent (or needs to be given enemas) 
5 = occasional accident 
10 = continent 
Bladder 
0 = incontinent, or catheterized and unable to manage alone 
5 = occasional accident 
10 = continent 
Toilet Use 
0 = dependent 
5 = needs some help, but can do something alone 
10 = independent (on and off, dressing, wiping) 
Transfers (bed to chair, and back)) 
0 = unable, no sitting balance 
5 = major help (one or two people, physical), can sit 
10 = minor help (verbal or physical) 
15 = independent 213 
             
Mobility (on level surfaces) 
0 = immobile or < 50 yards 
5 = wheelchair independent, including corners, > 50 yards 
10 = walks with help of one person (verbal or physical) > 50 yards 
15 = independent (but may use any aid; for example, stick) > 50 yards 
Stairs 
0 = unable 
5 = needs help (verbal, physical, carrying aid) 
10 = independent  
TOTAL (0–100): 
 
The Barthel ADL Index: Guidelines 
1.  The index should be used as a record of what a patient does, not as a 
record of what a patient could do.  
2.  The main aim is to establish degree of independence from any help, 
physical or verbal, however minor and for whatever reason.  
3.  The need for supervision renders the patient not independent.  
4.  A patient's performance should be established using the best available 
evidence. Asking the patient, friends/relatives and nurses are the usual 
sources, but direct observation and common sense are also important. 
However direct testing is not needed.  
5.  Usually the patient's performance over the preceding 24-48 hours is 
important, but occasionally longer periods will be relevant.  
6.  Middle categories imply that the patient supplies over 50 per cent of the 
effort.  
7.  Use of aids to be independent is allowed.  214 
             
Appendix C: Manuscripts reviewed and excluded from systematic 
study of modified Rankin Scale reliability. 
 
Papers recovered from original search 
Albanese MA.  1994 
Excluded as does not use mRS based assessments. 
Albanese MA.  Clarke WR.  Adams HP.  Woolson RF 
Ensuring reliability of outcome measures in multicenter clinical trials of 
treatments for acute ischemic stroke: the program developed for the Trial of 
ORG 10172 in acute stroke treatment (TOAST). Journal of Head Trauma 
Rehabilitation 1994;9:1746-51. 
   
Davidson I.  2001 
Excluded as does not use mRS based outcome assessments. 
Davidson I.  Booth J.  Hillier VF.  Waters K Inter-rater reliability of 
rehabilitation nurses and therapists.  British Journal of Therapy and 
Rehabilitation 2001;8:462-7. 
 
De Haan 1993 
Excluded as no inter / intra-observer mRS comparison. 
De Haan R.  Horn J.  Limburg M.  Van Der Meulen J.  Bossuyt P.  A comparison of 
five stroke scales with measures of disability, handicap, and quality of life. 
Stroke. 1993;24:1178-1181. 215 
             
Duncan PW.  2002 
Excluded as no inter / intra-observer mRS comparison. 
Duncan PW.  Lai SM.  Tyler D.  Perera S.  Reker DM.  Studenski S.Evaluation of 
proxy responses to the Stroke Impact Scale.  Stroke.  2002;33:2593-9. 
 
Celani MG 2002 
Excluded as uses Oxford Handicap Scale and dichotomised outcomes only. 
Celani MG.  Cantisani TA.  Righetti E.  Spizzichino L.  Ricci S.  Italian 
International Stroke Trial (IST) Collaborators. Different measures for assessing 
stroke outcome: an analysis from the International Stroke Trial in Italy. Stroke. 
2002;33:218-23. 
 
Halkes PH 2006 
Excluded as no inter / intraobserver mRS comparison. 
Halkes PH.  van Gijn J.  Kappelle LJ.  Koudstaal PJ.  Algra A. Classification of 
cause of death after stroke in clinical research. Stroke. 2006;37:1521-4. 
 
Hantson L 1994 
Excluded as no inter / intraobserver mRS comparison. 
Hantson L. De Weerdt W. De Keyser J. Diener H.C. Franke C. Palm R. Van 
Orshoven M. Schoonderwalt H. De Klippel N. Herroelen L. Feys H.  The European 
Stroke Scale. Stroke.1994;25:2215-9. 
 
Merino JG 2005 
Excluded as uses only dichotomised mRS. 
Merino, Jose G.  Lattimore, Susan U.  Warach, Steven. 
Telephone assessment of stroke outcome is reliable. Stroke. 2005;36:232-3. 216 
             
Meyer B.C. 2002  
Excluded as no inter / intraobserver mRS comparison. 
Meyer B.C. Hemmen T.M. Jackson C.M. Lyden P.D. Modified National Institutes 
of Health Stroke Scale for use in stroke clinical trials: prospective reliability 
and validity. Stroke. 2002;33:1261-6. 
 
Oveisgharan S 2006 
Excluded as no inter / intraobserver mRS comparison. 
Oveisgharan S. Shirani S. Ghorbani A. Soltanzade A. Baghaei A. Hosseini S. 
Sarrafzadegan N. Barthel index in a Middle-East country: translation, validity and 
reliability. Cerebrovascular Diseases. 2006;22:350-4. 
 
Quinn TJ 20008 
Excluded as mRS derived with no direct patient contact.  
Quinn TJ, Ray G, Atula S, Walters MR, Dawson J, Lees KR. Deriving Modified 
Rankin Scores from Medical Case-Records. Stroke. 2008;39:3421-3. 
 
Quinn TJ 2008 
Excluded as mRS derived with no direct patient contact.  
Quinn TJ, Dawson J, Walters MR, Lees KR. Variability in Modified Rankin Scoring 
Across a Large Cohort of International Observers. Stroke. 2008;39:2975-9 
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Reeves MJ 2008 
Excluded as mRS derived with no direct patient contact.  
Reeves M.J. Mullard A.J. Wehner S.  Inter-rater reliability of data elements 
from a prototype of the Paul Coverdell National Acute Stroke Registry.BMC 
Neurology. 8, 2008. Article Number: 19.  
 
Shinohara Y. 2006. 
Excluded as mRS derived with no direct patient contact. 
Shinohara Y. Minematsu K. Amano T. Ohashi Y. Modified Rankin scale with 
expanded guidance scheme and interview questionnaire: inter-rater agreement 
and reproducibility of assessment. Cerebrovascular Diseases.  2006;21:271-8. 
 
Visser MC. 1992  
Excluded as does not review stroke patients. 
Visser MC.  Koudstaal PJ.  van Latum JC.  Frericks H.  Berengholz-Zlochin SN.  
van Gijn J.Inter-observer variation in the application of 2 disability scales in 
heart patients. Nederlands Tijdschrift voor Geneeskunde. 1992; 136:831-4. 
 
Papers recovered from bibliographic review of retrieved reports and 
additional searches 
Atiya 2003 
Excluded as mRS derived with no direct patient contact. 
Atiya M, Kurth T, Berger K, Buring JE, Kase CS. Inter-observer agreement in the 
classification of stroke in the Women’s Health Study. Stroke. 2003; 34: 565–567 218 
             
 
Bamford 1989 
Exclude as does not use mRS based outcome assessments. 
JM Bamford, PA Sandercock, CP Warlow, and J Slattery Inter-observer 
agreement for the assessment of handicap in stroke patients Stroke. 
1989;20:828. 
 
Cup EH 2003 
Excluded as does not use mRS based outcome assessments. 
Cup EH.  Scholte op Reimer WJ.  Thijssen MC.  van Kuyk-Minis MA. 
Reliability and validity of the Canadian Occupational Performance Measure in 
stroke patients. Clinical Rehabilitation 2003;17:402-9. 
 
Côté R 1988 
Excluded as provides only review data.  
Côté R, Batista RN, Wolfson CM, Hachinski V. Stroke assessment scales: 
guidelines for development, validation and reliability assessment. Can 
J Neurol Sci 1988;15:261-265. 
 
Jaillard AS 
Exclude as does not use mRS based outcome assessments. 
Jaillard AS on behalf of the MAST-E group – value of the phone interview in 
stroke outcome assessment. (abstract) Cerebrovasc Dis 1995; 5:269 
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Loewen SC 1988 
Excluded as did not use mRS based outcome assessments. 
Loewen SC,  Anderson BA Reliability of the modified motor assessment scale and 
the Barthel index. Phys Ther 1988;68:1077-1081. 220 
             
Appendix D: Functional outcome measures used in contemporary 
stroke trials 
Action research activities index  
Author’s own (three) 
Barthel Index  
Berg balance  
Canadian stroke scale 
Composite / Global scale incorporating more than one of these tools 
Composite spasticity index 
Disability assessment scale 
EuroQOL  
Fugyl meyer 
Frenchay Activites Index 
Glasgow Outcomes Scale 
Geriatric depression scale 
Global health 
Global health status 
Human activity profile 
Katz Activities of Daily Living Scale 
Late Life Functional Dependence Index 
Lidcombe test plate 
Modified Ashford scale  
Modified Rankin Scale 
Motor activity log 
Motor assessment scale  
Motor skill performance 
MRC strength scale 
National Institutes of Health Stroke Scale 
Optotrak assessment 
Orgogozo scale  
Oxford Handicap Scale 
Physician assessment scale 
Physiological cost 
Porch Index of Communicative Ability 221 
             
Resource use questionnaire 
Rivermead Mobility Index 
Scandinavian stroke scale 
Short from 36 
Sickness impact profile 
Single question 
Six minute walk 
Stroke impact scale 
TEMPA (Upper Extremity Performance Test for the
 Elderly) 
Timed up and go 
Timed walk 
Tinetti scale 
Upper limb of BFM test 
Walking impairment questionnaire 
Wolf motor function test 222 
             
Appendix E: Pro-forma for assessment of video mRS. 
 
Assessor initials:          Date: 
 
Patient ID:           Audio only: Y     N    
 
Modified Rankin Score 
No symptoms at all                    0     
 
No significant disability despite symptoms; able to carry out all 
usual duties and activities                  1    
 
Slight disability; unable to carry out all previous activities, but able to 
look after own affairs without assistance              2     
 
Moderate disability; requiring some help, able to walk without assistance      3     
 
Moderately severe disability; unable to walk without assistance and 
unable to attend to own bodily needs without assistance          4    
 
Severe disability; bedridden, incontinent and requiring constant nursing care  5     
 
 
Were you able to confidently score the interview: Y     N    
If no, tick all the contributory factors: 
 
Technical 
Poor visual quality        ______________________________________ 
Poor sound quality        ______________________________________ 
Incomplete recording       ______________________________________ 
Other (please specify)       ______________________________________ 
 
Interview specific 
Incomplete mRs interview      ______________________________________ 
Lack of clarity on a specific      _______________________________________ 
Other (please specify)       _______________________________________ 
 
Patient specific 
Speech problem        ______________________________________ 
Cognitive impairment       ______________________________________ 
Insufficient information       ______________________________________ 
Inconsistent answers        ______________________________________ 
Other (please specify)       ______________________________________ 
 
 
Consensus reached on mRs Y     N    
 
Final group mRs score  223 
             
Appendix F: Original Rankin Stroke Scale and derivations. 
 
Rankin Stroke Scale 
 
Description 
Grade I  No significant disability, able to carry out all usual duties 
Grade II  Slight disability, unable to carry out shome of previous 
activities but able to look after own affairs without 
assistance 
Grade III  Moderate disability, requiring some help but able to walk 
without assistance 
Grade IV  Moderately severe disability, unable to walk without 
assistance and unable to attend to own bodily needs without 
assistance 
Grade V  Severe disability, bedridden, incontinent and requiring 
constant nursing care and attention 224 
             
Oxford Handicap Scale 
 
 
Handicap   Lifestyle   Grade  
none   no change   0  
minor symptoms   no interference   1  
minor handicap   some restrictions but able to look 
after self  
2  
moderate handicap   significant restriction; unable to lead 
a totally independent existence 
(requires some assistance)  
3  
moderate-to-severe 
handicap  
unable to live independently but 
does not require constant attention  
4  
severe handicap   totally dependent; requires constant 
attention day and night  
5  
  225 
             
Appendix G: Application for funding to support multi-centre study of 
video based mRS 226 
             
 
Chief Scientist Office    Form 2 
 
Grant application 
Form 
CSO reference number: 
CZB/4/595 
Please complete this form in Verdana 10 point font size 
Project title (not more than 25 words): 
 
Central Adjudication of Modified Rankin Scale Disability Assessments in Acute 
Stroke Trials 
 
 
 
 
 
 
 
Duration of Project (months): 18 
 
 
 
 
Chief Investigator: 
Name and title  Position  Institution 
Professor Kennedy R Lees  Professor of 
Cerebrovascular 
Medicine 
University of Glasgow 227 
             
Project summary (not more than 150 words): 
 
Clinical trials in acute stroke require assessment of functional outcome. Unfortunately, wide 
inter-rater variation hinders use of such assessments leading to frequent misclassification of 
the trial endpoint, which impacts upon statistical efficiency and trial power. Central reading of 
endpoint assessments using video recordings could reduce misclassification by improving 
reliability of assessments, reduce the number of trial observers and will allow central 
adjudication of “misclassified” patients. This could enhance ability to assess treatment effects 
with smaller required sample sizes providing major cost savings to study sponsors, research 
councils and industry. 
 
We will demonstrate feasibility, reliability and acceptability of centrally adjudicated endpoints 
in acute stroke trials via a multi-centre study of at least 300 patients over 2 years. Then, 
through both simulations and practical application to ongoing clinical trials, we will estimate 
the improvements brought to sample size and power of stroke trials. 
 
1.  Application for a research grant in:    (please tick) 
 
  Full grant  Small grant 
Biomedical & Therapeutic Research  √   
Health Services Research     
 
2.  Project category:        (please tick) 
New project  √ 
Resubmission   
Clinician Scientist   
Request for Supplementary Funding   
 
3.  Research category:      (please tick) 
Clinical Trial subject to the Clinical Trial Regulations   
Other  √ 
 
 
 228 
             
4.  Keywords (please use suggested lists): 
 
  Primary: 
Stroke 
 
  Secondary: 
Outcomes  Disability  Telemedicine     
 
5.  Dates:  
 
Proposed start date  1/8/2008 
Proposed finish date  1/2/2010 
 
              Section 1  
(Not more than 8 pages) 
 
Proposed research project: 
 
1.   Title 
2.   Introduction (citing key references, searches used, etc.) 
3.   Results of any pilot studies 
4.   Aims 
5.   Research questions 
6.   Plan, methods, expertise available, statistical power 
7.   Timetable 
8.   Existing facilities 
9.   Justification of requirements 
10.  Research outcomes relating to NHS implementation potential 
11.  Dissemination 
12.  Key references 
13.  Relevant additional material    
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1. CENTRAL ADJUDICATION OF MODIFIED RANKIN SCALE DISABILITY 
ASSESSMENTS IN ACUTE STROKE TRIALS 
2. INTRODUCTION - Stroke is among the most important causes of severe disability, 
death and health care resource consumption in the Western world (1,2,3). Despite this 
there are few effective treatments and many neuroprotectant trials have failed 
(4,5,6); up to 50 drugs have been discontinued after initial studies. While this may be 
partly explained by lack of treatment efficacy, inadequate study design has 
contributed. Assumptions regarding anticipated treatment effect and event rates have 
been overambitious and inaccurate (7) leading to trials that were underpowered (8). 
Even with recent innovations in trial design (9), standard power calculations still 
suggest, because outcomes are variable and there is marked heterogeneity of causes, 
that several thousand patients are required for functional outcome trials of 
neuroprotectant strategies. 
Acute stroke trials therefore require being large and expensive. The need for a robust 
measure of functional outcome makes them yet more challenging. At present, the 
modified Rankin Scale (mRs) is the most popular outcome measure (table 1) and is an 
ordinal scale with 6 categories ranging from zero (no symptoms) to five (complete 
physical dependence). However, there are concerns with its use - considerable inter-
observer variability is recognised (10,11) and traditional dichotomised methods of 
outcome analysis disregard important differences between adjacent mRs groups (12).  
Trial power is influenced by many factors and inter-observer variability is a particular 
concern. Single centre studies typically give weighted kappa statistics for inter-
observer agreement of 0.7 to 0.8 with use of the mRs (10). A three-site comparison 
which involved 15 raters found an un-weighted kappa statistic of only 0.25 (10). Such 
variability increases the risk of assigning patients to the wrong outcome group 
(endpoint misclassification) which can introduce bias and increase type two error rates 
(13,14) and reduce trial power. This is likely to feature in large multi-centre stroke 
trials which involve many hundred observers and this potential for misclassification of 
endpoint represents a major design flaw in acute stroke trials. 
The Importance of Endpoint Misclassification - Data exist to support a significant 
detrimental effect of endpoint misclassification. For example, in a trial of 
pneumococcal vaccine (13) in which accuracy of identification of fatal respiratory tract 
infection (the trial endpoint) was erroneously assumed to be 100%, trial power was 
compromised: modest misclassification of the cause of death occurred and reduced 
trial power by 40% (from 93% to 54%). Analysis of data from a trial in neurotrauma 
(14) reveals that erroneous misclassification of patient outcome has a significant 
impact on estimates of effect size: without misclassification, the treatment effect was 
7.5% (p=0.039). With 10% misclassification, this dropped to 6% (p=0.102), while 
with 20% misclassification it was only 4.5% (p=0.228). We have performed 
preliminary analysis to show this is likely to be an important factor in acute stroke 
trials. Using the distribution of mRs scores seen in the SAINT trial (9), an 18% rate of 
Table 1 – The Modified Rankin Score 
Description  Score 
No symptoms at all  0 
No significant disability despite symptoms; able to carry out all usual duties and activities  1 
Slight disability; unable to carry out all previous activities, but able to look after own affairs without 
assistance 
2 
Moderate disability; requiring some help, but able to walk without assistance  3 
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily 
needs without assistance 
4 
Severe disability; bedridden, incontinent and requiring constant nursing care and attention  5 
Dead  6 230 
             
mRs misclassification (19) for categories of 1 and 2 would have a minor impact on the 
treatment effect seen if favourable outcome were defined as mRs 0 or 1 (absolute 
treatment benefit of 3.64% with misclassification and 4% without). Although these 
appear little different, the corresponding sample sizes required 
for 80% power under a continuity-corrected chi-squared test are 2605 and 
2218 per group; a large difference which could bring significant time and cost savings.  
Neurosurgical and Other Interventional Trials - Several neurosurgical and neuro-
radiological trial programmes have yielded encouraging results. For example, the 
recently reported MELT study (MCA Embolism
 Local fibrinolytic intervention Trial) (15) 
suggests that the intra-arterial approach represents a viable treatment option in those 
with middle cerebral artery (MCA) occlusion: this observation is supported by registry 
data of patients treated with mechanical thrombectomy using the Multi-MERCI device 
(16). There is a clear ethical and scientific need to build on these observational data 
with prospective randomised controlled trials comparing intervention with best medical 
therapy. Further, a pooled meta-analysis of three randomised controlled trials 
(DECIMAL, DESTINY and HAMLET) (17) revealed startling evidence of benefit of 
decompressive hemicraniectomy in those with malignant MCA syndrome. Important 
questions raised during these trials (for example, identification of patients most likely 
to benefit and the optimal timing of surgery) now need to be addressed. 
These interventions are, by their nature, difficult to study and treatment masking is 
difficult to ensure. Ideally, a prospective randomised open-label blinded end point 
evaluation (PROBE) design would be employed. This could be employed in acute 
stroke trials if mortality or recurrent event rate was the endpoint but is not feasible 
when measures of post stroke disability such as the mRs assessment are used. These 
measures mandate a clinical assessment of the participant which for practical reasons 
is typically performed in the local trial centre by a research nurse or doctor. It is 
unlikely that these individuals can guarantee being blinded to treatment allocation, 
making a PROBE design impractical. 
Central adjudication of endpoint assessment could reduce misclassification and ensure 
blinded endpoint assessment. This is not entirely without precedent in stroke trials and 
is routinely employed in the context of imaging related endpoints. We hypothesise that 
central adjudication of endpoint assessment is feasible and can be achieved by digital 
recording of mRs assessments. 
Potential Benefits of Central Adjudication - Digital video recording of mRs 
assessments in a large clinical trial will limit the effect of inter-observer variability by 
allowing central “off-line” scoring by a small number of expert investigators. It will 
also permit validation and re-scoring of initially misclassified patients, help ensure 
quality of data (via source data verification and by ensuring adherence to interview 
procedures) and improve blinding of endpoint assessment. 
Central adjudication may also afford examination of more subtle gradations of 
disability. We believe a central outcomes adjudication panel could compare and rank a 
large series of patients, thereby giving a measure of spread within, as well as 
between, mRs categories. Again, this is not without precedent. When using a 
subjective ranking technique (18), raters rank each patient in a clinical trial according 
to their trial experiences and the distribution of ranks between treatment groups is 
compared. This method has been applied to data from the Systolic Hypertension in the 
Elderly Program (18) and provides a sensitive measure of treatment effect. This novel 
approach requires careful evaluation and is an important secondary aim of our project. 
As an example, such an approach could include information derived from other 
assessments such as the NIHSS. 
Before video recording of outcomes and central adjudication could be widely adopted, 
it must be rigorously assessed. Even though the technique is based upon an 
adaptation of a commonly used method there are several areas of note. First, the mRs 231 
             
by nature is subjective and whether important extra information (such as how the 
patient travelled to hospital or other background details) contributes and by how much 
is unclear. This approach will add to complexity of trial design and although we feel by 
an insignificant amount, the technique must yield benefit before it could be deemed 
worthwhile.  
3. Pilot Work. Pilot Work to Clarify the Extent of Variability and Endpoint 
Misclassification - We have reviewed the results of over 1500 observers who 
assigned mRs scores to the example cases used in our mRs training DVD – a unique 
dataset (19). Substantial interobserver variability was confirmed – only 81% of 
observers achieved a “pass” on the first attempt and less than one third of these 
individuals scored all 5 cases correctly. Disagreement was especially evident in cases 
where the correct mRs score was in the range of 2 to 3. In three separate example 
cases approximately 40% of observers misclassified the patient. The junction between 
mRs scores 2 and 3 is critical; it defines independence or dependence after stroke and 
is a commonly used cut-off for dichotomised endpoints. Major acute stroke trials 
involve as many as 400 hospitals, each with 2-5 raters, ensuring that endpoint 
misclassification will be a frequent and major confounding issue. 
Pilot Work to Support Use of Video mRs Assessments and Central 
Adjudication - We have performed a pilot study of this technique in our centre on 
100 post-stroke patients (manuscript in preparation, abstract published (20). Patients 
were graded by two independent assessors, one of whom was randomly assigned to 
record their assessment on video. These recordings were reviewed at least 3 months 
later by four experienced researchers and three experienced research nurses who 
independently assigned an mRs score. This was done blinded to both the initial mRs 
score and that of other observers. We showed the technique to be feasible with a high 
technical success rate and excellent precision compared to “correct mRs”. Agreement 
between the seven observers was good on review of the recorded mRs assessment 
(k=0.64) and superior to agreement during the standard mRs assessments (k=0.57) 
and was as good or better than that seen in previous studies using traditional mRs 
assessments. Thus, remote review of a recorded mRs assessment is not inferior to 
standard techniques, could be employed in a PROBE design and interestingly, 
performed better than use of a structured interview. Work to establish methods of 
central adjudication of cases of disagreement is ongoing. 
4. AIMS - We aim to establish whether central adjudication of locally recorded mRs 
assessments can be performed in a multi-centre trial setting, to clarify the extent of 
endpoint misclassification and to assess whether this can be addressed with 
demonstrable improvements in trial statistical power. We will also explore whether a 
subjective ranking technique can be applied to mRs outcomes and thus provide a 
more sensitive measure of post-stroke disability. 
5. RESEARCH QUESTIONS - Does central adjudication of video recordings of mRs 
assessments; 
1. Provide a feasible method of measuring outcome in a multi-centre trial setting? 
2. Offer a more accurate measure of outcome. i.e. Does outcome from central 
adjudication correlate better than on-site raters’ assessments with factors known to 
influence outcome (such as baseline NIHSS, glucose and blood pressure)? 
3. Exert meaningful effects on statistical power and required sample size in clinical 
trials? 
4. Allow measurement of more subtle effects on outcome through grading of outcomes 
within mRs categories, and if so, which statistical approaches allow this to be 
undertaken practically? 
6. PLAN, METHODS, EXPERTISE AVAILABLE, STATISTICAL POWER - We will 
perform a “virtual” acute stroke trial. Baseline data will be gathered and endpoint 
assessments performed as in an interventional trial. Briefly, patients with a diagnosis 232 
             
of stroke (ischaemic or haemorrhagic) presenting within 48 hours who have a 
demonstrable deficit on the NIHSS will be studied. Exclusion criteria will include a pre-
morbid modified Rankin score of ≥3. Follow up will occur at 30 and 90 days where an 
mRs assessment will be performed and recorded. All observers will be trained and 
certified in the use of the mRs and the video equipment. We will also perform video 
NIHSS assessments at 90 days. 
We aim to recruit a minimum of 300 patients from between 5 and 10 centres. This is 
the minimum number of patients likely to be required in a phase III acute stroke trial 
of a reperfusion strategy and will provide sufficient video assessments for us to 
evaluate the technique and its impact on trial design.  
The mRs Assessment – These will be performed on survivors in standard fashion 
according to each centre’s normal practice. This is likely to be in a clinic room, by a 
patient’s bedside or at home if they are unable to attend the hospital. The mRs 
assessment will be recorded using a digital video camera. The local investigator will 
assign an mRs score which will be inserted to the eCRF (the standard mRs score). 
They will also be asked to comment whether there is significant dysarthria or 
dysphasia. When possible, investigators who have been closely involved in 
management of a patient should not assess the patient for outcome. Whenever 
possible, the assessor should remain constant across the follow-up period for a given 
patient. We recognise these restrictions may be impractical for smaller sites but 
should be possible for the major centres. 
Video Equipment - A high definition video camera will be used (we currently use a 
HDR-HV1E 1080i digital HD video camera recorder (Sony, Japan; specifications: 
CCDType: Single CMOS Chip; Video Recording Format: DV Tape; Optical Zoom: 10 
times) or equivalent system). Cameras will record to digital video tape. In conjunction, 
a desktop omni-directional condenser boundary microphone will be used (we currently 
use an ATR97, Audio-technica, Ohio USA; Specifications: Frequency response: 50-
1500Hz). An easily portable tripod will be used to mount the video camera (we 
currently use a Manfrotto 117B movie tripod, Italy). 
Transfer of Recording and Upload to Co-ordinating Centre - The digital 
recordings will be transferred to a secure computer hard drive via a FireWire (IEEE) or 
USB 2 connection. Windows Movie Maker software (Microsoft, USA) will be used to 
anonymise and code the recording and convert it to MPEG format. A title will be placed 
at the start of the clip stating only the patient’s study number, study centre, mRs 
assessor’s initials and investigator code. No other editing will take place, unless 
required to maintain patient anonymity. If this is required, it will be recorded in the 
eCRF along with the length and nature of clip removed. 
The edited clip will be uploaded to the Rankin Outcome Adjudication web 
portal. It will also be recorded to compact disc (CD) which, along with the 
digital video tape, will be archived locally. From our experience with the 
technique and equipment, clips will be between 5 and 10 minutes long and 7 
and 15 MB in MPEG format. Central archiving and storage of copies of clips 
will be as for other trial related data specified in the protocol and University 
of Glasgow procedures.  
The Rankin Outcome Adjudication Web Portal – This will provide tools for 
investigators to enter their subjects’ modified Rankin Scale assessments and upload 
accompanying videos. The portal will be administered by the Robertson Centre for 
Biostatistics. The web portal will include a system that will make new videos available 
to the outcomes manager for quality checks and pre-review editing and transcription, 
assign new videos and data to assessors, permit them to make notes and to complete 
an adjudication form online. In addition, allocation to endpoint review committee for 
further assessment can be implemented in the case of disagreement. Assessors and 
committee members will be able to record periods of leave to facilitate timely 233 
             
turnaround of assessments. Standard performance metrics will be created and stored. 
The system will allow reminders (e-mail and at next log-in) to be initiated. 
The web portal will be secure and end-users will access the system by entering a 
username and password. Assessors will be grouped by centre. On first use, users will 
be asked to change their password. Smart passwords will be required and users will be 
prompted to change these routinely. 
Review of the Digital mRs Assessment – Recorded assessments will be reviewed 
at the outcome coordinating centre (Western Infirmary Acute Stroke Unit, Glasgow, 
UK) which will employ an adjudication procedure and review all endpoint assessments. 
Upon upload of an mRs assessment, the Outcomes Manager (a clinical research fellow) 
will be notified by an automated email. The fellow or a designee will then review the 
assessment (via the web portal and within 72 hours of submission) and remove any 
patient identifiable information from the assessment clip using Windows Movie Maker 
software. The fellow will also verify that assessor is currently certified in mRs 
assessment. If the assessor is not trained, the assessment will need to be repeated by 
a trained observer. If assessor training is valid, the fellow will assign an mRs score 
and then release the assessment for review by the endpoint assessment committee. If 
any editing has occurred to ensure blinded assessment, the original clip will be 
maintained and the nature of this editing recorded in the eCRF. The edited clip will be 
re-uploaded to the web portal and noted as the clip to be used by the endpoint 
assessment committee. The endpoint committee members will be notified by email. 
The endpoint committee will be made up of the named clinical applicants. A minimum 
of four will review the mRs assessment and assign an mRs score. This will be done 
independently to the local investigator score, blinded to all other patient information 
and within seven days of the fellow releasing the clip. The assessment will be viewed 
via the web portal and the score entered into the portal. An automated process will 
establish whether these scores agree with the initial local score and if so, the patient is 
assigned to the common mRs category.  If there is any disagreement, the patient is 
‘misclassified’ and the video clip will be submitted for further review by the entire 
endpoint assessment committee. Note that the website will indicate to the fellow that 
disagreement has occurred but not the original investigator’s score or the nature of 
the disagreement. Once the fellow is notified of a disagreement, he or she will inform 
the committee by email. After group review, the committee will assign the patient to 
one of the following groups: technically inadequate assessment, inadequate 
assessment, adequate assessment with unanimous committee agreement or adequate 
assessment with non-unanimous committee decision (where majority opinion as to 
which score is correct will apply). Where committee classification is possible, the 
patient will be assigned to that Rankin category. Otherwise, the submitting centre may 
be asked for further information (for example, to put a specific additional question to a 
patient) or to repeat the assessment if deemed necessary.  
Observer Training – All investigators will be trained in mRs assessment using a 
validated DVD based training programme. During the training sessions in 
mRs, observers will be shown how to operate the video camera and given a 
practical demonstration on video upload procedures and use of the Rankin 
Outcome Adjudication web portal. The minimum requirement is that one 
individual from each centre will be given one-to-one training by a member of 
the endpoint assessment team and will therefore be able to provide further 
training and demonstration to other individuals should it be required. A 
written instruction manual and summary pamphlet will be delivered with the 
video equipment to each active centre. Repeat training will be offered if video 
quality is below the required standard or on request from sites. Technical 
questions will be answered by email and/or telephone. 
Development of The ’outcome ranking’ Technique - It is not possible for an 
observer to watch and accurately rank a large series of patients - a full review for a 
trial of 1700 patients would require nearly 1.5 million pairwise comparisons ([n
2-n]/2). 234 
             
However, patients are already partially ordered by mRs category and sorting 
algorithms exist to identify the pairwise comparisons required to rank the outcomes. 
Because this is entirely novel, it is not possible to state exactly which technique will be 
most suitable for use in an acute stroke trial, although the shell, library and quicksort 
algorithms are possibilities. Identifying the most suitable technique is an express and 
key secondary aim of this project. 
Expertise Available – This study will be a collaboration between departments of the 
University of Glasgow and we expect several acute centres of the UK Stroke Research 
Network. Personnel at the coordinating centre have extensive experience in acute 
stroke trial design and outcome assessment and have developed the mRs training 
programme outlined above. The team is led by Professor KR Lees. The endpoint 
assessment committee members are Professor Lees (chair), Dr J Dawson (Lecturer in 
Medicine), Dr MR Walters (Senior Lecturer in Medicine), Dr K Muir (Senior Lecturer in 
Neurology), Prof P Langhorne (Professor of Stroke Care) and Dr T Quinn (Research 
Fellow in Stroke). Statistical expertise is provided by Dr C Weir from the Robertson 
Centre for Biostatistics. The team will also include an Outcomes Manager (a clinical 
research fellow) who will be specifically employed to handle all trial outcome data and 
video assessments and will be fully trained in mRs assessment.  
We have a strong research record in acute stroke and received a 5 rating in the last 
RAE. We have performed extensive research into outcome assessment after stroke 
(8,9) and have developed a DVD based training for mRs assessment and contributed 
to development of a structured interview for the mRs (10,11). We have led the largest 
acute stroke trial programmes (SAINT, IMAGES and GAIN trials). Our statistical team 
is also vastly experienced, has been involved in several large projects (WOSCOPS, 
IMAGES) and has contributed extensively to stroke trial design (21,22). The Robertson 
Centre for Biostatistics is an internationally renowned centre with extensive experience 
in eCRF design and data handling procedures in accordance with ICH Good Clinical 
Practice and industry regulatory guidelines. The Centre is accredited for ISO 
9001:2000 for its quality systems and has TickIT accreditation for its software 
development.  
The UK SRN is a recently launched DoH & CSO initiative with the express aim of 
facilitating conduct of randomised prospective trials and other well-designed studies of 
stroke. We are one of the coordinating centres and hold two Associate Director posts 
(Prof Lees and Ford), chair of the acute care group (ACG) (Prof Lees) and positions on 
the ACG (Dr Muir) and rehabilitation committees (Professor Langhorne). We are 
certain that we have all the required expertise and resources to make this project a 
success. 
Statistical Analysis - We will assess agreement, using the weighted kappa statistic, 
between the standard mRs score and central video assessment and establish 
misclassification rates. We will then assess the effect of local misclassification rates, 
and the potential benefits of our approach, on trial power and treatment effect 
estimates via standard statistical formulae.  
7. TIMETABLE - The study will take 18 months to complete. It is feasible to recruit 
300 plus patients in one year. We anticipate involvement of at least 5 centres and 
expect to recruit well in excess of 100 patients at the coordinating centre (we 
recruited this figure in a year during our pilot study). Our collaborators at the Glasgow 
Royal Infirmary (Prof Langhorne) and the Southern General Hospital (Dr Muir) will also 
recruit significant numbers and with the aid of the other centres (a minimum of 2) we 
will reach our target.  
8. EXISTING FACILITIES - All facilities and staff required to make this project a 
success are already available (except the video equipment for which we seek funding). 
Our pilot work ensures project implementation will be quick and smooth. All involved 
staff have extensive experience of acute stroke trials and have published on outcome 235 
             
assessment after stroke. Training materials for mRs use are available and validated. 
We expect the project will be adopted by the UK SRN which will ensure recruitment 
targets are met. 
9. JUSTIFICATION OF REQUIREMENTS - The total funding sought is £183289. This 
will provide the required equipment for up to 10 active centres, cover the gathering 
and uploading of patient information, ensure the availability of required statistical time 
and that of a dedicated Clinical Research Fellow. The salaries in this application have 
been calculated using current salary scales which came into effect on 1 August 2005. 
Assimilation to new pay scales will occur either before or during the period of the 
proposed research and, as agreed with RCUK, it is expected that a request for 
remuneration of additional net costs due to this restructuring will be made at the 
reconciliation stage of any award. Total equipment costs are £13533 with a further 
£1500 required for consumables (digital video tape). 
A dedicated clinical research fellow is required. The fellow will recruit a large number 
of patients at the coordinating and other local centres, have day to day responsibility 
for liaising with the other centres, coordinate the review committee, review all 
assessments, issue data queries and have primary responsibility for the writing of any 
manuscripts. This easily necessitates a full time commitment for the project duration. 
We believe a fellow, rather than a trained nurse is required to perform these duties 
and this represents little extra cost.  
The other applicants will make up the endpoint assessment committee. We estimate 
that up to 20% of cases (approximately 120) will be “misclassified.” Allowing 
approximately 10 minutes per case, this will amount to 20 hours per committee 
member with a further 30 hours available for the initial review and performing 
assessments. Extra time (a further 50 hours) is required for Prof Lees and Dr Dawson, 
who have primary responsibility for project implementation and for assisting in 
preparing the manuscript and meetings. They will also directly support the new Fellow 
and to allow the project to continue during periods of annual leave. 
We estimate that 3 months of principal study statistician time will be spent on 
methodological development, simulation work and study data analysis. Due to cost 
constraints the scope of the statistical methodological work will be restricted to the 
key components of this proposal but we have ensured availability of senior statistician 
time to ensure success of the project. Support is required to cover the development 
and use of case report forms, and to edit and store the digital video assessments. 
These are estimated at equivalent to 225, 525 and 112.5 hours months of 
administrative, IT and data management and management support. 
The costs of staffing at each local centre will be met by the local host institution and 
with the aid of the SRN. However, we must reimburse centres for actual expenditure 
incurred during patient follow-up (telephone, stationery and patient taxi costs). From 
our experience, £100 per patient recruited is the minimum necessary – amounting to 
£30000 for the study. 
30% of our costs relate to the virtual stroke trial. We have explored whether we could 
collect sufficient data from any ongoing trial but the costs of incorporating this to a 
pharmaceutical trial as an add-on would be prohibitive unless it was sponsored by a 
company; until our methodology is established, no company will wish to risk 
compromising their trial recruitment. Academic trials are recruiting in UK too slowly to 
deliver the recruitment needed within a practical timescale. By excluding the need for 
experimental treatment or testing of other hypotheses, inclusion criteria can be wide, 
consent will be readily obtained and this important study can be performed promptly. 
10. RESEARCH OUTCOMES RELATING TO NHS IMPLEMENTATION POTENTIAL - 
It is vital that we improve endpoint assessment in acute stroke trials. If this method is 
successful we hope that the increase in trial efficiency will ease the conduct of further 236 
             
research and facilitate discovery of new treatments for what is a devastating 
condition. Conduct of this virtual trial will also facilitate training within each SRN 
centre and provide evidence of expertise to attract externally funded research trials. 
11. DISSEMINATION - This research will clarify important issues regarding acute 
stroke trial design and we envisage such an important development will be published 
in a major peer reviewed journal. Data will also be incorporated in to the VISTA, 
making it available to all academic collaborators. However, in order to ensure its 
dissemination and use in future clinical trials we will liaise closely with industry and 
hold training sessions at investigator meetings; we have a clear record of 
dissemination at academic meetings. 
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Modifications to Thesis of Dr. T J Quinn:  
“Improving outcome assessment for clinical trials in stroke”  
 
Following the recommendations of internal and external examiners at the oral 
examination on 21
st January 2010, the following changes have been made to the 
MD thesis: 
 
1/ All use of first person plural has been removed in favour of first person 
singular. 
 
2/ Additional references have been added, in certain areas reference is to an 
online electronic resource rather than traditional published periodical and these 
are described in the main body of the text. 
 
3/ Grammatical, formatting and typographic errors have been corrected. 
 
4/ Certain key phrases (“Clinimetrics”; “Functional outcome”; “Convenience 
sample”) have been better defined with corresponding references to original 
published work. 
 
5/ Figures 11 and 12 have been redrawn with a corresponding legend to better 
explain the data presented.  
 
 